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The antiphospholipid syndrome (APS) is a rare systemic autoimmune disease, that affects 
approximately 0.05% of the general population 1. APS contributes to 6.1% of all pregnancy 
failures, and less than 1% of  thrombosis cases 1. However, APS is the most common cause of 
acquired hypercoagulability for people under the age of 50 years, accounting for 20% of all 
thrombotic complications 2. APS is diagnosed when a patient suffers from thrombosis or 
pregnancy morbidity and has persistent circulating antiphospholipid antibodies (aPLs) (Table 1) 
3. Vascular thrombosis and pregnancy-related morbidity frequently occur in the general 
population irrespective of APS. As patients with APS often need a more intense anticoagulant 
therapy, a heavy burden rests on the assays used to detect the presence of circulating aPLs. 
The current revised laboratory criteria for APS classification requires a combination of different 
laboratory tests to detect aPLs. These laboratory criteria include one functional coagulation assay 
known as lupus anticoagulant (LAC), and two immunological assays measuring immunoglobulin 
(Ig) G and/or IgM with either cardiolipin (antiCL) or beta2-glycoprotein I as antigen (antiβ2GPI). 
To avoid false-positive tests related to infections, positive tests should be repeated with an 
interval of at least 12 weeks 3.  
Table 1. Revised classification criteria for the antiphospholipid syndrome. Classification of APS needs to 
meet at least of one of the clinical criteria and one of the laboratory criteria. Modified from Miyakis S 
2006 3. 
Clinical criteria 
   1. Vascular thrombosis: 
        One or more clinical episodes of arterial, venous, or small vessel thrombosis, in any tissue or organ. 
   2. Pregnancy morbidity: 
        a. One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week of 
gestation, with normal fetal morphology, or 
        b. One or more premature births of a morphologically normal neonate before the 34th week of gestation 
because of: (i) eclampsia or severe preeclampsia or (ii) recognized features of placental insufficiency, or 
        c. Three or more unexplained consecutive spontaneous abortions before the 10th week of gestation, 
with maternal anatomic or hormonal abnormalities and paternal and maternal chromosomal causes 
excluded. 
Laboratory criteria 
    1. Lupus anticoagulant (LAC) present in plasma, on two or more occasions at least 12 weeks apart, detected 
according to the guidelines of the International Society on Thrombosis and Haemostasis-Scientific 
Subcommittee (ISTH-SSC) on LAs/phospholipid-dependent antibodies 
    2. Anticardiolipin antibody (antiCL) of IgG and/or IgM isotype in serum or plasma, present in medium or 
high titer (i.e. >40 GPL or MPL, or >the 99th percentile), on two or more occasions, at least 12 weeks apart, 
measured by a standardized ELISA 
    3. Anti-β2glycoprotein-I antibody (antiβ2GPI) of IgG and/or IgM isotype in serum or plasma (in titer >the 
99th percentile), present on two or more occasions, at least 12 weeks apart, measured by a standardized 





Although the exact pathogenesis of APS is unknown, the relevant aPLs antibodies are not directed 
against phospholipids, but against phospholipid-binding proteins, e.g. β2GPI, which have an 
affinity for anionic phospholipids 4. Autoantibodies against many different plasma proteins have 
been described 4.  β2GPI has proven to be a major antigen target for aPLs 5-7.  
Antiβ2GPI antibodies 
β2GPI consists of four similar complement control protein (CCP)-like domains (DI, DII, DIII, DIV) 
and one domain (DV) with extensions of a CCP like domain. DI-DIV have evolutionary conserved 
sequences and DV harbors a large positively charged lysine patch that has affinity for anionic 
phospholipids. The phospholipid-binding site is located at the bottom of DV and consists of a 
hydrophobic loop. β2GPI has two different conformation: a native closed (circular)  conformation 
and  an open (fish hook shaped) conformation 8.  It has been hypothesized that both the N-
terminal domain I (DI) and the C-terminal domain V (DV) are partly hidden in the native circular 
β2GPI.  When the lysine loop on DV interacts with anionic phospholipid or other negatively 
charged molecules on cell surfaces 9-11, β2GPI undergoes a conformational change. Consequently, 
the DI-IV stretches resulting in a more open fish hook shape, thereby exposing a dominant 
epitope in the glycine40-arginine43 (G40-R43) region of DI and allowing the binding of antiDI of 
β2GPI antibodies 12-17 (illustrated in Figure 1). 
It is not immediately clear how antibodies against β2GPI could induce the clinical manifestations 
of APS. Figure 2 illustrates the possible mechanisms behind the clinical manifestations of APS by 
autoantibodies against β2GP.  In plasma, β2GP is present as a circular protein in which DI 
interacts with DV. After a small injury, cells express phospholipids on their surface (the so-called 
second hit theory). Closed β2GPI will bind to the anionic membrane. On binding to anionic 
surfaces, the protein patches and changes into a stretched structure, thereby exposing a cryptic 
epitope on DI for the autoantibodies. The antibodies will bind to and stabilize β2GPI in its 
stretched conformation. Binding of aPLs to this epitope on β2GPI may subsequently target 
different cell types (endothelial cells, monocytes, platelets) by several surface receptors thereby 
activating these cells. Tissue factor expression will be one of the consequences of these 
activations, and complement activation is also involved in the induction of the clinical 
manifestation of APS 18,19. 
In vivo models demonstrated the pathogenicity of antibodies directed against DI of β2GPI 20-23. 
The subpopulation of aPLs that recognizes an epitope on DI of β2GPI comprising at least G40-R43 
have been proved to be pathogenic and displays a significant correlation with clinical 
manifestations 16,24,25. Antibodies against other domains of β2GPI appear to be unrelated to the 






Figure 1. Open structure and closed structure of β2GPI. Domain I-V represent the five domains of β2GPI. 
(A) β2GPI circulates in the closed circular structure. DI and DV are partly hidden in the native circular 
β2GPI. (B) The open fish hook form of β2GPI. In this conformation, a cryptic epitope on DI is exposed and 
allows binding of antiDI of β2GPI antibodies. It is proposed that β2GPI binding to anionic phospholipid, 
through its phospholipid binding site on DV, results in conformational changes.  
 
 
Figure 2. Schematic diagram of the pathogenic mechanisms of autoantibodies against β2GP. (A) 
Antiβ2GPI-β2GPI complex dimerization. By binding to anionic phospholipid membrane (marked as red 
color), closed β2GPI will change into a stretched structure thereby exposing a cryptic epitope on domain 
I for autoantibodies to bind. One antibody can bind to two molecules and stabilizes β2GPI to form a dimer 
complex. (B) Cells, factors and complement activation. The antiβ2GPI-β2GPI dimer complex may 
subsequently target surface receptors of different cell types (endothelial cells, monocytes, platelets) 
resulting in activating of these cells. Activation via soluble coagulation-related factors and complement 
factors activation will be also involved in these mechanisms. (C) The clinical manifestations of APS. 
Antibodies initiate clinical events via interactions of these pathways. The clinical manifestations of APS 




Other autoantibodies than antiβ2GPI  
Prothrombin is one of the major coagulation factors in the circulation, and it can be converted 
into thrombin during coagulation. Antibodies directly against prothrombin (PT) enhance 
clearance of prothrombin from the circulation, can decrease levels of prothrombin and thereby 
cause bleeding. Strangely enough, anti-prothrombin antibodies (antiPT) have been described to 
correlate with thrombosis 30. Autoantibodies against a phosphatidylserine/prothrombin (PS/PT) 
complex differ from autoantibodies against prothrombin. Autoantibodies against PS/PT 
recognize prothrombin only when it is bound to anionic phospholipid, suggesting that 
prothrombin undergoes a conformational change when it is bound to PS, exposing a cryptic 
epitope. Antibodies directed against this cryptic epitope correlate better with thrombosis than 
antibodies against the rest of the prothrombin molecule. Autoantibodies against PS/PT showed 
a significant correlation with thrombosis in APS  in a systematic review 31. 
In addition, other than β2GPI and prothrombin, autoantibodies to a number of other proteins, 
such as protein S, protein C, tissue factor pathway inhibitor, factor X, XI and XII, Factor H, Annexin 
A5, Annexin A2, or antibodies to phospholipid antigens, including antibodies directed against 
phosphatidic acid (PA), phosphatidyl inositol (PI), phosphatidyl serine (PS), phosphatidyl 
ethanolamine (PE), cardiolipin (CL) are found in a small subgroup of patients with APS 32. Some 
correlate with clinical manifestations (level of evidence is even low), and mechanisms regarding 
how these autoantibodies might induce a prothrombotic state have been proposed, however, 
most of the studies do not support an association between these antibodies and thrombosis or 
pregnancy morbidity. There is no convincing evidence that they play a role in thrombosis or 
pregnancy complications in APS. 
Detection of antiphospholipid antibodies  
Lupus anticoagulant (LAC) 
LAC can be caused by a heterogeneous subset of inhibitors. The antibody is in most cases directed 
against β2GPI and prothrombin, but a positive LAC can also be found in the absence of these 
antibodies. Although the current guidelines for LAC detection have proved to be very helpful for 
a better standardization of this assay, LAC detection still has a number of unresolved issues. The 
heterogeneity of LAC antibodies leads to differences in detection performance. The high inter-
laboratory variability also results from multiple handling procedures between collection of the 
blood and the actual LAC testing 33 and a wide variation in phospholipid concentration and 
composition in the commercial clotting regents 34. Residual platelet material (platelet-derived 
phospholipids) can shorten the clotting times thereby generating false-negative results 35.  
Carrying out LAC tests during anticoagulation therapy increases the risk of false positive or 
negative results 36. Moreover, there are still a number of uncertainties in the interpretation of a 
weak LAC 37. 
LAC is a clotting time-based assay used to detect aPLs antibodies. When testing for LAC, it is 
important to realize that coagulation factor deficiencies should be excluded and that a lupus 




three steps: screen, mix and confirm 38,39. In the screening step, the presence of aPLs is 
demonstrated by the use of sensitive reagents containing a low concentration of phospholipids. 
In the mixing step, the presence of an inhibitor (antibodies) is demonstrated and a deficiency of 
the coagulation factors can be excluded by mixing the patient plasma with normal pooled plasma 
in a 1:1 proportion. In the confirmation step, the phospholipid dependent character of the 
inhibitor/antibodies is illustrated by the attenuation of the prolonged clotting time due to 
increasing the concentration of phospholipid used.   
Several coagulation assays have been described to measure LAC. Figure 3 shows a simplified 
schematic diagram of the coagulation pathways evaluated by each coagulation test used to 
detect LAC activity. The activated partial-thromboplastin time (APTT), colloidal-silica clotting time 
(CSCT) and kaolin clotting time (KCT) assays detect coagulation defects in the intrinsic coagulation 
pathway via contact activation on glass, silica or kaolin, in the presence of high-molecular-weight 
kininogen and prekallikrein. The dilute prothrombin time (dPT) assay detects coagulation through 
the extrinsic coagulation pathway by adding tissue factor (TF) and subsequently the formation of 
a complex between TF and factor (f) VIIa. Both the intrinsic and extrinsic pathways result in the 
conversion of FX (i.e. FXa). Finally, both intrinsic and extrinsic pathways converge in a final 
common pathway, the activation of prothrombin to thrombin followed by the conversion of 
fibrinogen to fibrin.  The dilute Russell’s viper venom time (dRVVT) assay starts coagulation by 
directly activating FX to FXa. The Taipan, Textarin, and Ecarin snake-venoms directly activate 
prothrombin. The activation of prothrombin to thrombin and several other reactions in the 
coagulation cascade require the presence of phospholipids and calcium. It is generally believed 
that the prolongation of phospholipid-dependent coagulation assays is due to competition 
between coagulation factors and aPLs with lupus anticoagulant activity for negatively charged 
phospholipids, although recently new data has been published that other mechanisms might also 
play a role 40.  
To measure LAC, all three steps should be performed in two distinct assays with different test 
principles. To reach more harmonization between the laboratories, the updated International 
Society on Thrombosis and Haemostasis (ISTH)- Scientific and Standardization Committee (SSC) 
guidelines recommend performing only aPTT and dRVVT based assays 38. The Clinical and 
laboratory Standards Institute (CLSI) guidelines are a bit less outspoken and do not exclude other 
assays 41. The conclusion of positivity for LAC can be drawn when all three steps of at least one 
assay are positive. 
Anticardiolipin assay and antiβ2GPI assay 
According to the Sydney criteria, the presence of antiCL or antiβ2GPI antibodies are a laboratory 
criterion for APS in addition to LAC 3. AntiCL and antiβ2GPI antibodies are measured by solid 
phase assays according to the ISTH-SSC guideline 42. In contrast to LAC detecting all functional 
aPL, the quantification of one group of aPL is detected by solid phase assays. AntiCL assays detect 
different types of antibodies depending on the coating of the solid phase assays: antibodies 
directed against cardiolipin itself, directed against the complex of cardiolipin with β2GPI and 
directed against other cardiolipin-binding protein 43. The Antiβ2GPI assays detect antibodies 




Figure 3. Lupus anticoagulant assays to detect antiphospholipid antibodies.  A simplified schematic 
diagram of the coagulation pathway. Activated partial-thromboplastin time (APTT), colloidal-silica clotting 
time (CSCT) and kaolin clotting time (KCT), dilute prothrombin time (dPT) or dilute Russell’s viper venom 
time (dRVVT), Taipan, Textarin and Ecarin snake-venom time are shown. It is generally believed that the 
prolongation of a phospholipid-dependent coagulation time is due to competition between coagulation 
factors and aPLs with lupus anticoagulant activity for negatively charged phospholipids.  
Traditionally, antiCL and antiβ2GPI antibodies were measured by ELISA 3. Nowadays, automated 
systems have been introduced into the market using a variety of solid phase surfaces (magnetic 
beads, microbeads, membranes and coated polystyrene cups) and various detection techniques 
of chemiluminescence (CLIA), flowcytometry, and multiplex systems42,44,45. However, despite the 
current guidelines and the introduction of internal calibrators to improve solid phase assay 
comparability, detection of antiCL and antiβ2GPI IgG/M show large inter-platform and inter-
laboratory variation 46,47. The heterogeneity of aPL and the lack of standardization of the assays 
make the laboratory diagnosis of APS full of challenging. 
In theory, the efficacy of the antiCL assay depends on the coating efficiency of cardiolipin and the 
presence of a cofactor β2GPI. AntiCL antibodies directed against cardiolipin itself are thought to 
be infection-related and transient. The specificity of antiCL assays can be improved by performing 
them in a β2GPI-dependent manner 48. Therefore, Antiβ2GPI assays using immobilized β2GPI 
antigen to detect antibodies directed towards β2GPI should have a better correlation with clinical 
manifestations of APS. As there is only a single β2GPI antigen, the antiβ2GPI assay is easier to 




assays 49,50. Futhermore, antiβ2GPI antibodies are frequently encountered in infectious diseases 
as well 51. A lack of correlation of antiβ2GPI with thrombosis and pregnancy morbidity was shown 
in a meta-analysis 52. This can be explained by differences in the conformation of β2GPI, which 
will affect the exposure of cryptic epitopes53.  
 
Figure 4. Anticardiolipin and antiβ2GPI assays for detecting antiphospholipid antibodies. (A) The antiCL 
assay detects a heterogeneous antibody population, including antibodies directly against cardiolipin itself 
and antibodies against cardiolipin-binding proteins. These cardiolipin-binding proteins can be β2GPI-
independent antiCL antibodies, but also β2GPI-dependent antiCL antibodies, as well as antibodies against 
DI or other domains of β2GPI.  (B-C) The antiβ2GPI assay detects a group of antibodies that bind directly 
to β2GPI, including antibodies against DI of β2GPI and antibodies against other domains of β2GPI. (B) 
When β2GPI is coated on hydrophilic surface, β2GPI undergoes a conformational change, exposing the 
cryptic epitope on DI allowing antiDI antibodies to bind. (C) When β2GPI is coated on a hydrophobic 
surface, the exposure of the epitope on DI of β2GPI is reduced and a part of the antiDI antibodies are not 
able to recognize β2GPI.  
Chapter 1 
16 
The cryptic epitope theory is that this epitope on DI is only exposed after the conformational 
change of β2GPI. In the antiCL assay, cardiolipin is first immobilized to a solid surface, β2GPI acts 
as a cofactor and binds to cardiolipin (which is negatively charged), which results in the 
conformational change thereby exposing the cryptic epitope on DI. In the antiβ2GPI assay, the 
nature of solid surface needs to be considered. Whenβ2GPI is bound onto a negatively charged 
surface (hydrophilic surface), the conformation of β2GPI changes thereby exposing the cryptic 
epitope on DI, allowing antibodies that recognizes the epitope to bind. When β2GPI is coated on 
a neutral-charged surface (hydrophobic surface), the exposure of the epitope on DI of β2GPI is 
reduced resulting in loss of binding by a sub-population of antiβ2GPI antibodies (Figure 4). 
APLs that recognize the epitope on DI of β2GPI have been shown to be pathogenic 16,20-25, 
antibodies against other domains of β2GPI appear to be unrelated to the clinical symptoms of 
APS 26-29. Based on these findings, the antiDI assays with directly coated DI of β2GPI as antigen 
were developed and were expected to have a very powerful role in the identification of APS 
patients. Several in-house antiDI and one commercial antiDI assay have been reported in the 
literature. Most of the reported assays are solely detecting IgG isotype antiDI antibodies.   
Other aPLs assay 
In addition to β2GPI, detecting various non-criteria aPLs against other plasma proteins, such as 
anti- phosphatidic acid (PA), anti-phosphatidylcholine, anti-phosphatidylethanolamine, anti-
phosphatidylglycerol, anti-phosphatidylinositol, anti-phosphatidylserine, anti-Protein S, anti-
Protein C, anti-annexin A2 anti-annexin5, antiPT and antiPS/PT have been published. However, 
the clinical significance of most of these antibodies is unclear 37,54-57. Recent literature showed 
that antiPS/PT antibodies are associated with thrombosis and pregnancy morbidity 58-60 and the 
presence of antiPS/PT antibodies increases the risk of thrombosis recurrence 61. Moreover, 
antiPS/PT antibodies are frequently present in APS patients and are strongly associated with LAC 
62,63. However, the evidence for a predictive value of antiPS/PT was considered insufficient. Until 
now, antiPS/PT testing is not included in the official laboratory criteria for diagnosing APS 3.  
Isotype of antiCL and antiβ2GPI antibodies 
After the revised criteria were published in 2006 3, the discussion about the relevance of antiCL 
and antiβ2GPI isotypes was resumed 37.  IgG and IgM have been included in the criteria 3. A meta-
analysis literature review showed that IgG antibodies correlate significantly more with 
thrombosis than IgM antibodies. There was also a significant association for IgM, but it remains 
a question whether IgM is an independent risk factor64. So far, IgA has not been included in 
laboratory criteria of APS. In a mouse model, IgA antibodies isolated from APS patients, reactive 
against DI and DIV/DV, demonstrated the pathogenic potential by increased thrombus area 
compared to control IgA 5. Moreover, multiple studies have shown that IgA antiCL and antiβ2GPI 
antibodies are associated with thrombosis and pregnancy morbidity 65-81. Furthermore, some 
studies concluded that the presence of IgA antiCL (and/or antiβ2GPI) is an independent risk factor 
for thrombosis 73,77.  However, positivity for IgA antiCL and IgA antiβ2GPI is usually associated 
with IgG and/or IgM positivity, which makes it difficult to understand the role of isolated IgA. A 
recent systematic review indicated that several studies failed to demonstrate utility of adding IgA 




association with other aPL, or the lack of improved diagnostic accuracy when routine evaluation 
of IgA antibodies 82. Other studies found that isolated IgA antiCL and/or antiβ2GPI positivity was 
linked to non-criteria clinical manifestations of APS and was not associated with thrombosis or 
pregnancy morbidity 72,76,77,82-85. Therefore, the importance of a non-criteria (isolated) IgA isotype 
of antiCL antibodies and antiβ2GPI antibodies need to be further investigated. 
Antiphospholipid profile 
The current laboratory criteria include detection of LAC, antiCL IgG and IgM and/or antiβ2GPI IgG 
and IgM. For the diagnosis of APS, it is sufficient to have one positive test when the patient also 
has one of the clinical criteria 3. However, not every test has the same predictive value and 
positivity in more than one test has a higher predictive value for developing a thrombotic event 
and/or pregnancy morbidity. Therefore, it has been advised to categorize patients according to 
the number of positive tests, as well as to investigate the antiphospholipid antibody profile for 
risk stratification 86. The concept of antibody profile for risk stratification is shown in Table 2. A 
combination of tests is used to stratify patients at risk for thrombosis and/or pregnancy 
complications. Taking into account the type and the number of positive tests, triple positivity is 
defined as combined positivity for LAC, antiCL and antiβ2GPI antibodies. Triple positivity has been 
shown to be associated with the highest risk of both a first thrombotic event and recurrence 87,88. 
Triple positivity is also an independent risk factor for pregnancy failure 89. Interestingly, patients 
with triple-positive profile are always still positive when the tests are repeated after 12 weeks 90. 
Patients with double positivity for both antiCL and antiβ2GPI positivity, but LAC negative, are at 
lower risk for clinical events of APS compared to triple-positive patients. The double positive 
combination of LAC and antiβ2GPI or antiCL correlates much better with thrombosis than does 
an isolated positive test for LAC or antiβ2GPI or antiCL 86,91,92. Single positives are positive for only 
one aPL positive 86. Single antiCL or antiβ2GPI positivity did not mark an increased risk 93. 
Moreover, single positive patients are less likely to develop APS related clinical symptoms 43,89. 
Isolated positivity for antiCL, with antibodies directed against cardiolipin itself, has a questionable 
clinical relevance 94. Equally, isolated antiβ2GPI positivity does not show any association with 
thrombosis 43.The precise clinical relevance of isolated LAC positivity is still unknown. As LAC 
measures the functional effect of a heterogeneous group of aPL antibodies, LAC could be 
mediated by either antiβ2GPI  antibodies 25 or anti-PS/PT antibodies 95, or possibly other 
inhibitors 55,96 (Figure 3). LAC is a much better predictor of clinical events than the antiCL and 
antiβ2GPI 97-99. When LAC is positive together with antiCL and antiβ2GPI antibodies, it carries a 
significant hazard for thrombotic as well as obstetric complications87,88,100. In the absence of 
antiCL and antiβ2GPI IgG and IgM antibodies, the clinical relevance of an isolated LAC has been 
widely debated. Although the clinical relevance of an isolated LAC has been suggested in both 
retrospective and prospective studies 98,99,101-103, however, not everybody is convinced by these 




Table 2. Antiphospholipid antibodies profile. 
 
Outline of my thesis 
Laboratory assays used to detect antiphospholipid antibodies are a major criterium for the 
classification of APS and tailored treatment for patients with APS. Standardization of the assays 
used to detect antiphospholipid antibodies remains difficult, which makes the laboratory 
diagnosis of APS challenging. The currently criteria rely on the detection of a heterogeneous 
antibody population. Which proteins and factors contribute to the production of 
antiphospholipid antibodies, and how these antibodies induce clinical events (thrombosis and 
pregnancy morbidity) related to APS, are particularly complicated issues, for which there still are 
no good explanations. Therefore, non-criteria aPLs assay might be potentially useful in the 
diagnosis and management of APS. Therefore, in this thesis, data of a multicenter study are used 
in order to investigate whether applying a new assay (in-house antiDI assay), non-criteria aPL (IgA 
antiCL and IgA antiβ2GPI) or re-evaluation of the current aPL assays (isolated LAC) contribute to 
a better laboratory diagnosis of APS.  
The following topics were addressed: 
1. Is there added value of detecting anti-domain I of β2GPI IgG on top of the current APS 
laboratory criteria? (Chapter 2-4) 
2. Is there added value of detecting IgA isotype of antiCL antibodies and antiβ2GPI antibodies 
in APS? (Chapter 6) 








IgG/IgM Categorization of patients 
Triple 
positive Positive Positive Positive Strongest association with risk events 
Double 
positive Negative Positive Positive 
Lower association with thrombotic risk than triple 
positive 
Pregnancy complications unknown 
Double 
positive Positive Negative Positive 
Better associated with clinical risk compared to 
isolated positive 
Double 
positive Positive Positive Negative 
Better associated with clinical risk compared to 
isolated positive 
Single 
positive Positive Negative Negative 
Most of studies show associated with thrombosis 
and pregnancy morbidity, although Pengo’s study 
showed poor predictive value for thrombosis 
event 104 
Single 
positive Negative Positive Negative No association with risk events 
Single 
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As the clinical symptoms of the antiphospholipid syndrome (APS) frequently occur irrespective 
of the syndrome, diagnosis predominantly depends on the laboratory assays measuring the level 
or function of antiphospholipid antibodies (aPLs). β2-glycoprotein I (β2GPI) is increasingly 
accepted as the most important target of aPLs. Antiβ2GPI  antibodies constitute a heterogeneous 
population, but current in vivo and in vitro evidence show that especially the first domain (DI) of 
β2GPI contains an important pathogenic epitope. This epitope containing Glycine40-Arginine43 
(G40-R43) has proven to be cryptic and only exposed when β2GPI is in its open conformation. A 
previous study demonstrated a highly variable exposure of the cryptic epitope in commercial 
antiβ2GPI  assays, with implications on correct patient classification. Unexpectedly, recent 
unpublished data revealed impaired exposure of the pathogenic epitope in the commercially 
available antiDI chemiluminescence immunoassay (CLIA) assay detecting specific antibodies 
directed to DI.  
In this review we summarize the laboratory and clinical performance characteristics of the 
different antiDI assays in published data and conclude with inconsistent results for both the 
correlation of antiDI antibodies with clinical symptoms and the added value of antiDI antibodies 
in the classification criteria of APS. Additionally, we hypothesize on possible explanations for the 
observed discrepancies. Finally, we highly advise manufacturers to use normal pooled plasma 
spiked with the monoclonal antiDI antibodies to verify correct exposure of the cryptic epitope. 
 




APS is a systemic autoimmune disease characterized by thrombotic complications, either venous, 
arterial, or small-vessel thrombosis, or pregnancy-related morbidity. The latter includes fetal 
death, premature births attributed to placental insufficiency, eclampsia or severe pre-eclampsia 
and spontaneous abortions 1. Given the high frequency of these clinical symptoms irrespective 
of the syndrome, apart from a clinical characteristic an APS patient needs to fulfil at least one of 
the laboratory criteria 2. Current revised laboratory criteria for APS classification detect the 
presence of aPLs through a combination of laboratory assays, including one functional 
coagulation assay lupus anticoagulant (LAC) and two immunological assays measuring 
immunoglobulin (Ig) G and/or IgM anti-cardiolipin antibodies (antiCL) and IgG and/or IgM 
antiβ2GPI  antibodies (antiβ2GPI ). To avoid false positive tests due to infections, positive tests 
should be repeated with an interval of at least 12 weeks 3. Of note, the presence of these aPLs 
has also been demonstrated to associate with other clinical symptoms that are not included in 
the APS criteria, such as epilepsy and migraine 4,5.  
Probably due to the fact that LAC measures a functional effect of the antibodies, LAC is a better 
predictor of thrombosis than the quantitative solid phase  immunoassays. However, currently it 
is not advised to carry out LAC tests during treatment with direct oral anticoagulants because of 
the risk of false-positive results 6. The exact pathogenesis of APS is unknown, but aPLs have been 
described to activate monocytes, neutrophils, dendritic cells and the placental tissue 
(summarized in 7). Despite the fact that many different proteins have been identified as being 
involved in the pathogenesis of APS, accumulating evidence from in vitro experiments as well as 
animal studies has revealed that β2GPI is the main target for aPLs 8-10. Based on this evidence, 
one would expect that testing for antibodies with reactivity towards β2GPI has a good correlation 
with clinical manifestations. Although numerous studies have demonstrated a significant 
correlation 11-13, a meta-analysis performed by Galli et al. failed to show a significant correlation 
between single antiβ2GPI  positivity with a history of thrombosis or fetal loss 14. The lack of 
correlation with thrombotic complications as well as pregnancy morbidity was also shown in 
more recent studies 15-17.  
The reason for this variation may at least in part result from the availability of numerous 
commercial and home-made antiβ2GPI  assays and the lack of standardization 18,19. The available 
assays differ from each other in assay design [method/principle: enzyme-linked immunosorbent 
assay (ELISA) versus chemiluminescence immunoassays (CLIA)], the source of β2GPI and coating 
principles, the calculation of cut-off values, the reference material and the units used to express 
positivity 20,21. Additionally, various subsets of antiβ2GPI antibodies targeting different domains 
of the protein have been described with clear differences in clinical potential 22-25. β2GPI consists 
of five homologous domains (DI-DV) arranged differently in its native versus open conformation 
26. Importantly, in the native circular or S-shaped β2GPI the critical DI epitope is not exposed. 
Upon binding to an anionic (phospholipid) surface through the positively charged patch on DV, 
β2GPI undergoes a conformational change. Consequently, the DI-IV spreads out resulting in a 
more open J shape, exposing a cryptic epitope G40-R43 in DI and allowing antiDI of β2GPI 
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autoantibodies to bind 27-29. This subpopulation of aPLs that recognize an epitope on DI of β2GPI 
comprising at least G40-R43 proved to be pathogenic 27,30-37 and displayed a significant 
correlation with clinical manifestations 16,38. The detection of antibodies to DI versus DIV/V has 
therefore been suggested to help in the diagnosis of APS 39,40. 
As to the in vivo evidence for the pathogenicity of antibodies directed to DI, administration of 
recombinant human DI was found to inhibit the induction of thrombosis by polyclonal human IgG 
from patients with APS in a mouse model 41,42. In addition, a recombinant antibody recognizing 
DI of β2GPI induced thrombosis and fetal loss in animal models following priming with 
lipopolysaccharide (LPS) , while a CH2-deleted version of this antibody prevented the 
procoagulant and abortion-inducing effect of aPLs from APS patients 43. In a proof-of-concept 
study, using polyclonal IgG from patients with APS, antiDI-rich IgG significantly induced larger 
thrombi and enhanced the procoagulant activity in vivo compared with antiDI-poor IgG 44.  
Interestingly, a study in our laboratory demonstrated that the exposure of this pathogenic 
epitope G40-R43 on domain I was highly variable in commercial full-length antiβ2GPI  assays. This 
reduced exposure of G40-R43 may account for the variable results obtained concerning the 
clinical correlation of the assays as reduced exposure was found to result in false negative 
classification of APS patients 45. More recently, various assays specifically measuring antiDI 
antibodies have been developed. As these assays are measuring a specific pathogenic population, 
one would expect antiDI assays to highly correlate with clinical symptoms. Nonetheless, as for 
the full length antiβ2GPI  assays, no consensus has been reached for the antiDI antibodies 
concerning the correlation with clinical symptoms. Whereas some studies have demonstrated a 
higher correlation with thrombosis compared to the full-length assays, other studies failed to 
show an added value of antiDI assays. In this review, we summarize the laboratory and clinical 
performance characteristics of the various antiDI assays and elaborate on the possible reasons 
for the observed discrepancies. 
2. Available antiDI assays 
So far five major assays have been described in literature to specifically measure antibodies 
directed to DI of β2GPI (summarized in Table 1). These five assays differ in the source of DI, the 
coating and measuring principle and the interpretation of results. As these factors may influence 
the clinical performance of the test, we aim to summarize and compare the sensitivity and 
specificity, the odds ratio (OR) of antiDI for clinical manifestations, as well as the added value of 
antiDI to the existing laboratory criteria when measured with the different available assays in 
various patient populations (summarized in Table 2-4).  
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Table 1. Overview of assays used for the detection of anti-domain I antibodies (antiDI)  
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β2GPI: β2-glycoprotein I; CLIA: chemiluminescence immunoassay; CV: coefficient of variation; DI: domain 
I of β2GPI; ELISA: enzyme-linked immunosorbent assay; IC50: the concentration of DI able to inhibit 50% 




2.1 In-house developed two-step antiDI ELISA assay 
In 2005, the first antiDI assay was developed by de Laat et al 38. The DI used for coating was 
produced by a baculovirus expression system as described before 34. In this assay, DI is coated on 
a hydrophobic as well as a hydrophilic plate. The arbitrary binding of DI on a hydrophobic plate 
will ensure satisfactory exposure of the G40-R43 epitope. On the contrary, on a hydrophilic plate 
the positive epitope G40-R43 will be strongly directed downwards making the epitope not 
available for binding. The result of the assay is expressed as a ratio between the optical densities 
(OD) measured with the hydrophobic plate versus the hydrophilic plate. A ratio higher than two 
indicates DI reactivity of the sample.  
This two-step antiDI ELISA has been utilized in three studies 16,38,46. In a single-center study 
including 198 patients with various systemic autoimmune diseases both IgG antiDI and IgG 
antiβ2GPI  antibodies measured with an in-house ELISA correlated strongly with a history of 
thrombosis [OR 18.9, 95% confidence interval (95% CI) 6.8-52.3; OR 6.7, 95% CI 3.4-13.5, 
respectively] 38. In contrast, those with affinity for other domains of β2GPI were not significantly 
correlated with thrombosis (OR 1.1, 95% CI 0.4-2.8). Interestingly, only 58% of IgG antiβ2GPI  
positive patients were IgG antiDI positive, and 93% of the antiDI positive samples proved to be 
LAC positive 38. These findings were confirmed in the consecutive multicenter study conducted 
on 442 patients positive for IgG/IgM antiβ2GPI  16. The prevalence of IgG antiDI antibodies 
positivity was 57% and IgG antiDI was significantly associated with thrombosis (OR 3.5, 95% CI 
2.3-5.4) and with obstetric complications (OR 2.4, 95% CI 1.4-4.3). On the other hand, no 
significant positive correlation was found for IgG antiβ2GPI  with obstetric complications (OR 1.5, 
95% CI 0.6-3.7), nor for IgG reactive against other domains of β2GPI with thrombosis (OR 0.4, 95% 
CI 0.3-0.6) 16. 
In a separate study, 25% of 183 children with systemic lupus erythematosus (SLE) were found to 
be antiDI positive, whereas all pediatric controls were negative 46. A multivariate analysis showed 
that both the presence of antiDI antibodies and LAC are independently associated with reduced 
annexin A5 anticoagulant activity 46. Due to the relatively low rate for histories of thrombosis 
(3.8%) in the population, the study was not sufficiently powered to determine the association of 
antiDI antibodies with thrombosis. 
2.2 In-house developed direct antiDI ELISA  
In addition to the baculovirus system for recombinant DI, a bacterial expression system to 
produce human DI 47 was used to develop a simple direct ELISA that does not require the usage 
of hydrophobic versus hydrophilic plates. In a population consisting of 22 APS patients, 20 SLE 
patients and 10 healthy controls, significantly higher binding was observed for polyclonal purified 
IgG from APS patients compared to that from the other groups 35. Interestingly, the creation of 
multiple mutants of DI using the same bacterial system identified that aside from G40-R43 also 
R39, the domain I-II interlinker, and possibly D8 and D9 play a major role in the binding to 
antibodies 35. 
This assay has been used for detection of IgG antiDI in two studies 48,49. In a population of 40 
seropositive APS and 40 seronegative APS patients (i.e. individuals with typical clinical features 
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highly suggestive for APS, but persistently negative for laboratory criteria), the prevalence of 
antiDI positivity was 27.5% in seropositive APS and 7.5% in seronegative APS 48. Additionally in a 
population of 111 APS patients, 119 SLE patients and 200 healthy controls, a lower sensitivity of 
the IgG antiDI compared to IgG antiβ2GPI  measured by an in-house ELISA for APS (40.5% versus 
64.8%) was demonstrated 49. Single positivity for IgG antiDI (hazard ratio (HR) 6.6, 95% CI 3.8-
11.4) was strongly associated with APS, but to a lesser extent than single IgG antiβ2GPI  (HR 33.4, 
95% CI 13.0-86.1). However, in the same study, of 136 patients positive for IgG antiCL or 
antiβ2GPI , 52 were also IgG antiDI positive, and the presence of IgG antiDI positivity raised the 
HR for APS approximately 3-fold [(HR 36.9, 95% CI 17.7-76.9) versus (HR 11.5, 95% CI 6.3-21.0)]. 
In addition, positivity for IgG antiDI increased the strength of association between 
antiCL/antiβ2GPI  positivity measured by an in-house ELISA and thrombotic manifestations in the 
group of 111 patients with APS, suggesting antiDI positivity can be used for thrombotic risk 
stratification. None of the tested profiles was significantly associated with pregnancy morbidity 
49.  
2.3 In-house developed competitive inhibition ELISA 
A competitive inhibition ELISA assay was developed in which a chemically synthesized DI 50 was 
used to inhibit binding of antibodies in APS patients plasma to whole β2GP1 immobilized on a 96 
wells plate 51. In this assay, at first the DI concentration able to inhibit 50% of patient IgG binding 
to β2GPI (IC50) was calculated. Consecutively, this concentration of DI was used to calculate the 
percentage inhibition obtained in different patient categories. The level of inhibition proved to 
be higher in samples from triple positive APS patients (positive for LAC, IgG antiCL and IgG 
antiβ2GPI ) compared to double (positive for IgG antiCL and IgG antiβ2GPI ) or single positive 
(positive only for IgG antiβ2GPI ) APS patients and healthy controls 51. Since triple positive APS 
patients are at high risk of developing future thromboembolic events 52, this result supports the 
idea that IgG antiDI antibodies play an important pathogenic role 51. Interestingly, in preliminary 
experiments, antiDI antibodies were not detected by direct coating of DI onto ELISA plates. More 
specifically, when plasma from APS patients and healthy controls was tested for IgG binding to 
the same chemically synthesized DI coated on either a hydrophobic or a hydrophilic plate, the 
IgG antiDI levels did not differ between APS patients and healthy controls 51.  
2.4 Commercially developed antiDI ELISA  
The first commercially developed assay to measure antiDI antibodies was from INOVA 
Diagnostics. Recombinant DI of β2GP1 was expressed and purified from the baculovirus 
expression system 34. This assay has been used for detection of IgG antiDI in three patient studies 
24,40,53. 
Using this ELISA, IgG antiDI antibodies were found to be the most prevalent antibodies (75%) in 
64 patients with APS 24. A low prevalence of IgG antiDI was reported in 57 healthy children born 
to mothers with various systemic autoimmune diseases (AID) and 33 children with atopic 
dermatitis (16% and 27%, respectively). On the other hand, IgG antibodies recognizing DIV/DV of 
β2GPI were preferentially detected in children (37% and 33%, respectively), whereas isolated IgG 
antiDIV/DV was rare (5%) in APS and not associated with thrombosis. This study speculated that 
antibodies targeting DI are pathogenic, whereas those reactive with DIV/DV are probably 
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‘innocent’ 24. In another study including 159 antiβ2GPI  positive patients (measured by an in-
house ELISA) 40, 70% of the 87 patients with primary APS (PAPS) were positive for antiDI reactivity. 
30 asymptomatic aPLs-carriers displayed significantly lower levels of antiDI IgG and higher levels 
of antiDIV/DV compared to the PAPS group and the rheumatic disease (RD) group. Interestingly, 
no association was found between IgG antiDI and APS classification, thrombosis and obstetric 
complications in a multivariate logistic regression model, although compared to patients with a 
single event, those with recurrent thrombosis displayed significantly higher titers of IgG antiDI 40. 
Likewise, IgG antiDIV/DV positivity was not associated with APS clinical manifestations 
thrombosis and pregnancy morbidity 40,54. However, positive antiDI reactivity was associated with 
triple positivity, suggesting it may be used as a risk stratification tool in APS patients. Additionally, 
the ratio of antiDI to antiDIV/DV antibodies in this study emerged as an informative tool to 
identify those subjects carrying “nonpathogenic” or “less-pathogenic” antiβ2GPI  antibodies 40. 
Another study including 326 SLE patients showed that IgG antiβ2GPI  (measured by Quanta Lite 
ELISA,INOVA) but not IgG antiDI reactivity was significantly associated with thrombosis (OR 3.3, 
95% CI 1.2-8.9; OR 1.1, 95% CI 0.4-2.9, respectively) 53.  
2.5 CLIA for antiDI 
Using the same recombinant DI of β2GP1 from the baculovirus expression system 34 coupled to 
paramagnetic beads, more recently a CLIA assay 55 has been developed for the measurement of 
antiDI antibodies. After incubation of the paramagnetic beads with serum samples, isoluminol-
labeled anti-human IgG antibodies are incubated with the aPLs previously captured by the 
paramagnetic particles. Finally, an agent is added to induce chemiluminescence. Currently, two 
systems are available that measure antiDI antibodies using this technology, including the BIO-
FLASH CLIA from INOVA Diagnostics, Werfen, Austria and the HemosIL Acustar CLIA from 
Instrumentation Laboratory, Bedford, MA, USA. The BIO-FLASH CLIA and the HemosIL Acustar 
CLIA are identical assays using the same analytic method and reagent kits. Since 2014, this 
commercially available CLIA antiDI assay has been evaluated in 17 published studies 15,17,54,56-69. 
For the classification of APS, the CLIA IgG antiDI assay has a higher specificity (from 82.1% to 
100.0%) and a lower sensitivity (from 35.9% to 62.5%) compared to IgG antiβ2GPI  test (from 
71.7% to 99.1 % and from 46.2% to 82.3% for specificity and sensitivity, respectively) among 
seven studies (summarized in Table 2). For the association with clinical manifestations of APS, 
the ORs of IgG antiDI assays varied in eleven studies, ranging from 3.3 to 31.5 for thrombosis and 
from 1.5 to 14.6 for obstetric symptoms, probably originating from different patient and control 
cohorts and different cut-off values (summarized in Table 3). Few studies failed to demonstrate 
a significant association of antiDI reactivity with thrombosis 63,68. In one study on thrombotic APS 
patients, 54% of the patients displayed antiβ2GPI  antibodies, versus only 25% for antiDI 63. IgG 
antiDI proved not to be associated with the site of the first event of thrombosis (OR 0.6, 95% CI 
0.2-1.9), thrombosis recurrence (OR 1.0, 95% CI 0.4-2.7) nor pregnancy morbidity (OR 1.5, 95% 
CI 0.3-7.3) 63. Another study in 178 SLE patients indicated that both the IgG antiDI titer and IgG 
antiβ2GPI titer were not associated with venous events (n = 22), arterial events (n = 20), 
composite venous events or arterial events (n = 37), respectively (P = 0.90, 0.76 and 0.89 for IgG 
antiDI titer and P = 0.86, 0.84 and 0.86 for IgG antiβ2GPI titer, respectively) 68. Looking at a total 
population of 426 APS and control patients or at a subpopulation of 74 IgM/IgG antiβ2GPI  
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positive patients, IgG antiDI positivity was significantly associated with thrombosis (OR 14.4, 95% 
CI 6.0-34.8 and OR 31.5, 95% CI 5.4-182.1, respectively) 60. However, in a subgroup of 60 
antiβ2GPI  IgG positive patients from the same study no significant association of IgG antiDI 
positivity with thrombosis was observed (OR 10.3, 95% CI 0.6-166.7) 60. On the other hand, three 
out of five studies indicated IgG antiDI was associated with pregnancy morbidity 54,59,62. In a cross-
sectional study with 65 positive antiβ2GPI  IgG patients, pregnancy loss was present in 16 out of 
39 women (41%) positive for antiDI reactivity and in three out of 19 women (16%) with negative 
values. The association of IgG antiDI with obstetrical APS nearly reached statistical significance 
(P = 0.07) 59. In a case-control study including 195 control women, 199 non-severe pre-eclampsia 
patients and 143 severe pre-eclampsia patients, antiDI IgG reactivity was associated with severe 
pre-eclampsia patients in the univariate analysis. However, in the final multivariate analysis, 
positive anti-β2GP1 IgG but not positive IgG antiDI was identified as a risk factor for severe pre-
eclampsia 62. A recently published study including 135 well-characterized female patients with 
persistent medium-high titre of antiβ2GPI  antibodies and at least one pregnancy showed that 
reactivity against DI is a predictor for pregnancy morbidity (OR 2.4, 95% CI 1.2-5.0) 54. More 
specifically, IgG antiDI significantly predicted late pregnancy morbidity (OR 7.3, 95% CI 2.1-25.5) 
54. In addition to the clinical symptoms of APS included in the criteria, one study in 32 APS patients 
indicated that the non-criteria manifestations livedo reticularis (n = 8) and heart value disease (n 
= 9) were associated with higher levels of IgG antiDI (p = 0.005 and P = 0.01, respectively) 56.  
Furthermore, several studies assessed whether testing for antiDI adds value to current criteria 
laboratory tests (summarized in Table 3). Upon comparison of IgG antiDI assays and IgG 
antiβ2GPI  assays, in four of seven studies the ORs of IgG antiDI exceeded those of IgG antiβ2GPI  
for clinical manifestations (three for thrombosis, one for thrombosis and pregnancy morbidity) 
15,17,57,61. In the remaining three studies, despite significant correlation of IgG antiDI with the 
clinical manifestations of APS, ORs of IgG antiDI positivity proved to be lower than IgG antiβ2GPI  
positivity 60,62,65. In severe pre-eclampsia patients, a significant association was shown for IgG 
antiβ2GPI  but not IgG antiDI in the final multivariate analysis 62. Of note, one study also 
investigated the clinical significance of testing for IgG targeting other domains of β2GPI: neither 
thrombosis nor pregnancy morbidity was significantly correlated with IgG targeting other 
domains of β2GPI 17.  
Different score systems have been formulated to quantify the risk of thrombosis/obstetric events 
in APS, including triple positivity (i.e. positive for LAC, IgG or IgM antiCL, IgG or IgM antiβ2GPI ) 70 
and antiphospholipid score (aPL-S) 71. Eleven studies showed that triple positive patients tend to 
have a significantly higher prevalence and higher levels of IgG antiDI than those with double-
positive or single-positive profile (summarized in Table 4). In 180 patients with hypercoagulability, 
the thrombotic risk of the newly defined triple positive group (positive for LAC, IgG antiCL, IgG 
antiDI) was more than twice than that of the triple positive group (positive for LAC, IgG antiCL, 
IgG antiβ2GPI ) 15. Similarly, in 138 SLE patients, the test results of IgG antiDI raised the accuracy 
of predicting thrombosis compared to the test results of antiCL/ antiβ2GPI -ELISA, resulting in an 
increased area under the receiver operating characteristic (ROC) curve (AUC) (0.84 versus 0.80, 
respectively) 67. However, in a retrospective study including 202 AID patients adding positivity for 
antiDI to the triple positivity profile did not increase the predicting capacity for APS thrombotic 
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complications 65. Similar results were obtained in a cohort study in which no added value was 
demonstrated for antiDI to the criteria panel 60. Also in this study, patients with a high aPL-S were 
shown to display higher titers of antiDI IgG 60. In another study, an adjusted aPL-S was determined, 
measuring reactivity against DI instead of the whole molecule β2GPI (aPL-S-DI) 57. When 
comparing the aPL-S-DI with the traditional aPL-S reaching the same specificity of 95%, the aPL-
S-DI resulted in slightly lower OR for clinical symptoms of APS. However, when the optimal cut-
off for each aPL-S was calculated, the aPL-S -DI resulted in the highest relative risk of having 
clinical manifestations of APS 57. In a separate study, testing IgG antiDI and IgG/M anti-
phosphatidylserine/prothrombin (PS/PT) showed a high positive predictive value for the 
diagnosis of APS and a strong correlation with the aPL-S was obtained 66. Similarly, the thrombotic 
risk associated with the combination of IgG anti-PS/PT and IgG antiDI was elevated 4.5 times 
compared to double positivity for IgG anti-PS/PT and IgG antiβ2GPI 15. 
3.Combined results on the clinical value of antiDI 
antibodies 
3.1 Inconsistency on clinical value of antiDI antibodies  
Most studies have shown that antiDI positivity significantly correlates with clinical manifestations 
of APS (Table 2, 3 and 4). In terms of clinical performance, compared with the antiβ2GPI  assays 
the antiDI assays in general seem to be less sensitive, but (slightly) more specific for the diagnosis 
of APS (Table 2). As the antiDI assays detect a pathogenic subpopulation of antibodies, the ORs 
for manifestations of APS were expected to be higher than the ORs of full length antiβ2GPI  assays. 
However, results were inconsistent and dependent on the assays used to detect both antiβ2GPI  
and antiDI reactivity (Table 3). Nonetheless, significantly higher titers and prevalence of antiDI 
antibodies were found in high risk patients with triple positivity compared with double and single 
positive patients (Table 4). Moreover, adding of IgG antiDI or IgG antiDI instead of IgG antiβ2GPI  
in combined positive profile markedly raised the correlation with the risk of thrombosis in APS in 
several studies 15,49,66,67. Furthermore, as with triple positivity, positive and negative values of IgG 
antiDI in initial test were consistently confirmed after 12 weeks, illustrating that IgG antiDI 
positivity is a robust and reproducible marker 59,72. 
For different assays detecting IgG antiDI, the two-step antiDI ELISA in particular showed that the 
ORs of IgG antiDI are markedly higher than the OR of IgG antibodies targeting the whole length 
β2GPI or other domains of the protein 16,38. Moreover, this assay emphasized the exposure of 
epitope G40-R43 domain I is important for antibody binding. CLIA is currently the most widely 
used method to detect IgG antiDI antibodies. IgG antiDI measured by CLIA seem to represent a 
strong indicator for clinical manifestations of APS. However, the results of the added clinical value 
of IgG antiDI are not consistent. Some studies showed that antiDI display no added clinical value 
to the classical aPLs panel 60,62,65. None of the remaining three assays, the direct antiDI ELISA, the 
competitive inhibition ELISA and the commercial developed INOVA antiDI ELISA showed an added 
value of IgG antiDI compared to IgG antiβ2GPI. Taken together, the observed inconsistency 
probably explains why antiDI antibodies have not yet been included in the laboratory criteria 19. 
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Table 2. Clinical performance characteristics of different IgG antiDI assays: the sensitivity and specificity 
for APS 
APS: antiphospholipid syndrome; AID: non- APS autoimmune diseases; AU: arbitrary unit; β2GPI: β2-
glycoprotein I; CLIA: chemiluminescence immunoassay; CS: cross-sectional study; CU: chemiluminescence 
units; CTD: connective tissue diseases; DC: disease control i.e. non-APS with clinical symptoms of APS 
(thrombosis, pregnancy complication); DI: domain I of β2GPI; ELISA: enzyme-linked immunosorbent assay; 
GDIU: IgG antiDI units; GBU: IgG anti- β2GPI units; HC: healthy control; ID: infectious disease; IU: 
international units; LLD: lupus like disease; Mean ± 3 or 10SD: mean optical density (OD) plus 3 or 10 times 
standard deviation (SD); Manuf.: manufacturer; N: number of population; NA: not application; NS: not 
specified; SLE: systemic lupus erythematosus; non-SLE CTD: non-SLE connective tissue diseases; PAPS: 
primary antiphospholipid syndrome; R: retrospective study; RD: rheumatic disease; SN-APS: seronegative 
APS; U: units; 99thp.: 99th percentile.  *IgG and/or IgM positive, ** for APS thrombotic complications. 
  
Year First author Design Patients N Control N Assay Cut-off Sensitivity Specificity Assay Cut-off Sensitivity Specificity
2009 de Laat B 16
R,multi-
center APS 364 SLE+LLD 78
Two-step 
ELISA Mean ± 3SD 59.9% 67.9%
In-house 
ELISA Mean ± 10SD NA NA









































49 R APS 111 SLE+HC 319 Direct ELISA
10.0 GDIU 
(99thp.)





2016 Zhang S 17 R APS 86 DC+SLE+ HC 143 CLIA
20.0 CU 
(Manuf.) 46.5% 97.9% CLIA NS 66.3%* 92.3%*
2017 Iwaniec T 65 R,CS APS 103 SLE 99 CLIA
13.8 CU 
(99thp.)
62.5%** 82.1%** CLIA NS 82.3%** 71.7%**
2017
Nakamura H 
66 CS APS 51 AID 106 CLIA
20.0 CU 
(99thp.)





Publication Study population IgG antiDI IgG antiβ2GPI 
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Table 3. Clinical performance characteristics of different IgG antiDI assays: the correlation of IgG antiDI 
with clinical manifestations of APS by odd radios (ORs)  
 
APS: antiphospholipid syndrome; AID: non- APS autoimmune diseases; aPLs-carriers: asymptomatic 
antiphospholipid antibodies carriers; AU: arbitrary units; β2GPI: β2 glycoprotein I; CC: case-control; CLIA: 
chemiluminescence immunoassay; CS: cross-sectional study; CU: chemiluminescence units; DC: disease 
control, i.e. non-APS with clinical symptoms of APS (thrombosis, pregnancy complication); DI: domain I of 
β2-glycoprotein I (β2GPI); ELISA: enzyme-linked immunosorbent assay; HC: healthy control; IU: 
international units; LLD: lupus like disease; Mean ± 3 or 10SD: mean optical density (OD) plus 3 or 10 times 
standard deviation (SD); Manuf.: manufacturer; N: number of population; NA: not application; NS: not 
specified; NS-PEecl: non-severe pre-eclampsia; OR (95% CI): odds ratio (95% confidence interval); P: 
pregnancy morbidity; PAPS: primary antiphospholipid syndrome; R: retrospective study; RD: rheumatic 
disease; SLE: systemic lupus erythematosus; S-PEecl: serve pre-eclampsia; T: thrombosis; U: units; 
95th/97th/99th/99.5thp.: 95th/97th/99th/99.5th percentile. *by univariate analysis; **by multivariate analysis.  
®OR (95% CI) for venous thrombosis; #OR (95% CI) for P: only women with at least 1 previous pregnancy 
were included; $OR (95% CI) for P: only women were included; §OR (95% CI) for P: only married women of 




Design Population N Assay Cut-off OR (95%CI) for 
T
OR (95%CI) for 
P
OR (95%CI) for 
T/P
Assay Cut-off OR (95%CI) for 
T
OR (95%CI) for 
P
OR (95%CI) for 
T/P
2005 de Laat B 
38
R 176 SLE+16 LLD+6 PAPS 198 Two-step 
ELISA
Mean ± 3SD 18.9 (6.8-53.2) NS NS In-house 
ELISA
Mean ± 3SD 6.7 (3.4-13.5) NS NS
IgG antiβ2GPI  positive 52 Two-step 
ELISA
Mean ± 3SD 10.7 NA NA In-house 
ELISA
Mean ± 3SD NA NA NA
2009 de laat B 16 R,multic
erter
IgG/ IgM antiβ2GPI  




Mean ± 3SD 3.5 (2.3-5.4) 2.4 (1.4-4.3) # NS In-house 
ELISA
Mean ± 10SD NA 1.5 (0.6-3.7) # NA
IgG antiβ2GPI  positive 420 Two-step 
ELISA
Mean ± 3SD 3.3 (2.1-5.2) NS NS In-house 
ELISA
Mean ± 10SD NA NA NA
2013 Akhter E 53 CS SLE 326 Commercial 
ELISA
25.0 U (97thp.) 1.1 (0.4-2.9) NS NS Commercial 
ELISA
NS 3.3 (1.2-8.9) NS NS
2014 Mondejar 
R 57
R 39 APS+47 RD+30 HC 116 CLIA 20.0 AU 
(99thp.) 
NS NS 21.0 (4.5-98.9) CLIA 20.0 AU 
(99thp.) 
NS NS 8.6 (3.2-23.3) 
2015 Andreoli L 
40
R IgG antiβ2GPI  positive (87 




15.0AU (95thp.) 1.7 2.4# NS Commercial 
ELISA
NS NA NA NA






R 101 APS+123 AID+ 82 
DC+120 HC
426 CLIA 20.0 CU 
(Manuf.) 
14.4 (6.0-34.8) NS 17.0 (7.1-40.5) CLIA 60.0 IU/ml 
(99thp.) 
29.2 (8.8-95.9) NS 36.2 (11.1-
117.9) 
IgG/ IgM antiβ2GPI  
positive






CLIA 60.0 IU/ml 
(99thp.) 
NS NS NS




NS 6.6 (0.5-89.8) CLIA 60.0 IU/ml 
(99thp.) 
NA NA NA
2016 Mahler M 
61
CS APS 106 CLIA 20.0 CU 
(99.5thp.) 
4.0 NS NS CLIA 20.0 CU 
(99.5thp.) 
2.3 NS NS
CLIA 190.2 CU 
(optimized) 





CC 143 S-PEecl+199 NS-
PEecl+195 HC
537 CLIA 14.4 AU(99thp.) NA 14.6 (1.8-
115.6) *#
NS CLIA 17.0 IU/ml 
(99thp.) 
NS 16.9 (3.7-77.1) 
**#
NA
2016 Zhang S 17 R 86 APS+62 DC+42 SLE+39 
HC
229 CLIA 20.0 CU 
(Manuf.) 
3.3 (1.6-6.7) 1.6 (0.6-3.7) § NS CLIA NS 2.8 (1.5-5.1) 1.3 (0.6-2.7) § NS
2017 Iwaniec T  
65
R,CS 103 APS+99 SLE 202 CLIA 13.8 CU (99thp.) 7.6 (4.0-14.5) NS NS CLIA NS 11.8 (6.0-23.0) NS NS
2017 Lee JS 15 R hypercoagulability 180 CLIA 40.0 CU (99th 
p.) 
15.4 (4.3-54.9) NS NS CLIA 20.0 CU (99th 
p.) 
2.5 (0.98-6.5) NS NS
2017 Nojima J 67 SLE 138 CLIA NS 9.2 (2.5-34.2)® NS NS ELISA NS NS NS NS
2018 Chighizola 
CB 54
CC women IgG antiβ2GPI  
positive
130 CLIA 20,0 CU (NS) 5.4 (2.4-12.0) 2.4 (1.2-5.0) NS CLIA 20.0 CU (NS) NA NA NA
Publication Study IgG antiDI IgG antiβ2GPI 
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Table 4. The prevalence of IgG antiDI positive in triple, double and single positive patients  
 
AU: arbitrary units; CLIA: chemiluminescence immunoassay; CS: cross-sectional study; CU: 
chemiluminescence unit; DI: domain I β2-glycoprotein I (β2GPI); ELISA: enzyme-linked immunosorbent 
assay; HC: healthy control; Manuf.: manufacturer; N: number of population; NA: not applicable; NS: not 
specified; R: retrospective study; SN-APS: seronegative APS; 95th/99thp.: 95th/99th percentile; S*: 
significantly higher prevalence or levels of IgG antiDI positive were found in patients with triple positivity, 
compared with patients with double and single aPL positivity; &: median value of IgG antiDI; §: mean ± 
standard deviation (SD) value of IgG antiDI; A: IgG triple positive = positive lupus anticoagulant (LAC) , IgG 
antiCL, IgG antiβ2GPI ; B: Triple positive = positive LAC, IgG or IgM antiCL, and IgG or IgM antiβ2GPI . 
  
Year First author Design Population N Assay Cut-off Prevalence P value
Triple positive A 22 25.5%
Double positive 15 5.0%
Single positive 9 2.0%
Control 20 0.0%
Triple positive B 87 80.4%
Double/single positive 72 48.6%
Triple positive B NS 94.1%
Double positive NS 45.5%
Single positive NS 4.8%
SN-APS/HC NS 1.6%/0.6%
Triple positive A 32 97.0%
Double positive 23 43.0%
Single positive 10 10.0%
Triple positive B 62 83.9%
Double positive 4 50.0%
Single positive 4 0.0%
Triple negative 222 0.9%
Triple positive B 13 46.0%
Double/single positive 28 17.0%
2016 Zhang S 17 R Triple/Double/single positive B 229 CLIA 20.0 CU (Manuf.) NS S*
Triple positive B 79 308.2 &
Double positive 10 6.2 &
Single positive 14 2.0&
Triple positive A 17 58.8%
Double positive 27 7.4%
Single positive 93 0.0%
Triple negative 43 0.0%
Triple positive B 82 195.0 ± 628.3§
Double/single positive 53 4.0 ± 11.0§
Triple positive B 22 365.4 ± 596.1§
Double positive 13 137.9 ± 434.1§
Single positive 40 3.8 ± 8.7§
S*








2015 Andreoli L 40 R
Commercial 





58 R CLIA 7.1 CU (99thp.) S*









R CLIA 20.0 CU (Manuf.)
S*
2017 Iwaniec T 65 R,CS CLIA 13.8 CU (99thp.) S*











CLIA 14.4 AU (99 thp.)
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3.2 Towards an explanation for the observed discrepancies 
The studies included in this review differ in study design, study population and the methodology 
to measure the antiDI antibodies. These factors, together with the absence of standardization or 
calibration, make it very difficult to compare results of clinical studies and accurately assess the 
clinical value of measuring antiDI. Even using the same assay for detection of antiDI has led to 
discrepant results in determination of the added value of antiDI antibodies. Differences in 
methods of calculating cut-off values, statistical analysis method, laboratory-specific handlings 
or protocols and different study populations may affect the interpretation of the results and lead 
to the observed discrepancies. Two studies independently showed the effect of different cut-off 
values: increasing cut-off values resulted in significantly higher ORs 61,73. One study including 
patients with APS, AID, disease controls and healthy controls showed different results for 
correlation of IgG antiDI positivity with thrombosis in the total population of 426 patients versus 
in 60 IgG antiβ2GPI  positive patients 60.  
A similar situation is observed for the antiβ2GPI  assays, in which external quality assessment 
program reports show a wide variability in results over different centers 74-77. Previous research 
has shown the importance of a certain antigen density to enable divalent binding of antibodies 
78,79, as well as a hydrophilic solid phase surface to coat β2GPI thereby inducing a conformational 
change resulting in the exposure of a cryptic pathogenic epitope in DI. Antibodies directed to this 
cryptic epitope G40-R43 are a major pathological subset of antibodies 27-29,35-38,41. Hence, results 
obtained by antiβ2GPI  assays depend on the density and the conformation of the coated β2GPI 
(i.e. the exposure of the epitope G40-R43), which are affected by the type of solid phase surface 
used to immobilize β2GPI and source of protein. As in antiDI assays DI is coated instead of the 
full protein, similar problems were not expected. However, taken into account the positive 
charge of epitope G40-R43, the charge of the coating surface possibly influences the availability 
of the G40-R43 epitope. A neutral coating surface is hypothesized to result in an arbitrary 
orientation of the DI, resulting in exposure of epitope G40-R43. On the other hand, a negative 
surface binds the positive epitope preventing its availability for antibodies. Based on this 
hypothesis and the evidence provided with the two-step ELISA, we assume that the differences 
in the type of solid phase surface used to immobilize DI and hence the exposure of the pathogenic 
DI epitope in the available antiDI assays that add up to the variation in results. Looking at the 
other antiDI assays, a possible charge of the beads cannot be excluded, rendering the exposure 
of epitope G40-R43 on DI uncertain. Exactly the same question can be made for the other 
available assays, as except for the two- step antiDI ELISA, the charge of the solid phase surfaces 
used to immobilize DI are unknown. This may provide an explanation why both studies using the 
commercially developed antiDI ELISA from INOVA Diagnostics to measure antiDI showed that 
there is no significant association with thrombosis 40,53. A clinical study using an in-house 
developed direct antiDI ELISA showed significantly but less clinical value of antiDI compared to 
antiβ2GPI  49. Similarly, although with a competitive inhibition antiDI ELISA a significant difference 
was found in patients with triple positivity compared with patients with double or single positivity 
and healthy controls, a direct antiDI ELISA with the same DI did not find differences in IgG antiDI 
between APS patients and controls, independent of using hydrophobic or hydrophilic plates, 
different coating/washing/blocking buffers and concentrations of DI 51. In addition, although CLIA 
Review: the clinical value of assays detecting antiDI in APS  
43 
2 
can provide a greater surface for antibodies binding to DI, three studies showed significantly but 
less clinical value of IgG antiDI compared to IgG antiβ2GPI  60,62,65. This problem seems to be 
avoided in the in-house developed two-step ELISA, where the ratio between the OD measured 
with a hydrophobic plate versus hydrophilic plate is used to determine positivity.  
We aimed to verify our hypothesis by determining the exposure of the pathogenic G40-R43 
epitope in the commercially available aDI CLIA method. Therefore, normal pooled plasma was 
spiked with two human-derived monoclonal antibodies P1-117 and P2-6. Antibody P1-117, 
recognizing epitope G40-R43 only available when β2GPI is in its open conformation, and P2-6, 
recognizing domain I independently of its conformation 80.  Our unpublished results show that 
P2-6 can be detected while no signal is obtained for P1-117 (data not shown). Contrary to the 
expectation, this antiDI assay thereby does not expose the epitope G40-R43 on the surface of the 
beads, therefore patient samples with antibodies recognizing the epitope G40-R43 will be missed. 
Our results are consistent with previous results obtained with the CLIA antiβ2GPI  assay (HemosIL 
Acustar) in which P1-117 showed lower reactivity compared to P2-6, demonstrating a reduced 
G40-R43 availability 81. In addition, a high agreement (69%～92%) was observed between 
antiβ2GPI  and antiDI in the same CLIA device 17,59,60,65, suggesting that both assays measure 
almost the same antibody population directed against domain I but not to the G40-R43 epitope. 
On the other hand, two studies detecting IgG antiDI using the two-step ELISA found that 
approximately half (58% and 57%, respectively) of IgG antiβ2GPI  bound DI 16,38. Taken together, 
these results suggest that the two-step ELISA measures a more specific antiDI antibody 
population directed against G40-R43, compared to the commercially available antiDI CLIA assay 
detecting all antibodies to domain I, as well as to other domains. As a result, the two-step ELISA 
did show an added clinical value of the antiDI positivity compared to the full-length antiβ2GPI , 
demonstrated by the higher OR for thrombosis and pregnancy morbidity 16,38. Our data highlight 
the importance of not only measuring G40-R43 exposure in the full length antiβ2GPI  assays, but 
also in the antiDI assays to be certain that at least this pathogenic antibody population is not 
missed.  
Apart from the coating principle, also the density of the coated DI and the source of DI may 
influence the results. Regarding the density, especially the CLIA with paramagnetic beads provide 
a three-dimensional platform and larger surface for antibodies binding to DI 82. Three different 
sources of DI are used in the available assays: DI obtained through a baculovirus expression 
system, an Escherichia Coli expression system or by a chemical synthesis. So far, the effect of 
production on the conformation of DI and hence the availability of the pathogenic G40-R43 
epitope is not known.  
4. Conclusion 
In summary, given all the in vitro and in vivo evidence, antiDI assays were expected to be very 
powerful in the classification of APS patients. The majority of clinical studies did find a significant 
association of antiDI antibodies with clinical symptoms of APS and a higher specificity was 
demonstrated compared with antiβ2GPI  antibodies. As specifically antibodies to DI are detected, 
a more uniform result was expected, resulting in an improved risk stratification and tailored 
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treatment for APS patients. However, multiple antiDI assays are available and suffer from the 
same problems as the full-length antiβ2GPI  assays. To assess the added value of antiDI assays, 
several important issues urgently need to be addressed. As for antiβ2GPI  assays, standardization 
of antiDI assays is of utmost importance. This standardization in our view also includes the 
confirmation of a satisfactory exposure of the epitope G40-R43 to ascertain that at least one 
specific pathogenic antibody population is measured. Additionally, so far only retrospective 
studies were performed to determine the added value of DI antibodies. Prospective, well 
designed multicenter studies are urgently required to clarify the clinical utility of the antiDI assays.  
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Background: Classification of the antiphospholipid syndrome (APS) relies predominantly on 
detecting antiphospholipid antibodies (aPLs). Antibodies against a domain I (DI) epitope of anti-
β2 glycoprotein I (β2GPI) proved to be pathogenic, but are not included in the current 
classification criteria. 
Objectives: Investigate the clinical value of detecting antiDI IgG in APS. 
Patients/Methods: From eight European centers 1005 patients were enrolled. Anti-cardiolipin 
(CL) and antiβ2GPI were detected by four commercially available solid phase assays; antiDI IgG 
by the QUANTA Flash® β2GPI domain I assay.  
Results: Odds ratios (ORs) of antiDI IgG for thrombosis and pregnancy morbidity proved to be 
higher than those of the conventional assays. Upon restriction to patients positive for antiβ2GPI 
IgG, antiDI IgG positivity still resulted in significant ORs. When antiDI IgG was added to the criteria 
aPLs or used as a substitute for antiβ2GPI IgG/antiCL IgG, ORs for clinical symptoms hardly 
improved. Upon removing antiDI positive patients, LAC remained significantly correlated with 
clinical complications. AntiDI IgG are mainly present in high-risk triple positive patients, showing 
higher levels. Combined antiDI and triple positivity confers a higher risk for clinical symptoms 
compared to only triple positivity. 
Conclusions: Detection of antiDI IgG resulted in higher ORs for clinical manifestations than the 
current APS classification criteria. Regardless of the platform used to detect antiβ2GPI/antiCL, 
addition of antiDI IgG measured by QUANTA Flash® did not improve the clinical associations, 
possibly due to reduced exposure of the pathogenic epitope of DI. Our results demonstrate that 
antiDI IgG potentially helps in identifying high risk patients.
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Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by recurrent 
thrombosis and/or pregnancy morbidity in combination with the persistent presence of 
antiphospholipid antibodies (aPLs) 1. Due to the high prevalence of thrombosis and pregnancy 
morbidity in the general population, classification of APS mainly relies on laboratory results 2. 
Five different assays that detect aPLs are included in the current revised laboratory criteria: lupus 
anticoagulant (LAC), detecting a phospholipid-dependent prolongation of in vitro clotting times 
and two immunological quantitative assays measuring immunoglobulin (Ig) G and/or IgM anti-
cardiolipin antibodies (antiCL) and antiβ2GPI antibodies (antiβ2GPI). Positive tests should be 
repeated with an interval of at least 12 weeks, to avoid transient positivity due to infections 3. 
Although laboratory testing of aPLs is critical to the classification of APS, the application and 
interpretation of these tests remain challenging 4,5. The variable clinical performance in 
conventional commercial and home-made aPL assays not only results from the lack of 
standardization 6,7, but also from the heterogeneity in aPLs 8.  
Accumulating evidence revealed that aPLs are directed against phospholipid-bound plasma 
proteins, of which β2GPI proved to be the main target 9-11. β2GPI consists of five homologous 
domains (Domain (D)I-DV). In the native circular or S-shaped conformation, the critical DI epitope 
is not exposed. Upon binding to an anionic phospholipid (PL) surface through the positively 
charged patch on DV, β2GPI undergoes a conformational change 12. Consequently, the DI-IV 
spreads out resulting in a more open J shape, exposing a cryptic epitope G40-R43 on DI and 
allowing a subset of antiDI of β2GPI autoantibodies to bind 13-15. Various subsets of antiβ2GPI 
antibodies targeting different domains of the protein have been described with clear differences 
in clinical potential. The subpopulation of aPLs that recognize this epitope comprising at least 
G40-R43 on DI proved to be pathogenic in vitro/in vivo, and in clinical studies 16-20, while aPLs 
that recognize other domains of β2GPI seem to be innocent 21-24 . 
The aim of this study is to assess the clinical relevance of antibodies against DI of β2GPI in APS 
patients in an international multicenter study and evaluate the added value of detecting antiDI 
IgG compared to the conventional assays, as well as whether the added value of the antiDI IgG 
assay measured by this QUANTA Flash® depends on the platform used to detect antiβ2GPI and 
antiCL IgG. The commercially available chemiluminescence (CLIA) assay for antiDI IgG was used 
in combination with antiCL and antiβ2GPI assays of different manufacturers. Assays were 
selected based on frequently used assays in the external quality control program of the ECAT 
(External quality Control of diagnostic Assays and Tests, Voorschoten, The Netherlands) and 






Patient and control samples were collected from eight medical European centers. The study was 
approved by the local ethical committees. General characteristics (e.g. age, gender, ethnicity), 
clinical characteristics (e.g. thrombotic events with specification of the type, pregnancy morbidity, 
autoimmune disease) and previous laboratory determinations (e.g. LAC tests, IgG/IgM antiCL and 
antiβ2GPI reactivity) were recorded. In total, the database enrolled 1005 samples and samples 
were allocated to six different groups according to the information of the centers.  
The classification of APS was based on the Sydney criteria 3. Classification was determined using 
the local aPL assay panel for LAC and IgG/IgM antiCL or antiβ2GPI antibodies. Control populations 
consisted of patients with an autoimmune disease other than APS (e.g. systemic lupus 
erythematosus and systemic sclerosis), meeting the criteria for the classification of autoimmune 
disease without Sydney criteria thrombotic or pregnancy morbidity complications (AID controls); 
patients that were referred for aPLs testing for other reasons than the clinical criteria of APS (e.g. 
subfertility and prolonged activated partial thromboplastin time (aPTT), normal controls); 
patients with a previous thrombotic event negatively tested for aPLs (non-APS thrombosis); and 
patients that experienced obstetric complications in the absence of aPLs (non-APS obstetric). In 
the normal control-female population (n=169) there was no history of pregnancy morbidity. Of 
the 169 women 119 (70.4%) were characterized by subfertility without previous pregnancy, of 
the 50 other control females information on whether they were (successfully) pregnant before 
was not available. 
Methodology 
AntiCL IgG, antiCL IgM, antiβ2GPI IgG and antiβ2GPI IgM were detected by four solid phase assays: 
BioPlex®2200 (Bio-Rad, Bio-Rad Laboratories, Hercules, USA), Phadia® (Thermo Fisher 
Scientific/Phadia, Uppsala, Sweden), HemosIL AcuStar® (Instrumentation Laboratories, Bedford, 
USA) and QUANTA Lite® ELISA (Inova Diagnostics, San Diego, USA). AntiDI IgG by the CLIA of 
QUANTA Flash® β2GPI domain I assay (Inova Diagnostics) on the ACL AcuStar® platform. All tests 
were performed between February 2016 and October 2016 by a single technician in the Ghent 
University Hospital following the instructions of the manufacturer. Values below the calculated 
limit of detection (LOD) were replaced by the LOD. The cut-off values from the manufacturers’ 
recommendation were confirmed in 20 healthy individuals according to the Clinical and 
Laboratory Standards Institute (CLSI) guidelines 25 and guidance from the SSC of the ISTH 5. Based 
on the cut-off values (20 arbitrary units i.e. U/mL, GPL, MPL, SGU, SMU on platforms of HemosIL 
AcuStar®, BioPlex®2200 and QUANTA Lite® ELISA, 10 arbitrary units on Phadia® for antiCL 
IgG/IgM and antiβ2GPI IgG/IgM, 20 chemiluminescence units (CU) on QUANTA Flash® for antiDI 
IgG), positive samples were identified. LAC positivity was determined by the individual center, 
according to the ISTH guidelines 7. 
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Statistical analyses were performed using IBM SPSS® Statistics 24 (IBM SPSS, New York, NY, USA). 
To avoid a possible bias induced by the classification performed by the eight individual centers, 
we selected ‘clinically affected versus clinically not-affected’ as outcome variable instead of ‘APS 
versus non-APS classification’. Relationships between the different laboratory assays and the 
clinical events (thrombosis or pregnancy morbidity) of the patients were investigated by 
calculating odds ratios (ORs) and 95% confidence intervals (95% CI) in the respective 
subpopulations. To determine the association with thrombosis and pregnancy morbidity, analysis 
was restricted to the thrombosis subpopulation (thrombotic APS, non-APS thrombosis, AID and 
normal controls (n = 851)) and the pregnancy morbidity subpopulation (obstetric APS, non-APS 
obstetric, female AID and female normal controls (n = 481)), respectively. Subsequently, the chi-
squared test was used for the comparison of dichotomous variables, and antiDI IgG titers were 
compared between groups by the Kruskal–Wallis H test (more than 2 groups) or Mann–Whitney 
U test (2 groups). Finally, the kappa agreement of antiDI IgG and conventional aPL tests was 
studied via the chi-squared test, and the correlation between the titer of antiDI IgG, antiβ2GPI 
IgG and antiCL IgG was performed by a Spearman rank correlation test. P-values less than 0.05 
(two-tailed) were considered as statistically significant.   
Results 
Characteristics of the study population 
The patients’ demographic data and clinical characteristics are summarized in Table 1. To 
evaluate associations with thrombotic events and pregnancy morbidity separately, the 
characteristics of two subpopulations are shown in Table 1A and 1B.  
Association between antiDI IgG and clinical symptoms of APS 
Independent of the platform, a significant association with clinical events was found for all tested 
aPL assays, with ORs varying from 2.7 (95%CI 1.9-3.9) to 5.4 (95%CI 3.0-9.6) for thrombosis, 2.3 
(95%CI 1.5-3.3) to 4.1 (95%CI 2.5-6.6) for arterial thrombosis, 2.0 (95%CI 1.4-2.8) to 2.8 (95%CI 
1.9-4.2) for venous thrombosis and 2.7 (95%CI 1.7-4.3) to 5.6 (95%CI 3.1-9.9) for pregnancy 
morbidity (Table 2). Compared to the criteria aPL assays, detection of antiDI IgG was less sensitive 
(21.9% / 26.6% for thrombosis / pregnancy morbidity), but more specific (94.9% / 93.9% for 
thrombosis / pregnancy morbidity), overall resulting in higher ORs for both clinical criteria of APS 
compared to LAC, antiβ2GPI or antiCL IgG except for the QUANTA Lite® ELISA platform. Similar 
ORs of antiDI were found for thrombosis and pregnancy morbidity, and no difference in 
association was observed between venous versus arterial thrombosis. Interestingly, upon 
restriction to patients positive for antiβ2GPI IgG, antiDI IgG positivity still resulted in significant - 




Table 1. Demographic and clinical characteristics of the study population.  
A. The thrombosis subpopulation (N = 851) 
  Thrombotic APS AID Non-APS thrombosis Normal controls 
Patients (N) 258 196 204 193 
Gender 
    
  Female [N(%)] 165 (64.0) 158 (80.6) 116 (56.9) 169 (87.6) 
Age (Mean ± SD, years) 49.6 ± 14.7 46.4 ± 14.2 46.5 ± 14.1 39.4 ± 11.0 
Clinical features [N (%)] 
    
  Thrombosis 258 (100.0) 0 204 (100) 0 
    AT 54 (20.9) 0 47 (23.0) 0 
    VT 160 (62.0) 0 149 (73.0) 0 
    AT + VT 26 (10.1) 0 5 (2.5) 0 
    Small vessel 4 (1.6) 0 0 (0) 0 
  Pregnancy morbidity 23 (8.9) 2 (1.0) 0 0 
   A 6 (2.3) 0 0 0 
   B 6 (2.3) 0 0 0 
   C 6 (2.3) 0 0 0 
   NS/ non-Sydney criteria 5 (1.9) 2 (1.0) 0 0 
B. The pregnancy morbidity subpopulation (N = 481)  
  Obstetric APS AID-female Non-APS obstetric Normal controls-
female 
Patients (N) 121 158 33 169 
Age (Mean ± SD, years) 34.3 ± 6.6 45.4 ± 14.5 32.7 ± 5.6 38.4 ± 9.6 
Clinical features [N (%)] 
    
  Thrombosis 9 (7.4) 0 0 0 
    AT 3 (2.5) 0 0 0 
    VT 5 (4.1) 0 0 0 
    AT + VT 1 (0.8) 0 0 0 
    Small vessel 0 (0) 0 0 0 
  Pregnancy morbidity 121 (100.0) 2 (1.3) 33 (100.0) 0 
    A 35 (28.9) 0 9 (27.3) 0 
    B 10 (8.3) 0 4 (12.1) 0 
    C 67 (55.4) 0 6 (18.2) 0 
    B+C 2 (1.7) 0  1 (3.0) 0 
    A+C 3 (2.5) 0 1 (3.0) 0 
    NS/non-Sydney criteria 4 (3.3) 2 (1.3) 12 (36.4) 0 
APS, antiphospholipid syndrome; AID, autoimmune disease other than APS; AT, arterial thrombosis; N, 
number of patients; SD, standard deviation; VT, venous thrombosis; A, history of fetal death after the 10th 
weeks of gestation; B, history of premature birth (s) before the 34th weeks due to preeclampsia or 
placental insufficiency; C, history of three or more consecutive unexplained losses before the 10th weeks 
of gestation based on the Sydney classification criteria. NS, non-specified pregnancy complications; non-
Sydney criteria, not fulfilling Sydney criteria for pregnancy morbidity  
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Table 2. ORs of aPLs for the indicated clinical manifestation of APS.  
 
 
In the pregnancy population 
  
  
Manufacturer  Pregnancy complications** 
N Sensitivity (%) Specificity (%) OR 95%CI 
LAC   481 48.7 81.7 4.2 2.8-6.4 
AntiCL IgG HemosIL AcuStar® 481 29.2 91.4 4.4 2.6-7.4 
BioPlex® 2200  481 31.8 88.1 3.4 2.1-5.5 
Phadia® 481 29.2 92.4 5.0 2.9-8.5 
QUANTA Lite ELISA®  481 24.7 93.9 5.0 2.8-9.0 
Antiβ2GPI  
IgG 
HemosIL AcuStar® 481 33.1 84.7 2.7 1.7-4.3 
BioPlex® 2200  481 31.8 87.5 3.3 2.0-5.2 
Phadia® 481 25.3 91.1 3.5 2.1-5.9 
QUANTA Lite ELISA®  481 14.3 96.0 4.0 2.0-8.2 
AntiDI IgG QUANTA Flash®  481 26.6 93.9 5.6 3.1-9.9 
Triple  
positivity 
HemosIL AcuStar® 481 22.1 93.3 3.9 2.2-7.0 
BioPlex® 2200  481 22.7 91.7 3.3 1.9-5.6 
Phadia® 481 19.5 93.6 3.5 1.9-6.4 





HemosIL AcuStar® 481 18.8 96.0 5.6 2.8-11.1 
BioPlex® 2200  481 18.8 96.0 5.6 2.8-11.1 
Phadia® 481 16.2 96.3 5.1 2.5-10.4 


















LAC 851 43.7 81.5 3.4 2.5-4.7 834 47.0 71.8 2.3 1.5-3.3 834 43.2 77.1 2.6 1.9-3.5
HemosIL AcuStar® 851 24.7 92.5 4.1 2.6-6.3 834 31.8 86.2 2.9 1.9-4.4 834 24.4 88.7 2.5 1.7-3.7
BioPlex® 2200 851 26.4 89.7 3.1 2.1-4.6 834 34.1 83.9 2.7 1.8-4.1 834 25.9 85.8 2.1 1.5-3.0
Phadia® 851 23.6 93.1 4.1 2.7-6.5 834 31.1 87.2 3.1 2.0-4.7 834 22.6 89.1 2.4 1.6-3.5
QUANTA Lite 
ELISA® 
851 21.4 94.3 4.6 2.8-7.4 834 28.8 88.6 3.1 2.0-4.9 834 20.9 90.5 2.5 1.7-3.7
HemosIL AcuStar® 851 30.1 86.4 2.7 1.9-3.9 834 36.4 80.2 2.3 1.6-3.5 834 30.0 82.8 2.1 1.5-2.9
BioPlex® 2200 851 26.2 88.7 2.8 1.9-4.1 834 34.1 83.5 2.6 1.7-3.9 834 25.6 85.0 2.0 1.4-2.8
Phadia® 851 22.5 92.3 3.5 2.6-5.4 834 29.5 87.0 2.8 1.8-4.3 834 21.8 88.7 2.2 1.5-3.2
QUANTA Lite 
ELISA® 
851 16.7 96.4 5.4 3.0-9.6 834 25.8 92.2 4.1 2.5-6.6 834 15.3 92.5 2.2 1.4-3.5
AntiDI IgG QUANTA Flash® 851 21.9 94.9 5.2 3.1-8.5 834 27.3 88.5 2.9 1.8-4.5 834 21.5 91.1 2.8 1.9-4.2
HemosIL AcuStar® 851 24.0 94.1 5.0 3.1-8.1 834 28.8 87.2 2.7 1.8-4.3 834 24.1 90.7 3.1 2.1-4.6
BioPlex® 2200 851 25.5 92.8 4.4 2.9-6.9 834 31.1 86.2 2.8 1.8-4.3 834 24.7 89.1 2.7 1.8-3.9
Phadia® 851 21.9 93.8 4.3 2.7-6.8 834 26.5 88.0 2.7 1.7-4.2 834 21.5 90.7 2.7 1.8-4.0
QUANTA Lite 
ELISA® 
851 19.3 95.6 5.2 3.0-8.9 834 24.2 90.3 3.0 1.9-4.8 834 18.5 92.5 2.8 1.8-4.3
HemosIL AcuStar® 851 18.8 96.7 6.7 3.7-12.2 834 24.2 90.9 3.2 2.0-5.1 834 18.2 93.1 3.0 1.9-4.7
BioPlex® 2200 851 19.0 96.7 6.8 3.7-12.4 834 24.2 90.7 3.1 2.0-5.0 834 18.5 93.1 3.1 2.0-4.8
Phadia® 851 16.9 96.9 6.4 3.4-11.9 834 22.0 91.9 3.2 1.9-5.2 834 16.2 93.7 2.9 1.8-4.6
QUANTA Lite 
ELISA® 
851 15.6 97.4 7.0 3.6-13.8 834 21.2 92.7 3.4 2.1-5.7 834 14.7 94.1 2.8 1.7-4.5































192 69.8 62.3 3.8 2.0-
7.4 
101 78.4 60.0 5.5 2.3-
13.1 
BioPlex® 2200  165 79.3 54.5 4.6 2.2-
9.6 
90 81.6 51.2 4.7 1.8-
12.0 
Phadia® 134 82.7 40.0 3.2 1.3-
7.8 




91 89.6 14.3 1.4 0.3-
7.6 
35 95.5 7.7 1.8 0.1-
30.6 
aPLs, antiphospholipid antibodies; APS, antiphospholipid syndrome; β2GPI, β2glycoprotein I; CL, 
cardiolipin; DI, domain I; IgG, immunoglobulin G; LAC, lupus anticoagulant; N, number of patients; OR, 
odds ratio; 95% CI, 95% confidence interval;Triple positivity, LAC positive, antiCL IgG/IgM positive and 
antiβ2GPI IgG/IgM positive.  
Significant ORs are shown in bold and calculated according to the outcome variable ‘clinically affected 
versus clinically not-affected patients’.   
*: Thrombotic APS + non-APS thrombosis versus non-thrombotic population (AID + normal controls); **: 
Obstetric APS + non-APS obstetric versus non-obstetric population (AID-female + normal controls-female).  
#: In the thrombosis subpopulation, 17 individuals without specified thrombosis type were defined as 
missing data.  
$: Arterial thrombosis versus non-arterial thrombosis; &: Venous thrombosis versus non-venous 
thrombosis. 
 
Additional clinical value of detecting antiDI IgG on top of the currently used laboratory 
tests  
Table 3 shows the number of patients testing positive or negative for antiDI IgG in relation to 
positivity for LAC or antiβ2GPI IgG or at least one of the criteria aPL panel measured by HemosIL 
AcuStar® considering the previously defined subpopulations. The results of the other three solid 
phase assays can be found in Supplementary Table 1. 
From Table 3, looking at the thrombosis subpopulation, 13 out of the 19 LAC negative antiDI 
positive patients had thrombosis. Additionally, the four samples testing negative for antiβ2GPI 
IgG by HemosIL AcuStar® but positive for antiDI IgG, all had thrombosis. Similarly, the two 
individuals testing negative for the criteria aPL panel by HemosIL AcuStar® and positive for antiDI 
IgG, both suffered from thrombosis. Concerning the pregnancy morbidity subpopulation, 12 out 
of the 18 LAC negative antiDI IgG positive patients experienced pregnancy morbidity. One patient 
testing negative for antiβ2GPI IgG by HemosIL AcuStar® and positive for antiDI IgG, had 
pregnancy morbidity. Moreover, only one individual negative for the criteria aPL panel by 
HemosIL AcuStar® tested positive for antiDI IgG and suffered from pregnancy morbidity. Looking 
at Supplementary Table 1, both for the thrombosis subpopulation or the pregnancy morbidity 
subpopulation, similar results were found when antiβ2GPI or antiCL IgG/IgM were detected by 
BioPlex®2200. Although more samples tested negative for antiβ2GPI IgG by Phadia® and 
QUANTA Lite® ELISA but positive for antiDI IgG, and most of them had thrombosis or pregnancy 
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morbidity.  Including LAC, fewer individuals negative for the criteria aPL panel tested positive for 
antiDI IgG and suffered from clinical events. 
To assess the additional clinical value of antiDI IgG on top of the currently used aPL measured by 
different platforms, antiDI IgG was added to the criteria aPL panel or used as a substitute for 
antiβ2GPI IgG and antiCL IgG in the criteria aPL panel. For all platforms, the addition of antiDI IgG 
to the current criteria aPL panel hardly resulted in an increase of the OR for thrombosis or 
pregnancy morbidity. Replacement of antiβ2GPI IgG and antiCL IgG by antiDI IgG resulted in 
comparable ORs for both clinical symptoms. For all platforms, a small increase was observed in 
specificity when replacing antiβ2GPI IgG and antiCL IgG by antiDI IgG, mostly accompanied by a 
decrease in sensitivity (Table 4). 
To investigate if antiDI antibodies are the only pathogenic antibodies, we re-evaluated the 
correlation of LAC, antiCL IgG and antiβ2GPI IgG with clinical manifestations of APS in antiDI IgG 
negative patients. Interestingly, upon removal of antiDI positive samples, positivity for LAC still 
resulted in significant ORs for thrombosis (2.5, 95%CI 1.7-3.5) and for pregnancy morbidity (3.9, 
95%CI 2.4-6.4) while correlations for antiβ2GPI IgG and antiCL IgG antibodies were no longer 
statistically significant except for when the antiCL IgG was measured by Phadia® and QUANTA 





Table 3. Number of patients testing positive (+) or negative (-) for antiDI IgG in relation to positivity for 
LAC or antiβ2GPI IgG or at least one of the criteria aPL panel measured by HemosIL AcuStar®, see 
supplementary table 1 for the other platforms. 
aPL, antiphospholipid antibody; β2GPI, β2glycoprotein I; DI, domain I; IgG (M), immunoglobulin G (M); 
LAC, lupus anticoagulant; N, number of patients; P, pregnancy morbidity; T, thrombosis.  
* Criteria aPL panel positivity: patients testing positive for at least one of the criteria aPL panel (i.e. LAC, 
antiCL IgG/M and/or antiβ2GPI IgG/M). 
 
  
+ - + - + - + - + - + -
+ 102 19 88 13 14 6 43 18 29 12 14 6
- 172 558 114 247 58 311 92 328 46 67 46 261
Total 274 577 202 260 72 317 135 346 75 79 60 267
+ - + - + - + - + - + -
+ 114 7 95 6 19 1 59 2 40 1 19 1
- 29 701 19 342 10 359 14 406 5 108 9 298
Total 143 708 114 348 29 360 73 408 45 109 28 299
+ - + - + - + - + - + -
+ 117 4 97 4 20 0 60 1 40 1 20 0
- 75 655 42 319 33 336 41 379 11 102 30 277
Total 192 659 139 323 53 336 101 380 51 103 50 277
+ - + - + - + - + - + -
+ 119 2 99 2 20 0 60 1 40 1 20 0
- 230 500 142 219 88 281 134 286 63 50 71 236
Total 349 502 241 221 108 281 194 287 103 51 91 236
Anti-DI 
IgG





















Anti-CL IgG Anti-CL IgG Anti-CL IgG Anti-CL IgG Anti-CL IgG Anti-CL IgG
LAC LAC LAC LAC LAC
Pregnancy 
morbidity 
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Table 4. ORs of the current criteria aPL panel and two newly defined aPL panels including antiDI IgG for 
clinical manifestations of APS. 
aPL, antiphospholipid antibody; APS, antiphospholipid syndrome; β2GPI, β2glycoprotein I; CL, cardiolipin; 
DI, domain I; IgG(M), immunoglobulin G(M); LAC, lupus anticoagulant; N, number of patients; OR, odds 
ratio; 95% CI, 95% confidence interval; $Criteria aPL panel positivity: patients testing positive for at least 
one of the criteria aPL panel (i.e. LAC, antiCL IgG/M and/or antiβ2GPI IgG/M).   
Significant ORs are shown in bold and calculated according to the outcome variable ‘clinically affected 
versus clinically not-affected patients’. 
*: Thrombotic APS + non-APS thrombosis versus non-thrombotic population (AID + normal controls); **: 









(%) OR 95% CI
Criteria aPL panel$ 851 52.2 72.2 2.8 2.1-3.8 481 66.9 72.2 5.2 3.5-7.9
Criteria aPL panel with 
addition of antiDI IgG 851 52.6 72.2 2.9 2.2-3.8 481 67.5 72.2 5.4 3.6-8.2
Criteria aPL panel with anti-DI 
IgG replacing antiβ2GPI IgG 
and antiCL IgG 
851 49.6 73.5 2.7 2.0-3.6 481 64.3 73.4 5.0 3.3-7.5
Criteria aPL panel$ 851 48.9 75.1 2.9 2.2-3.9 481 63.0 74.6 5.0 3.3-7.5
Criteria aPL panel with 
addition of antiDI IgG
851 49.6 75.1 3.0 2.2-4.0 481 63.0 74.6 5.0 3.3-7.5
Criteria aPL panel with anti-DI 
IgG replacing antiβ2GPI IgG 
and antiCL IgG 
851 48.5 76.6 3.1 2.3-4.1 481 61.7 76.5 5.2 3.5-7.9
Criteria aPL panel$ 851 53.2 68.1 2.4 1.8-3.2 481 69.5 68.2 4.9 3.2-7.4
Criteria aPL panel with   
addition of antiDI IgG
851 54.1 68.1 2.5 1.9-3.3 481 70.1 68.2 5.0 3.3-7.6
Criteria aPL panel with anti-DI 
IgG replacing antiβ2GPI IgG 
and antiCL IgG
851 51.1 69.9 2.4 1.8-3.2 481 66.9 70.0 4.7 3.1-7.1
Criteria aPL panel$ 851 50.4 73.5 2.8 2.1-3.8 481 69.5 74.3 6.6 4.3-10.1
Criteria aPL panel with   
addition of antiDI IgG
851 51.7 73.0 2.9 2.2-3.9 481 70.1 73.7 6.6 4.3-10.1
Criteria aPL panel with anti-DI 
IgG replacing antiβ2GPI IgG 
and antiCL IgG












Table 5. ORs of LAC, antiCL IgG and antiβ2GPI IgG with clinical manifestations of APS upon the removal 
of antiDI IgG positive patients. 









OR 95% CI 
LAC 
 
730 172 2.5 1.7-3.5 420 92 3.9 2.4-6.4 
AntiCL IgG HemosIL AcuStar® 730 29 2.0 0.9-4.4 420 14 1.5 0.5-4.7 
BioPlex® 2200  730 47 1.3 0.7-2.3 420 29 1.2 0.5-2.8 
Phadia® 730 35 2.3 1.1-4.8 420 16 2.2 0.8-6.0 
QUANTA Lite 
ELISA®  
730 26 2.4 1.0-5.5 420 11 2.3 0.7-7.8 
Antiβ2GPI 
IgG 
HemosIL AcuStar® 730 75 1.3 0.8-2.2 420 41 1.0 0.5-2.1 
BioPlex® 2200  730 49 1.1 0.6-1.9 420 30 1.2 0.5-2.7 
Phadia® 730 30 1.6 0.7-3.3 420 16 1.2 0.4-3.7 
QUANTA Lite 
ELISA®  
730 10 4.2 0.9-19.7 420 2 2.7 0.2-44.1 
APS, antiphospholipid syndrome; β2GPI, β2glycoprotein I; CL, cardiolipin; DI, domain I; IgG, 
immunoglobulin G; LAC, lupus anticoagulant; N#, number of patients; N$, number of biomarker positive 
cases; OR, odds ratio; 95% CI, 95% confidence interval. 
Significant ORs are shown in bold and calculated according to the outcome variable ‘clinically affected 
versus clinically not-affected patients’. 
*: Thrombotic APS + non-APS thrombosis versus non-thrombotic population (AID + normal controls); **: 
Obstetric APS + non-APS obstetric versus non-obstetric population (AID - female + normal controls - 
female). 
Distribution of antiDI IgG titers according to the patient’s antibody profile 
For both the thrombosis and pregnancy morbidity subpopulation, all individuals were grouped 
according to their aPL profile into triple positive (LAC +, antiCL IgG/IgM +, antiβ2GPI IgG/IgM +), 
double positive (LAC -, antiCL IgG/IgM +, antiβ2GPI IgG/IgM + or LAC +, antiCL IgG/IgM +, 
antiβ2GPI IgG/IgM - or LAC +, antiCL IgG/IgM -, antiβ2GPI IgG/IgM +), and single positive (isolated 
positive for LAC, antiCL IgG/IgM or antiβ2GPI IgG/IgM). Results were compared with those of 
patients without any aPL reactivity (negative control). The different antibody profiles with their 
characteristics are shown in Table 6 for antiβ2GPI and antiCL measured by HemosIL AcuStar® and 
in Supplementary Table 2-4 for antiβ2GPI and antiCL measured by the three other solid phase 
assays.   
Furthermore, we compared antiDI IgG titers in the triple positive, solid phase double positive 
(antiCL IgG/IgM positive and antiβ2GPI IgG/IgM positive but LAC negative), combined single 
positive group (isolated LAC +, and isolated antiCL IgG/IgM +, and isolated antiβ2GPI IgG/IgM +) 
and the negative control. Comparison of antiDI IgG titers between four aPL profile groups for 
antiβ2GPI and antiCL measured by four assays is shown in Figure 1. Looking at HemosIL AcuStar®, 
in both the thrombosis subpopulation and pregnancy morbidity subpopulation antiDI titers were 
significantly higher in triple positive samples compared to the other aPL profile groups, followed 
by the solid phase double positive samples. No difference was observed between antiDI titers of 
combined single positive and negative samples. Similar results were found for the three other 
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assays, except that there was a significant difference between antiDI titers of combined single 
positive and negative samples for antiβ2GPI and antiCL measured by QUANTA Lite® ELISA (Figure 
1).  
Association of triple positivity with antiDI positivity 
The association between DI positivity and triple positivity was studied in detail for antiβ2GPI and 
antiCL measured by the Acustar® (Table 6). As to the thrombosis subpopulation (Table 6), 
positive values of antiDI IgG were found in 100 out of 134 individuals with triple positivity (74.6%), 
compared with 44.1% (15/34) in the solid phase double positive group (Pearson Chi-Square, P = 
0.002). Combined single positive (2/146 = 1.4%) and aPL negative patients (2/502 = 0.4%) hardly 
showed any antiDI IgG reactivity (Fisher’s Exact Test, P < 0.0001). A good agreement was found 
between triple positivity and antiDI IgG positivity (Kappa value = 0.746, P < 0.0001). In this triple 
positive group, 87.0% (87/100) of antiDI IgG-positive individuals had a history of thrombosis, 
compared with 70.6% (24/34) of antiDI IgG negative patients (Pearson Chi-Square, P = 0.028).  
Concerning the pregnancy morbidity subpopulation (Table 6), positive values of antiDI IgG were 
found in 42 out of 56 individuals with triple positivity (75.0%), compared with 48.6% (17/35) in 
the solid phase double positive group (Pearson Chi-Square, P = 0.013). As seen in the thrombosis 
subpopulation, the combined single positive group (0/81 = 0%) and aPL negative patients (1/287 
= 0.3%) hardly showed antiDI IgG reactivity (Fisher’s Exact Test, P < 0.0001). Albeit lower than for 
the thrombosis subpopulation, also in the pregnancy morbidity subpopulation a good agreement 
was demonstrated between triple positivity and antiDI IgG (Kappa value = 0.679, P < 0.0001). In 
this triple positive group, 69.0% (29/42) of antiDI IgG positive individuals had a history of 
pregnancy morbidity, compared with 35.7% (5/14) of antiDI IgG negative patients (Fisher’s Exact 
Test, P = 0.027). In general, similar conclusions can be drawn when antiβ2GPI and antiCL were 
measured by the other assays (Supplementary Table 2-5).  
Interestingly, both for thrombosis and pregnancy morbidity, the ORs of antiDI IgG were higher 
than the ORs of triple positivity except when antiCL and antiβ2GPI were measured by the 
QUANTA Lite® ELISA platform for thrombosis. To verify if antiDI positivity has an added value in 
risk stratification compared to triple positivity, ORs of combined triple positivity and DI positivity 
were calculated for thrombosis and pregnancy morbidity. As to thrombosis, combined positivity 
resulted in higher OR compared to the separate OR for both triple positivity and DI reactivity. For 
pregnancy morbidity, ORs of antiDI plus triple positivity were higher compared to ORs of triple 
positivity, but hardly improved compared to OR of antiDI positivity (Table 2).  
Furthermore, as to the thrombosis subpopulation, within the triple positive group for antiβ2GPI 
and antiCL measured by Acustar®, antiDI IgG titers varied greatly but no significant difference 
was observed between patients with thrombosis (n = 111) and unaffected individuals (n = 23), 
with a median (quartile(Q)25- Q75) antiDI IgG titer of, respectively, 169.0 CU (25.7-761.3) and 
63.7 CU (3.7-625.7) (Mann–Whitney U test, P = 0.084). Similarly, concerning the pregnancy 
morbidity subpopulation, antiDI IgG titers differed greatly but no significant difference between 
patients with pregnancy morbidity (n = 34) and unaffected individuals (n = 22) could be 
demonstrated median (quartile(Q)25- Q75) antiDI IgG titer of 200.2 CU (49.6-462.1) and 65.0 CU 
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(3.7-654.3), respectively, Mann–Whitney U test, P = 0.179). Similar results were obtained with 
the three other assays, although for the BioPlex®2200 (thrombosis and pregnancy morbidity) and 
Phadia® (thrombosis) results reached statistical significance (Supplementary Table 6).  
Correlation between detection of antiDI IgG and antiβ2GPI IgG and antiCL IgG  
Concordance was evaluated by comparing the results of the detection of IgG antiDI antibodies 
with antiβ2GPI IgG and antiCL IgG measured by four solid phase assays (Table 7). A good 
agreement was established between IgG antiDI antibodies and IgG antiCL as well as with IgG 
antiβ2GPI antibodies (Kappa value = 0.656 - 0.861) in the thrombosis subpopulation (Table 7A) 
and the pregnancy morbidity subpopulation (Table 7B). The IgG antiDI antibody titers were 
likewise significantly correlated with IgG antiCL titers and IgG antiβ2GPI titers (Spearman's rho = 
0.563 - 0.842) in the thrombosis subpopulation (Table 7A) and the pregnancy morbidity 
subpopulation (Table 7B) (all P < 0.0001).  
Table 6. Number of cases with distinct antibody profiles (antiCL IgG/IgM and antiβ2GPI IgG/IgM 
measured by HemosIL AcuStar®), see supplementary table2-3-4 for the other platforms. 
In the thrombosis 
subpopulation 

















Goup1 Triple positive 134 (16) + + + 100 (75) 87 (87) 13 (13) 34 (25) 24 (71) 10 (29) 
Goup2 Double positive 34 (4) - + + 15 (44) 9 (60) 6 (40) 19 (56) 7 (37) 12 (63) 
Goup3 Double positive 14 (2) + + - 0 0 0 14 (100) 7 (50) 7 (50) 
Goup4 Double positive 21 (2) + - + 2 (10) 1 (50) 1 (50) 19 (90) 7 (37) 12 (63) 
Goup5 Single positive 105 (12) + - - 0 0 0 105 (100) 76 (72) 29 (28) 
Goup6 Single positive 26 (3) - + - 1 (4) 1 0 25 (96) 11 (44) 14 (56) 
Goup7 Single positive 15 (2) - - + 1 (7) 1 (100) 0 14 (93) 10 (71) 4 (29) 
Goup8 Negative control 502 (59) - - - 2 (0.4) 2 (100) 0 500 (99.6) 219 (44) 281 (56) 
Total    851 (100) 
   
121 (14) 101 (83) 20 (17) 730 (86) 361 (49) 369 (51) 
In the pregnancy morbidity 
subpopulation 

















Goup1 Triple positive 56 (12) + + + 42 (75) 29 (69) 13 (31) 14 (25) 5 (36) 9 (64) 
Goup2 Double positive 35 (7) - + + 17 (49) 11 (65) 6 (35) 18 (51) 8 (44) 10 (56) 
Goup3 Double positive 9 (2) + + - 0 0 0 9 (100) 2 (22) 7 (78) 
Goup4 Double positive 13 (3) + - + 1 (8) 0 1(100) 12 (92) 1 (8) 11 (92) 
Goup5 Single positive 57 (12) + - - 0 0 0 57 (100) 38 (67) 19 (33) 
Goup6 Single positive 16 (3) - + - 0 0 0 16 (100) 5 (31) 11 (69) 
Goup7 Single positive 8 (2) - - + 0 0 0 8 (100) 4 (50) 4 (50) 
Goup8 Negative control 287 (60) - - - 1 (0.3) 1 (100) 0 286 (99.7) 50 (17) 236 (83) 
Total    481 (100) 
   
61 (13) 41 (67) 20 (33) 420 (87) 113 (27) 307 (73) 
aPL, antiphospholipid antibody; β2GPI, β2glycoprotein I; CL, cardiolipin; DI, domain I; IgG (M), 
immunoglobulin G (M); LAC, lupus anticoagulant; N, number of patients in each group; P, pregnancy 
morbidity; T, Thrombosis. 
#: the percentage of each group antibody profile; &: the percentage of antiDI IgG positive/negative in 
each group antibody profile; *: the percentage of individuals with/without clinical events. 
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Figure 1. Distribution of the titer of antiDI IgG according to distinct antibody profiles for antiCL and antiβ2GPI measured by 
HemosIL AcuStar®, BioPlex®2200, Phadia® and QUANTA Lite® ELISA in the thrombosis subpopulation (A) and pregnancy 
morbidity subpopulation (B). Investigated aPL profiles include triple positive (LAC+, antiCL IgG/IgM +, antiβ2GPI IgG/IgM +), solid 
phase double positive (LAC–, antiCL IgG/IgM +, antiβ2GPI IgG/IgM +) and combined single positive (isolated LAC +, and isolated 
antiCL IgG/IgM +, and isolated antiβ2GPI IgG/IgM +). Patients without any aPL reactivity were defined as negative controls. Titer 
of antiDI IgG are expressed as the median with interquartile ranges within each profile; dashed lines indicate the cut-off value of 
antiDI IgG (20 CU). *P < 0.05, **P < 0.01, ***P < 0.0001, ns: not significant. Abbreviations: aPL, antiphospholipid antibody; DI, 






























































































































































































































































Table7. Matrix of correlation between antiDI IgG and antiβ2GPI IgG or antiCL IgG in the 
indicated subpopulation. 





















antiDI IgG vs. 
antiβ2GPI IgG  





antiDI IgG vs. 
antiCL IgG  


























antiDI IgG vs. 
antiβ2GPI IgG  
0.808*** 0.842*** 0.679*** 0.581*** antiDI IgG vs. 




antiDI IgG vs. 
antiCL IgG  
0.756*** 0.800*** 0.645*** 0.734*** antiDI IgG vs. 




aPL, antiphospholipid antibody; β2GPI, β2glycoprotein I; CL, cardiolipin; DI, domain I; IgG, 
immunoglobulin G; LAC, lupus anticoagulant; ***P < 0.0001. 
Discussion 
Solid phase aPL assays included in the laboratory criteria suffer from a lack of standardization, 
limiting their utility in clinical practice. Variability results not only from methodological 
shortcomings but also from the heterogeneity of aPLs 5,7. More and more literature evidence 
suggests that detection of a subset of aPLs reactive against DI of β2GPI is a promising 
classification or risk stratification tool in APS 26,27. However, a recent review concluded 
inconsistent results about the added value of the detection of antiDI IgG compared to 
conventional aPL test, most probably due to differences in study design, study population and 
the methodology to detect the antiDI antibodies 28.  
In this multicenter study, all samples were measured for aPL reactivity by one technician in the 
same lab to avoid variability coming from differences in working conditions. In most studies 
evaluating the added value of antiDI IgG, the only commercially available assay (CLIA of QUANTA 
Flash®) is compared with antiβ2GPI and antiCL of the same manufacturer 29-35. Importantly, we 
hypothesized that the added value of the antiDI IgG assay measured by QUANTA Flash® depends 
on the platform used to detect antiβ2GPI and antiCL IgG. This hypothesis comes from our 
previously published results demonstrating a variable exposure of the G40-R43 epitope on 
domain I of β2GPI coated in the different commercially available antiCL and antiβ2GPI assays 
8,36,37. In this multicenter study, we therefore determined the added value of antiDI testing to the 
current APS classification criteria, when antiCL and antiβ2GPI were measured by four different 
commercially available assays.  
As literature is inconclusive whether the same aPL subset induces thrombosis and pregnancy 
morbidity, separate analyses were performed in a thrombosis and pregnancy morbidity 
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subpopulation, including proper control populations. Both for the thrombosis and the pregnancy 
morbidity subpopulation, we found that the detection of antiDI IgG was less sensitive but more 
specific compared to the laboratory criteria aPL tests, resulting in a higher OR for thrombosis and 
pregnancy morbidity compared to LAC, antiβ2GPI or antiCL IgG, except for the QUANTA Lite® 
ELISA. Interestingly, upon restriction to patients positive for antiβ2GPI IgG, antiDI IgG positivity 
still resulted in significant ORs for clinical complications, except for the QUANTA Lite® ELISA 
(Table 2), that could be explained by the lower number of antiβ2GPI IgG detected by this assay 
(Supplemental Table 1). These findings are consistent with previous studies 19,20,29,30,32. Based on 
these results, apart from those obtained by the QUANTA Lite® ELISA, we expected antiDI IgG to 
have an additional value on top of the current laboratory criteria, or to be a candidate to replace 
the antiβ2GPI IgG detection. Contrary to our expectation, the addition of antiDI or replacement 
of antiβ2GPI IgG by antiDI hardly improved the ORs for thrombosis or pregnancy morbidity. The 
absence of an added value of antiDI to the current aPL criteria panel was also found in previous 
studies 34,35.  
This at first sight contradiction can be explained by the results presented in Table 3 and 
Supplementary Table 1. Independent of the assay used, only a few individuals (n=11) negative 
for the criteria aPL panel (with one or more platforms) become positive when antiDI IgG is added 
to the criteria aPLs panel or used as a substitute for antiβ2GPI IgG and/or antiCL IgG, even though 
most of them experienced clinical events (n=7 with thrombosis, n=2 with pregnancy morbidity). 
Of note, despite of antiDI IgG positivity, the titers of antiDI IgG in these individuals proved to be 
low (from 21.1 to 73.2 CU).   
Interestingly, upon removal of antiDI IgG positive patients, antiCL IgG and antiβ2GPI IgG were no 
longer significantly correlated with thrombosis and pregnancy morbidity, except for antiCL IgG 
measured by Phadia® and by QUANTA Lite® ELISA (OR for thrombosis of 2.3 (95%CI 1.1-4.8) and 
2.4 (95%CI 1.0-5.5), respectively) (Table 5). Although the OR for thrombosis of antiCL IgG 
measured by Phadia® and by QUANTA Lite® ELISA was still significant, the lower limit was 
adjacent to 1. These findings are in agreement with previous studies demonstrating that 
especially antiDI antibodies are pathogenic while antibodies targeting other domains such as 
domain 4/5 are innocent or even protective antibodies 20,23,38,39. 
We previously demonstrated that the large variability observed in commercially available 
antiβ2GPI assays results at least in part from a variable exposure of the pathogenic G40-R43 DI 
epitope 8. Importantly, our recent data show that, as for antiβ2GPI IgG assays, the pathogenic DI 
epitope is not exposed correctly in the commercially available antiDI CLIA assay 28. Furthermore, 
both as categorical variables (positive/negative) and as quantitative variables (titer), antiDI IgG 
strongly correlated with antiCL IgG and antiβ2GPI IgG on the same AcuStar® CLIA. The high 
correlation between antiDI IgG and antiβ2GPI IgG suggests a high overlap between both assays 
performed on the automated CLIA platform. Previous studies also observed a high agreement 
(69% - 92%) between antiDI IgG and antiβ2GPI IgG when measured using the CLIA methodology 
29,34,35,40. These results may explain the absence of an added value of measuring antiDI using this 
assay. In this study, also for the other platforms, a high agreement was found between antiDI 
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and the antiCL IgG and antiβ2GPI IgG and no added value of measuring antiDI could be 
demonstrated (Table 7).  
Of note, apart from the antiDI CLIA assay used in this study, other methods are available to detect 
antiDI antibodies 28. Previously a home-made two-step ELISA strongly indicated that testing for 
IgG antiDI enables identification of the patients at highest risk for developing thrombosis or 
pregnancy morbidity 19,20. In contrast to the results obtained by CLIA assays, only 50% of the 
antiβ2GPI IgG antibodies testing by this home-made two-step ELISA were demonstrated to be 
reactive against DI. Importantly, using this two-step ELISA assay, correct exposure of the G40-
R43 epitope was already confirmed 20. The added value of measuring antiDI reactivity using this 
assay remains to be determined.  
Interestingly, LAC remained significantly correlated with thrombosis and pregnancy morbidity 
upon removal of antiDI IgG positive patients. Further illustrated by the only fair to moderate 
agreement between IgG antiDI and functional LAC in the thrombosis subpopulation (Kappa value 
= 0.398) and the pregnancy morbidity subpopulation (Kappa value = 0.320), these data illustrate 
that the CLIA antiDI IgG assay only detects part of the pathogenic aPLs. The presence of 
pathogenic anti-phosphatidylserine/prothrombin (anti-PS/PT) antibodies able to induce LAC 
positivity may explain the remaining correlation between LAC and thrombosis. Indeed, previous 
studies have demonstrated correlations of anti-PS/PT with clinical symptoms in APS patients and 
positivity proved to be associated with LAC 41,42 .  
Evidence is growing that the determination of combined antibody positivity helps to categorize 
patients according to their risk profile. Especially triple positive patients (positive for LAC and 
antiCL and antiβ2GPI IgG/IgM) show a strong association with thrombotic and obstetric 
manifestations 43,44. Clinical studies confirm that triple positivity in APS patients and 
asymptomatic aPL carriers indicates a high risk of recurrence of thrombosis or development of a 
first thrombotic event, respectively 44,45. Although identification of triple positives is dependent 
on the solid phase assay used 46, the percentage of antiDI IgG positives in individuals with distinct 
antibody profiles were comparable for the four tested solid phase assays. In this study, a very 
good agreement was found between triple positivity and antiDI IgG positivity, irrespective of the 
solid phase assay used (Supplementary Table 5), which is consistent with previous studies 30-
32,35,40. Moreover, independent of the used platform to measure antiCL and antiβ2GPI IgG/IgM, 
we observed that antiDI IgG antibodies are mainly present in triple positive individuals, also 
showing significantly higher titers compared to patients with other aPL profiles. More 
importantly, within the triple positive group, a higher percentage of clinically affected cases was 
present in the antiDI IgG positive compared to the antiDI IgG negative group. Furthermore, the 
higher ORs of combined DI and triple positivity for both thrombosis and pregnancy morbidity 
compared to only triple positivity, support the idea that detection of antiDI IgG is interesting to 
identify patients at risk.  
We acknowledge that our study has some limitations. First, as in both the thrombotic and 
obstetric patient groups, a small number of patients (8.9% and 7.4% respectively) also suffers 
from the other clinical manifestation, the correlation with the specific clinical manifestation may 
be affected by the comorbidity of the other manifestation. Also, the different groups in our study 
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population did not match according to age and gender, but were representative to population 
groups tested in daily practice. Another limitation of our study is the retrospective design. 
Interestingly, in the AID and normal control group, a number of the triple positives were also 
positive for antiDI reactivity (depending on the platform 11/22 (50%) - 9/14 (64%) for AID; 1/3 
(33%) – 2/4 (50%) for the normal controls). Prospective studies are necessary to verify the risk of 
patients with these characteristics to develop clinical manifestations of APS, with possible 
implications for their treatment.   
This study showed again that the choice of the commercial assays used to detect the presence 
of antiphospholipid antibodies influences the classification of APS. It is impossible to determine 
which commercial assay is the best because we lack a gold standard. However, a good agreement 
with a domain I specific assay seems to be essential because antibodies against DI have shown 
to be pathogenic in animal models of APS. 
Conclusion  
Despite the higher OR of antiDI antibody detection for clinical manifestations of APS, our study 
was unable to demonstrate an added value of measuring antiDI IgG on top of the laboratory 
criteria, independent of the platform used to measure antiCL and antiβ2GPI. We put the 
hypothesis forward that the reduced exposure of the pathogenic DI epitope in this automated 
assay possibly explains the absence of an added value. Therefore, it may be interesting to re-
evaluate the added value of antiDI using the in-house antiDI assay previously developed, for 
which correct exposure of the pathogenic epitope was already demonstrated. The high 
correlation between antiDI IgG and triple positivity indicates that antiDI IgG positivity confirms 
the patients at higher risk for clinical events in APS. Importantly, combined DI and triple positivity 
confirms a higher risk for both thrombosis and pregnancy morbidity compared to only triple 
positivity. As LAC positivity remains significantly correlated with thrombosis and pregnancy 
morbidity upon removal of antiDI positive patients, the antiDI IgG assay only detects part of the 
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Supplementary Table 1. Number of patients testing positive (+) or negative (-) for antiDI IgG in relation 
to positivity for LAC or antiβ2GPI IgG or at least one of the criteria aPL panel measured by other three 





(N = 851) 
With T  
(N = 462) 
Without T  




(N = 481) 
With P  
(N = 154) 
Without P  
(N = 327) 
  BioPlex®2200 AntiCL IgG AntiCL IgG AntiCL IgG AntiCL IgG AntiCL IgG AntiCL IgG 





115 6 96 5 19 1 59 2 40 1 19 1 
- 
 
47 683 26 335 21 348 29 391 9 104 20 287 
Total 
  
162 689 122 340 40 349 88 393 49 105 39 288 
  Phadia® AntiCL IgG AntiCL IgG AntiCL IgG AntiCL IgG AntiCL IgG AntiCL IgG 





101 20 85 16 16 4 54 7 38 3 16 4 
- 
 
35 695 24 337 11 358 16 404 7 106 9 298 
Total 
  
136 715 109 353 27 362 70 411 45 109 25 302 
  QUANTA Lite® 
ELISA 
AntiCL IgG AntiCL IgG AntiCL IgG AntiCL IgG AntiCL IgG AntiCL IgG 





95 26 81 20 14 6 47 14 33 8 14 6 
- 
 
26 704 18 343 8 361 11 409 5 108 6 301 
Total 
  
121 730 99 363 22 367 58 423 38 116 20 307 
  BioPlex®2200 Antiβ2GPI IgG Antiβ2GPI IgG Antiβ2GPI IgG Antiβ2GPI IgG Antiβ2GPI IgG Antiβ2GPI IgG 





116 5 96 5 20 0 60 1 40 1 20 0 
- 
 
49 681 25 336 24 345 30 390 9 104 21 286 
Total 
  
165 686 121 341 44 345 90 391 49 105 41 286 
  Phadia® Antiβ2GPI IgG Antiβ2GPI IgG Antiβ2GPI IgG Antiβ2GPI IgG Antiβ2GPI IgG Antiβ2GPI IgG 





104 17 86 15 18 2 52 9 34 7 18 2 
- 
 
30 700 18 343 12 357 16 404 5 108 11 296 
Total 
  
134 717 104 358 30 359 68 413 39 115 29 298 
  QUANTA Lite® 
ELISA 
Antiβ2GPI IgG Antiβ2GPI IgG Antiβ2GPI IgG Antiβ2GPI IgG Antiβ2GPI IgG Antiβ2GPI IgG 





81 40 69 32 12 8 33 28 21 20 12 8 
- 
 
10 720 8 353 2 367 2 418 1 112 1 306 
Total 
  
91 760 77 385 14 375 35 446 22 132 13 314  

















118 3 98 3 20 0 61 0 41 0 20 0 
- 
 
205 525 128 233 77 292 119 301 56 57 63 244 
Total 
  
323 528 226 236 97 292 180 301 97 57 83 244 

















117 4 97 4 20 0 60 1 40 1 20 0 
- 
 
253 477 149 212 104 265 151 269 67 46 84 223 
Total 
  
370 481 246 216 124 265 211 270 107 47 104 223 
  QUANTA Lite® 
ELISA 
Criteria  
aPL panel * 
Criteria  
aPL panel * 
Criteria  
aPL panel * 
Criteria  
aPL panel * 
Criteria  
aPL panel * 
Criteria  
aPL panel * 





113 8 95 6 18 2 58 3 40 1 18 2 
- 
 
223 507 138 223 85 284 133 287 67 46 66 241 
Total 
  
336 515 233 229 103 286 191 290 107 47 84 243 
aPL, antiphospholipid antibody; β2GPI, β2glycoprotein I; DI, domain I; IgG (M), immunoglobulin G (M); LAC, lupus 
anticoagulant; N, number of patients; P, pregnancy morbidity; T, thrombosis.  * Criteria aPL panel positivity: patients 
testing positive for at least one of the criteria aPL panel (i.e. LAC, antiCL IgG/M and/or antiβ2GPI IgG/M). 
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Supplementary Table 2. Number of cases with distinct antibody profiles (antiCL IgG/IgM and antiβ2GPI 
IgG/IgM measured by BioPlex®2200). 
In the thrombosis 
subpopulation 
N (%)# 






Total with T without T Total with T without T 
N (%)& N (%) N (%) N (%)& N (%) N (%) 
Goup1 Triple positive 146 (17) + + + 101 (69) 88 (87) 13 (13) 45 (31) 30 (67) 15 (33) 
Goup2 Double positive 37 (4) - + + 15 (41) 9 (60) 6 (40) 22 (59) 8 (36) 14 (64) 
Goup3 Double positive 3 (0.4) + + - 0 0 0 3 (100) 1 (33) 2 (67) 
Goup4 Double positive 5 (1) + - + 1 (20) 0 1 (100) 4 (80) 1 (25) 3 (75) 
Goup5 Single positive 120 (14) + - - 0 0 0 120 (100) 82 (68) 38 (32) 
Goup6 Single positive 6 (1) - + - 1 (17) 1 (100) 0 5 (83) 2 (40) 3 (60) 
Goup7 Single positive 6 (1) - - + 0 0 0 6 (100) 4 (67) 2 (33) 
Goup8 Negative control 528 (62) - - - 3 (1) 3 (100) 0 525 (99) 233 (44) 292 (56) 
Total    851 (100) 
   
121 (14) 101 (83) 20 (17) 730 (86) 361 (49) 369 (51) 
In the pregnancy morbidity 
subpopulation 
N (%)# 






Total with P without P Total with P without P 
N (%)& N (%) N (%) N (%)& N (%) N (%) 
Goup1 Triple positive 62 (13) + + + 42 (68) 29 (69) 13 (31) 20 (32) 6 (30) 14 (70) 
Goup2 Double positive 39 (8) - + + 17 (44) 11 (65) 6 (35) 22 (56) 9 (41) 13 (59) 
Goup3 Double positive 2 (0.4) + + - 0 0 0 2 (100) 1 (50) 1 (50) 
Goup4 Double positive 3 (1) + - + 1 (33) 0 1 (100) 2 (67) 0 2 (100) 
Goup5 Single positive 68 (14) + - - 0 0 0 68 (100) 39 (57) 29 (43) 
Goup6 Single positive 2 (0.4) - + - 0 0 0 2 (100) 0 2 (100) 
Goup7 Single positive 4 (1) - - + 1 (25) 1 (100) 0 3 (75) 1 (33) 2 (67) 
Goup8 Negative control 301 (63) - - - 0 0 0 301 (100) 57 (19) 244 (81) 
Total    481 (100) 
   
61 (13) 41 (67) 20 (33) 420 (87) 113 (27) 307 (73) 
aPL, antiphospholipid antibody; β2GPI, β2glycoprotein I; CL, cardiolipin; DI, domain I; IgG (M), 
immunoglobulin G (M); LAC, lupus anticoagulant; N, number of patients in each group; P, pregnancy 
morbidity; T, Thrombosis. 
#: the percentage of each group antibody profile; &: the percentage of antiDI IgG positive/negative in each 




Supplementary Table 3. Number of cases with distinct antibody profiles (antiCL IgG/IgM and antiβ2GPI 
IgG/IgM measured by Phadia®). 
In the thrombosis 
subpopulation N (%)
# 
aPL profile Anti-DI IgG positive Anti-DI IgG negative 
LAC anti-CL IgG/IgM 
anti-β2GPI 
IgG/IgM 
Total with T without T Total with T without T 
N (%)& N (%) N (%) N (%)& N (%) N (%) 
Goup1 Triple positive 125 (15) + + + 90 (72) 78 (87) 12 (13) 35 (28) 23 (66) 12 (34) 
Goup2 Double positive 36 (4) - + + 12 (33) 8 (67) 4 (33) 24 (67) 12 (50) 12 (50) 
Goup3 Double positive 18 (2) + + - 3 (17) 3 (100) 0 15 (83) 12 (80) 3 (20) 
Goup4 Double positive 14 (2) + - + 6 (43) 5 (83) 1 (17) 8 (57) 2 (25) 6 (75) 
Goup5 Single positive 117 (14) + - - 3 (3) 2 (67) 1 (33) 114 (97) 77 (68) 37 (32) 
Goup6 Single positive 52 (6) - + - 2 (4) 1 (50 1 (50) 50 (96) 20 (40) 30 (60) 
Goup7 Single positive 8 (1) - - + 1 (13) 0 1 (100) 7 (88) 3 (43) 4 (57) 
Goup8 Negative control 481 (57) - - - 4 (1) 4 (100) 0 477 (99) 212 (44) 265 (56) 
Total    851 (100) 
   
121 (14) 101 (83) 20 (17) 730 (86) 361 (49) 369 (51) 
In the pregnancy morbidity 
subpopulation N (%)
# 
aPL profile Anti-DI IgG positive Anti-DI IgG negative 
LAC anti-CL IgG/IgM 
anti-β2GPI 
IgG/IgM 
Total with P without P Total with P without P 
N (%)& N (%) N (%) N (%)& N (%) N (%) 
Goup1 Triple positive 51 (11) + + + 37 (73) 25 (68) 12 (32) 14 (27) 5 (36) 9 (64) 
Goup2 Double positive 33 (7) - + + 14 (42) 10 (71) 4 (29) 19 (58) 10 (53) 9 47() 
Goup3 Double positive 9 (2) + + - 2 (22) 2 (100) 0 7 (78) 4 (57) 3 (43) 
Goup4 Double positive 7 (1) + - + 1 (14) 0 1 (100) 6 (86) 1 (17) 5 (83) 
Goup5 Single positive 68 (14) + - - 3 (4) 2 (67) 1 (33) 65 (96) 36 (55) 29 (45) 
Goup6 Single positive 34 (7) - + - 2 (6) 1 (50) 1 (50) 32 (94) 7 (22) 25 (78) 
Goup7 Single positive 9 (2) - - + 1 (11) 0 1 (100) 8 (89) 4 (50) 4 (50) 
Goup8 Negative control 270 (56) - - - 1 (0.4) 1 (100) 0 269 (100) 46 (17) 223 (83) 
Total    481 (100) 
   
61 (13) 41 (67) 20 (33) 420 (87) 113 (27) 307 (73) 
Abbreviations: aPL, antiphospholipid antibody; β2GPI, β2glycoprotein I; CL, cardiolipin; DI, domain I; IgG 
(M), immunoglobulin G (M); LAC, lupus anticoagulant; N, number of patients in each group; P, pregnancy 
morbidity; T, Thrombosis. 
#: the percentage of each group antibody profile; &: the percentage of antiDI IgG positive/negative in each 
group antibody profile; *: the percentage of individuals with/without clinical events. 
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Supplementary Table 4. Number of cases with distinct antibody profiles (antiCL IgG/IgM and antiβ2GPI 
IgG/IgM measured by QUANTA Lite ELISA®). 
In the thrombosis 
subpopulation  N (%)
# 
aPL profile Anti-DI IgG positive Anti-DI IgG negative 
LAC  anti-CL IgG/IgM 
anti-β2GPI 
IgG/IgM  
Total with T without T Total with T without T 
N (%)& N (%) N (%) N (%)& N (%) N (%) 
Goup1 Triple positive 106 (12) + + + 82 (77) 72 (88) 10 (12) 24 (23) 17 (71) 7 (29) 
Goup2 Double positive 25 (3) - + + 8 (32) 5 (62) 3 (38) 17 (68) 6 (35) 11 (65) 
Goup3 Double positive 22 (3) + + - 6 (27) 5 (83) 1 (17) 16 (73) 9 (56) 7 (44) 
Goup4 Double positive 13 (2) + - + 2 (15) 2 (100) 0 11 (85) 8 (73) 3 (27) 
Goup5 Single positive 133 (16) + - - 12 (9) 9 (75) 3 (25) 121 (91) 80 (66) 41 (34) 
Goup6 Single positive 28 (3) - + - 3 (11) 2 (67) 1 (33) 25 (89) 15 (60) 10 (40) 
Goup7 Single positive 9 (1) - - + 0 0 0 9 (100) 3 (33) 6 (67) 
Goup8 Negative control 515 (61) - - - 8 (2) 6 (75) 2 (25) 507 (98) 223 (44) 284 (56) 
Total    851 (100)       121 (14) 101 (83) 20 (13) 730 (86) 361 (49) 369 (51) 
In the pregnancy 
morbidity subpopulation N (%)
# 
aPL profile Anti-DI IgG positive Anti-DI IgG negative 
LAC  anti-CL IgG/IgM 
anti-β2GPI 
IgG/IgM  
Total with P without P Total with P without P 
N (%)&  N (%)  N (%) N (%)&  N (%)  N (%) 
Goup1 Triple positive 36 (7) + + + 29 (81) 19 (66) 10 (34) 7 (19) 1 (14) 6 (86) 
Goup2 Double positive 28 (6) - + + 10 (36) 7 (70) 3 (30) 18 (64) 9 (50) 9 (50) 
Goup3 Double positive 13 (3) + + - 6 (46) 5 (83) 1 (17) 7 (54) 1 (14) 6 (86) 
Goup4 Double positive 6 (1) + - + 0 0 0 6 (100) 3 (50) 3 (50) 
Goup5 Single positive 80 (17) + - - 8 (10) 5 (62) 3 (37) 72 (90) 41 (57) 31 (43) 
Goup6 Single positive 20 (4) - + - 4 (20) 3 (75) 1 (25) 16 (80) 9 (56) 7 (44) 
Goup7 Single positive 8 (2) - - + 1 (13) 1 (100) 0 7 (88) 3 (43) 4 (57) 
Goup8 Negative control 290 (60) - - - 3 (1) 1 (33) 2 (67) 287 (99) 46 (16) 241 (84) 
Total    481 (100)       61 (13) 41 (67) 20 (33) 420 (87) 113 (27) 307 (73) 
aPL, antiphospholipid antibody; β2GPI, β2glycoprotein I; CL, cardiolipin; DI, domain I; IgG (M), 
immunoglobulin G (M); LAC, lupus anticoagulant; N, number of patients in each group; P, pregnancy 
morbidity; T, Thrombosis. 
#: the percentage of each group antibody profile; &: the percentage of antiDI IgG positive/negative in each 
group antibody profile; *: the percentage of individuals with/without clinical events. 
 
 
Supplementary Table 5. Agreement between antiDI IgG positivity and triple positivity for four platforms 
in the different subpopulations. 
Agreement1 HemosIL 
AcuStar® 
BioPlex®2200 Phadia® QUANTA Lite® 
ELISA 
In the thrombosis 
subpopulation 
0.746*** 0.712*** 0.686*** 0.680*** 
In the pregnancy morbidity 
subpopulation 
0.679*** 0.636*** 0.616*** 0.556*** 
1 Kappy values are shown 





Supplementary Table 6. Comparison of antiDI IgG titers between triple positive patients with and 
without clinical events. 
Manufacturers 
for antiCL and 
antiβ2GPI 
In the thrombosis population In the pregnancy morbidity population 
With T Without T P 
value 










































β2GPI, β2glycoprotein I; CL, cardiolipin; CU, chemiluminescence units; DI, domain I; P, pregnancy 
morbidity; T, thrombosis.   
Titers of antiDI IgG are expressed as the median (quartile(Q)25- Q75), Mann–Whitney U test was used to 
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The antiphospholipid syndrome has been an enigma for many years. The diagnosis of a patient is 
based on rather generally occurring clinical symptoms in combination with specific laboratory 
tests. In more detail, as stated in its criteria, it is a syndrome in which patients suffer from 
thrombosis and pregnancy morbidity1 . Diagnosis should be made on these clinical criteria in 
combination with laboratory criteria. Patients are tested positive for either one of three tests: 
anti-beta2-glycoprotein I (β2GP1) IgM/IgG antibodies, anti-cardiolipin IgM/IgG antibodies, or a 
prolongation of a phospholipid-dependent coagulation time. Recently the group of Devreese 
together with our group initiated a multicentre study in order to investigate whether we can 
improve the diagnosis of the syndrome2 .  
Over the years, many groups have studied different populations of antiphospholipid antibodies 
and their effect on initiating a prothrombotic phenotype. Many mechanisms have been proposed. 
Antibodies have been shown in vitro and in vivo to affect almost any protein or cell that is 
involved in the occurrence of thrombosis (Figure 1)3. At present, the complement system is 
gaining attention as one of the major pathogenic mechanisms 4.  
As many mechanisms have been proposed to be involved in the antiphospholipid syndrome, it is 
quite difficult to choose a protein or cell to target for treatment. With this in mind, the idea of 
the group of Hisada et al. is rather well thought out 4. Their main study objective was to identify 
the mechanism of antiphospholipid antibody production. Study and identification of which cells 
are involved may make targeting of these for treatment an option. Interestingly, they found that 
the primary cells involved in antibody production were plasmablasts, which are the earliest 
plasma cells capable of producing antibodies. Characteristics of these cells are that they can 
divide rapidly, and that they are capable of internalisation antigens, presenting antigen to T-cell 
and producing antibodies. In fact, these cells are capable of producing high amounts of IgG 
antibodies.  
In addition, the authors show that the subpopulation of isolated peripheral blood mononuclear 
cells (PBMCs) that are CD20-negative are more relevant regarding the production of 
antiphospholipid antibodies than PBMCs that are CD20-positive. Rituximab, a chimeric 
monoclonal antibody used as a treatment for autoimmune diseases, has been used within the 
antiphospholipid syndrome5. Rituximab binds CD20 and thereby silences CD20-positive B cells, 
preventing the production of autoimmune antibodies. Interestingly, trials with rituximab in 
patients with antiphospholipid syndrome have shown contrasting results. The failure of these 
trials might be partially related to the findings discussed above.  
Attempting to stop antibody production instead of preventing symptoms is not a new idea, as 
already in 1998, the group of Iverson et al studied treatment options in this respect6. 
Antiphospholipid antibodies have been shown to predominantly react with beta2-glycoprotein I. 
The first domain of beta2-glycoprotein I was shown to interact with auto-antibodies that were 
highly associated with thrombosis. In the early years when anti-domain I antibodies were gaining 
popularity, La Jolla Pharmaceutical Company developed a treatment strategy based on domain I 
reactivity. It produced a domain I tetramer in order to produce immune tolerance at the B-cell 
level. Unfortunately, this treatment has not reached the clinic. This might be because the 
population of antiphospholipid antibodies is heterogeneous. Although only antibodies that bind 
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beta2GPI have been included in the official criteria used to diagnose APS, even within the 
subpopulation of anti-beta2GPI antibodies there is heterogeneity as several different non-
continuous epitopes have been shown to react with antiphospholipid antibodies7. 
At present, different groups are working on different aspects of the antiphospholipid syndrome. 
More and more is being discovered about the mechanisms by which antiphospholipid antibodies 
induce thrombosis and pregnancy loss, although there is not yet absolute certainty regarding 
which mechanism is dominant. The recent multi-center study led by Devreese will, hopefully, 
further improves the diagnosis of antiphospholipid syndrome 2. Also, the study of Hisada et al 
has provided new paths that can be further investigated to potentially improve treatment of 
patients suffering from antiphospholipid syndrome 4. 
Figure 1. Mechanistical action of antiphospholipid antibodies (aPL): studies (2006 - March 2012). 
Adapted from Thromb. Res. 2013;132(3):319-326. CNS: central nervous system; EC: endothelial cells; HB-
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Background: Anti-cardiolipin (antiCL) and anti-β2glycoprotein I (aβ2GPI) IgA antiphospholipid 
antibodies (aPL) have shown to associate with thrombosis and pregnancy morbidity. However, 
inclusion of IgA aPL in the classification criteria of the antiphospholipid syndrome (APS) has been 
debated. 
Objectives: We investigated the value of antiCL and antiβ2GPI IgA aPL in the detection of 
thrombosis and pregnancy morbidity in addition to the current aPL panel for APS.  
Patients/Methods: We included 1068 patients from eight European medical centers: 259 
thrombotic APS patients, 122 obstetric APS patients, 204 non-APS thrombosis patients, 33 non-
APS obstetric patients, 60 APS patients with unspecified clinical manifestations, 196 patients with 
autoimmune diseases and 194 controls. antiCL and aβ2GPI IgG/M/A were detected with four 
commercial assays and LAC was determined by the local center.  
Results: Positivity for IgA aPL was found in 17-26% of the patients with clinical manifestations of 
APS and in 6-13% of the control population. Both antiCL and aβ2GPI IgA were significantly 
associated with thrombosis and pregnancy morbidity. Isolated IgA positivity was rare in patients 
with clinical manifestations of APS (0.3-5%) and not associated with thrombosis and/or 
pregnancy morbidity. Addition of IgA to the current criteria panel did not increase odds ratios for 
thrombosis nor pregnancy morbidity.  
Conclusions: antiCL and aβ2GPI IgA are associated with clinical manifestations of APS. However, 
isolated IgA positivity was rare and not associated with thrombosis or pregnancy morbidity. 
These data do not support testing for antiCL and antiβ2GPI IgA subsequent to conventional aPL 
assays in identifying patients with thrombosis or pregnancy morbidity. 
 




Clinical manifestations of the antiphospholipid syndrome (APS) include thrombosis and 
pregnancy morbidity 1. However, these manifestations occur frequently and often independent 
of APS. Therefore, classification of APS predominantly relies on antiphospholipid (aPL) assays 
detecting lupus anticoagulant (LAC) by coagulation tests or detection of anti-cardiolipin (antiCL) 
and anti-β2glycoprotein I (antiβ2GPI) antibodies from the IgG or IgM isotype by solid phase 
assays 1,2. Anti-cardiolipin and antiβ2GPI antibodies from the IgA isotype are not included in the 
current classification criteria 1,2. Multiple studies have illustrated an association of antiCL and 
antiβ2GPI IgA antibodies with thrombosis and pregnancy morbidity 3-12. Still, antiCL and aβ2GPI 
IgA are not included in the current guidelines 1,2. The main reason is unavailability of data to show 
the clinical significance of antiCL or antiβ2GPI IgA with clinical manifestations of APS in addition 
to the current aPL-panel 1,13. 
In a mouse model for thrombosis, IgA antibodies isolated from APS patients resulted in increased 
thrombus area, faster thrombus formation and decreased time of thrombus disappearance 
compared to control IgA 14. Outcomes of clinical studies have been contradictory regarding the 
association of antiCL and/or antiβ2GPI IgA with clinical symptoms of APS and their role in 
identifying additional APS patients with thrombosis or pregnancy morbidity 3-12,15,16. Multiple 
studies have shown that IgA is associated with thrombosis and pregnancy morbidity 3-12, other 
studies report no association of antiCL or antiβ2GPI IgA with thrombosis or pregnancy morbidity 
15,16. Isolated antiCL and/or antiβ2GPI IgA positivity was often found not to be associated with 
thrombosis or pregnancy morbidity 4,9,15-17. However, some studies concluded that antiCL and/or 
antiβ2GPI IgA is an independent risk factor for thrombosis 6,10,18. In addition to the clinical 
manifestations of APS, IgA positivity has also been associated with systemic lupus erythematosus 
(SLE), thrombocytopenia, heart valve disease, livedo reticularis and epilepsy 5,19. Comparison of 
clinical studies is difficult as multiple study designs are used with a wide variety of aPL assays and 
aPL cut-off values. Furthermore, solid phase assays detecting antiCL and antiβ2GPI antibodies 
are poorly standardized and produce variable results in a head-to-head comparison 20-22. 
In this multicenter study, we used four commercially available solid phase assays to detect antiCL 
and antiβ2GPI IgG/M/A, to assess for an association of antiCL and antiβ2GPI IgA and thrombosis 
or obstetric complications. 1068 patients were included of which 678 patients with clinical 
manifestations of APS and 390 patients that served as controls. We aimed to assess the added 
value of antiCL and antiβ2GPI IgA antibodies as a biomarker for thrombosis and pregnancy 




Materials and Methods  
Study population 
A total of 1068 patient samples were collected from eight medical European centers. The Sydney 
classification criteria were followed for the classification of thrombotic and obstetric APS (Table 
1) 1. Classification of thrombotic or obstetric APS was determined by the local center. In addition 
to APS patients, we included patients with an autoimmune disease other than APS (e.g. 54% SLE 
and 29% systemic sclerosis) without thrombotic complications (autoimmune disease (AID) 
controls); patients that were referred for aPL testing for other reasons (e.g. subfertility and 
prolonged activated partial thromboplastin time (aPTT)) than the clinical criteria of APS (controls); 
patients with a previous thrombotic event and negatively tested for aPL (non-APS thrombosis); 
and patients that experienced obstetric complications in the absence of aPL (non-APS obstetric). 
The study was approved by the local ethical committees. 
Laboratory assays  
Lupus anticoagulant  
Lupus anticoagulant assays were performed by the local center, according to the International 
Society of Thrombosis and Haemostasis-Scientific Standardization Subcommittee (ISTH-SSC) 
guideline 23. Briefly, citrated plasma was tested in a multiple step procedure (screening, mixing, 
confirmation step) with two test systems based on different principles (LA-sensitive aPTT and 
dilute Russell viper venom time) 1,23.  
Solid phase assays 
Commercially available solid phase assays were selected based on frequently used assays in the 
external quality control program of the ECAT (External quality Control of diagnostic Assays and 
Tests, Voorschoten, The Netherlands) and the willingness of manufacturers for providing the 
reagents. ACL and antiβ2GPI antibodies from the IgG, IgM and IgA isotype were detected at one 
occasion by four solid phase assays: BioPlex®2200 (Bio-Rad, Bio-Rad Laboratories, Hercules, USA), 
Phadia® (Thermo Fisher Scientific/Phadia, Uppsala, Sweden), HemosIL AcuStar® 
(Instrumentation Laboratories, Bedford, USA) and QUANTA Lite® ELISA (Inova Diagnostics, San 
Diego, USA) in the Ghent University Hospital (Ghent, Belgium). Detection of antiCL and antiβ2GPI 
antibodies was performed according to manufacturer’s instructions. Manufacturer’s 
recommended cut-off values were used upon confirmation in 20 healthy volunteers, in 
accordance with the ISTH-SSC guideline (Supplemental Table 1) 24. 
Statistical analyses 
Associations of antiCL and antiβ2GPI IgA positivity and clinical manifestations of APS were 
assessed by calculating odds ratios (ORs) with their respective 95% confidence intervals (CI). 
Thrombotic association with IgA aPL was assessed within patients with thrombotic APS, non-APS 
thrombosis, AID controls and controls (n=853). Obstetric association with IgA aPL was assessed 
within female patients with obstetric APS, non-APS obstetric APS, AID controls and controls 
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(n=483). The additional diagnostic value of antiCL and antiβ2GPI IgA antibodies was assessed by 
2x2 contingency tables. Kruskal–Wallis test was used to evaluate differences in IgA titers. To 
compare numbers (percentages) of positive tests between systems, the comparison of two 
proportions (from independent samples) was used. Statistical analyses were performed using the 
statistical package for social sciences (SPSS 23.0; SPSS, Chicago, IL) and MedCalc Statistical 
Software version 17.7.2 (MedCalc Software bvba, Ostend, Belgium). Statistical significance was 
set at P value less than 0.05. 
Results 
Patient characteristics  
We included 1068 patients of which 678 patients had clinical manifestations of APS and 390 
controls (Table 1). In thrombotic APS, venous thrombosis was more prevalent than arterial 
thrombosis (160 (62%) versus 55 (21%) patients, respectively; Table 1). From the 204 non-APS 
thrombotic patients, 149 (73%) had a history of venous thrombosis and 47 (23%) had a history of 
arterial thrombosis (Table 1). From the 259 thrombotic APS patients, the majority (40%) received 
Vitamin K antagonists, 5% received Low-Molecular-Weight Heparin (LMWH), 4% Direct Oral 
Anticoagulants (DOAC), 10% antiplatelet therapy, 8% a combination of oral anticoagulants and 
anti-platelet therapy. Details on anticoagulant and antiplatelet therapy of the remaining 83 (32%) 
patients are not available. Patients classified as non-APS thrombosis and non-APS obstetric were 
negatively tested for criteria aPL by the local medical center. However, retesting of the 204 non-
APS thrombosis patients resulted in 1.5 to 8% positives for antiCL and/or antiβ2GPI IgG/IgM, 
depending on the solid phase assay (►Table 2). Re-testing of 33 non-APS obstetric patients 
resulted in 0 to 12% positives for antiCL and/or antiβ2GPI IgG/IgM, depending on the solid phase 
assay (►Table 2). 
Prevalence of (isolated) antiCL and/or aß2GPI IgA  
Among patients with clinical manifestations of APS, 17-26% tested positive for antiCL and/or 
aβ2GPI IgA antibodies (Table 2). Positivity for antiCL and/or aβ2GPI IgA antibodies in thrombotic 
APS ranged between 26%-37%, dependent on the solid phase assay used to detect IgA antibodies. 
Within obstetric APS, positivity for antiCL and/or aβ2GPI IgA ranged between 16-34%, dependent 
on the solid phase assay. In the control group, consisting of AID patients and controls 6-8% were 
positive for antiCL and/or aβ2GPI IgA aPL. Isolated positivity for antiCL and/or aβ2GPI IgA 
(positive for IgA with negative LAC, IgG and IgM results) was rare in thrombotic and obstetric 
patients with a prevalence of 0%-3% and 1%-5%, respectively. Within AID and controls isolated 
antiCL and/or aβ2GPI IgA positivity ranged between 1%-4%. With two (BioPlex®2200 and 
HemosIL AcuStar®) out of the four tested solid phase assays, only 1% of the total study population 
was positive for IgA with negative LAC, IgG and IgM results. The other two solid phase assays 
detected more isolated IgA patients, 2% (Phadia®) and 3% (QUANTA Lite® ELISA).  
Correlation of antiCL and/or aß2GPI IgA with criteria aPL  
Within the total population consisting of 1068 patients, 408 (38%) were positive for LAC, thereby 
the most prevalent aPL (Supplemental Table 2). Immunoglobulin G was the most prevalent 
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antiCL or aβ2GPI antibody isotype in the total study population. Only 6% of the total patient 
population was positive for antiCL IgA, detected with QUANTA Lite® ELISA. By a comparison of 
two proportions, a significant difference (P<0.0001) was found for the number of patients 
positive for antiCL IgA and antiCL IgM, detected with either BioPlex®2200 or Phadia®. Detection 
of aβ2GPI IgM and IgA resulted in significant difference in number of positive samples with the 
BioPlex®2200 system only (P=0.0001). aβ2GPI IgG was more prevalent than aβ2GPI IgA 
antibodies, except when detected with BioPlex®2200 (P=0.0007). By a comparison of two 
proportions, significant differences were found between antiCL IgG and antiCL IgA for all solid 
phase assays. Prevelance of aPL in the subgroups (controls, AID, APS thrombosis, non-APS 
thrombosis, APS obstetric, non-APS obstetric and APS patients) are shown in Supplemental Table 
2. Lupus anticoagulant and antiCL or aβ2GPI IgA were highly correlated, as 63%-80% IgA positive 
patients were also characterized by positive LAC results (data not shown). Similar, 72%-83% of 
the patients positive for antiCL IgG, were also positive for LAC. aβ2GPI IgG and LAC showed an 
overlap of 77%-87%. Positive results for antiCL IgM or aβ2GPI IgM were less correlated with LAC, 
59%-74% and 72%-75%, respectively. Upon detection with BioPlex®2200, positivity for IgA aPL 
also highly correlated with triple positivity. Within the total population, the BioPlex®2200 
identified 221 triple positive patients of which 162 (73%) were positive for antiCL and/or aβ2GPI 
IgA antibodies. Other solid phase assays tested showed less correlation between IgA aPL and 
triple positivity (Phadia® (49%), HemosIL AcuStar® (60%) and QUANTA Lite® ELISA (48%)). 
Table 1. Demographic and clinical characteristics of the study population. 








































(81%) 46 (16-83) NA NA NA NA NA NA 
























(77%) 44 (16-87) 177 313 104 31 4 21 
*The medical center did not specify if the patient suffered from obstetric or thrombotic complications. 
NA, not applicable  
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Table 2. Additional diagnostic value of antiCL and antiβ2GPI IgA antibodies. Figures indicate the number 
of patients testing positive or negative for LAC, antiCL and antiβ2GPI IgG/M antibodies versus antiCL and 
antiβ2GPI IgA, for each solid phase assay.  

































































































+ 197 10 1 2 97 0 0 1 39 2 31 1 22 3 7 1 
2200 - 106 755 2 199 45 11
7 
0 32 20 61 9 19 22 149 8 17
8 












+ 121 26 2 7 60 4 1 2 17 4 21 1 17 7 3 3 
- 247 674 15 180 91 10
4 
3 27 49 52 22 16 44 128 23 16
5 














+ 147 6 0 0 77 0 0 0 24 1 26 1 15 4 5 0 
- 208 707 8 196 81 10
1 
1 32 41 56 18 15 44 133 15 17
4 














+ 102 34 1 7 62 5 0 1 14 6 15 1 8 10 2 4 
- 210 658 5 191 76 11
6 
3 29 45 57 31 13 40 138 10 17
8 




3 30 59 63 46 14 48 148 12 18
2 
Abbreviations: antiβ2GPI, anti-β2 glycoprotein I; antiCL, anticardiolipin; AID, autoimmune 
diseases; APS, antiphospholipid syndrome; IgA, immunoglobulin A; IgM, immunoglobulin M; LAC, 
lupus anticoagulant. 






Association of antiCL and/or aß2GPI IgA with thrombosis and pregnancy morbidity 
Both antiCL and aβ2GPI IgA positivity were significantly associated with thrombosis (Table 3). 
Positivity for antiCL IgA reached odds ratios (ORs) for thrombosis of 3.0 (95% confidence interval 
[CI], 1.9-4.9) to 9.9 (95% CI, 3.5-27.8). Anti-β2GPI IgA positivity showed ORs for thrombosis 
between 2.4 (95% CI, 1.5-3.9) to 3.1 (95% CI, 1.9-5.2). A stronger thrombotic association was 
found with antiCL IgA assays than the aβ2GPI IgA assay. Detection of antiCL IgA with QUANTA 
Lite® ELISA reached the highest OR for thrombosis (9.9 (95% CI, 3.5-27.8)). However, from the 47 
patients positive for antiCL IgA, only 43 patients with a history of thrombosis were detected with 
this assay, while the antiCL IgA assay from BioPlex®2200 detected 130 patients of which 100 
patients with a history of thrombosis. Positivity for antiCL and/or aβ2GPI IgA reached comparable 
ORs for thrombosis, between the tested assays with ORs between 2.2 (95% CI, 1.4-3.5) and 3.0 
(2.0-4.5).  
Positivity for both antiCL and aβ2GPI from the same isotype is considered to be more reliable for 
diagnosis of APS. Odds ratios for thrombosis did not increase in patients positive for antiCL and 
aβ2GPI IgA aPL, compared to patients positive for antiCL IgA or aβ2GPI IgA when detected with 
the BioPlex®2200 and HemosIL AcuStar. The other two tested solid phase assay showed an 
increase of OR for thrombosis in patients positive for antiCL and aβ2GPI IgA compared to ORs 
obtained from the antiCL and aβ2GPI IgA assay separately, most pronounced for QUANTA Lite 
ELISA. In comparison, patients positive for both antiCL and aβ2GPI IgG were characterized with a 
similar or slightly higher OR than positivity for antiCL IgG or aβ2GPI IgG. However, the increase 
in OR for double IgG positivity for QUANTA Lite ELISA was less pronounced compared to the 
increase observed in double IgA positivity for that platform. Also, for the IgM isotype similar 
results were obtained (Supplemental Table 3). Patients positive for both antiCL and aβ2GPI IgM 
antibodies were characterized with similar ORs for thrombosis than OR from an antiCL IgM or 
aβ2GPI IgM assay alone.  
IgA aPL were significantly correlated with pregnancy morbidity, independent of the solid phase 
platform (Table 3). Similar to thrombosis, the antiCL IgA assay from QUANTA Lite® ELISA reached 
the highest OR (5.0 (95% CI, 1.5-16.5)) for pregnancy morbidity. Double positivity for IgG or IgM 
resulted in slightly higher OR for three out of the four platforms (Supplemental Table 4). Double 
positivity for IgA (Table 3) resulted in significant higher OR for one platform (QUANTA Lite ELISA), 
in agreement with the thrombosis results.  
Association of antiCL and aβ2GPI IgA was calculated separately for venous and arterial 
thrombosis (Supplemental Table 5). ORs for venous thrombosis (n=309) ranged between 1.8 (95% 
CI, 1.1-2.8) to 7.0 (95% CI, 2.4-20.7) and 1.8 (95% CI, 1.1-3.0) to 2.4 (95% CI, 1.4-4.2), for antiCL 
and aβ2GPI IgA, respectively. ORs for arterial thrombosis (n=102) ranged between 2.2 (95% CI, 
1.2-4.0) to 14.1 (95% CI, 4.5-44.3) and 2.9 (95% CI, 1.5-5.6) to 3.8 (95% CI, 1.9-7.4) for antiCL and 
aβ2GPI IgA, respectively.  
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Association of isolated antiCL and/or aß2GPI IgA with thrombosis and pregnancy 
morbidity 
Isolated antiCL and/or aβ2GPI IgA positivity was not associated with thrombosis (Table 4). Odds 
Ratios varied between 0.4 (95% CI, 0.08-2.3) and 0.9 (95% CI, 0.4-2.2). In a more detailed analysis, 
no significant association was found for arterial or venous thrombosis and isolated IgA antiCL or 
aβ2GPI (Supplemental Table 5). Isolated antiCL or aβ2GPI IgA positivity was also not significantly 
associated with pregnancy morbidity with OR ranging between 0.7 (95% CI, 0.1-6.8) to 2.1 (95% 
CI, 0.4-10.7) (Table 4).  
 
Table 3. Thrombotic and obstetric association of antiCL and antiβ2GPI IgA antibodies. Odds ratios for 
thrombosis are calculated in a subpopulation including controls, AID, non-APS thrombosis and APS 
thrombosis patients (n=853). Odds ratios for pregnancy morbidity are calculated in a female 
subpopulation including controls, AID, non-APS obstetric and APS obstetric patients (n=483). 




Thrombosis antiCL 3.3 (2.1-5.1) 3.1 (1.6-6.1) 3.0 (1.9-4.9) 9.9 (3.5-27.8) 
n 130 49 101 47 
antiβ2GPI 2.8 (1.8-4.3) 2.4 (1.5-3.9) 2.5 (1.5-4.0) 3.1 (1.9-5.2) 
n 124 94 88 91 
antiCL and/or 
antiβ2GPI 
3.0 (2.0-4.5) 2.2 (1.4-3.5) 3.0 (1.9-4.9) 3.0 (1.8-4.8) 
n 133 103 101 99 
antiCL and 
antiβ2GPI 
3.1 (2.0-4.8) 4.2 (1.8-9.6) 2.4 (1.5-4.0) 35.8 (4.8-254.5) 
n 121 40 88 39 
Pregnancy 
morbidity 
antiCL 3.6 (2.1-6.1) 3.5 (1.5-8.3) 2.4 (1.3-4.5) 5.0 (1.5-16.5) 
n 67 23 47 13 
antiβ2GPI 2.9 (1.7-4.9) 1.9 (1.0-3.5) 2.2 (1.2-4.1) 2.7 (1.4-5.3) 
n 65 42 45 37 
antiCL and/or 
antiβ2GPI 
3.6 (2.1-5.9) 1.8 (1.0-3.4) 2.6 (1.4-4.7) 2.4 (1.3-4.6) 
n 73 49 48 41 
antiCL and 
antiβ2GPI 
2.9 (1.7-5.0) 4.9 (1.7-
14.5) 
2.1 (1.1-3.9) 17.8 (2.2-143.6) 
n 59 16 44 9 
Abbreviations: antiβ2GPI, anti-β2 glycoprotein I; antiCL, anticardiolipin; CI, confidence interval; n, number 
of patients positive for antiCL or antiβ2GPI IgA within the population; OR, odds ratio. 
Note: Odds ratios for thrombosis are calculated in a subpopulation including controls, AID, non-APS 
thrombosis, and APS thrombosis patients (n= 853). Odds ratios for pregnancy morbidity are calculated in 





Table 4. Thrombotic and obstetric association of isolated antiCL and antiβ2GPI IgA antibodies. Odds 
ratios for thrombosis are calculated in a subpopulation including controls, AID, non-APS thrombosis and 
APS thrombosis patients (n=853). Odds ratios for pregnancy morbidity are calculated in a female 
subpopulation including controls, AID, non-APS obstetric and APS obstetric patients (n=483).  




Thrombosis antiCL 0.6  1.3  0.5  1.7  
(0.1-3.4) (0.4-4.5) (0.4-0.5) (0.2-18.7) 
n 5 10 4 3 
antiβ2GPI 0.5  1.1  0.5  0.6 
(0.4-0.5) (0.4-2.9) (0.4-0.5) (0.3-1.5) 
n 4 16 4 23 
antiCL and/or 
antiβ2GPI 
0.4 0.9 0.5 0.7 
(0.08-2.3) (0.4-2.2) (0.4-0.5) (0.3-1.6) 
n 6 21 4 26 
antiCL and 
antiβ2GPI 
0.5  3.4  0.5  - 
(0.4-0.5) (0.4-30.5) (0.4-0.5) 
n 3 5 4 0 
Pregnancy 
morbidity 
antiCL 2.1  2.1 0.7 2.1  
(0.3-15.3) (0.4-10.7) (0.1-6.8) (0.1-34.2) 
n 4 6 4 2 
antiβ2GPI 2.1  1.7 0.7  1.5  
(0.4-10.7) (0.5-6.5) (0.6-0.7) (0.6-4.0) 
n 6 9 3 17 
antiCL and/or 
antiβ2GPI 
2.1 1.1 0.7 1.4 
(0.4-10.7) (0.3-3.6) (0.1-6.8) (0.5-3.6) 
n 6 12 4 18 
antiCL and 
antiβ2GPI 
2.1 0.3 0.7  0.3  
(0.3-15.3) (0.3-0.4) (0.6-0.7) (0.3-0.4) 
n 4 3 3 1 
Abbreviations: antiβ2GPI, anti-β2 glycoprotein I; antiCL, anticardiolipin; CI, confidence interval; n, number 
of patients positive within the indicated subpopulation; OR, odds ratio. 
Note: Odds ratios for thrombosis are calculated in a subpopulation including controls, AID, non-APS 
thrombosis, and APS thrombosis patients (n=853). Odds ratios for pregnancy morbidity are calculated in 
a female subpopulation including controls, AID, non-APS obstetric, and APS obstetric patients (n= 483). 
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Titers of isolated antiCL and/or aß2GPI IgA positive patients  
Within the total population, the QUANTA Lite® ELISA assay detected the highest number of 
isolated IgA samples (n=34 patients). Only 12%, 47% and 6% of these 34 patients were also 
positive for isolated IgA with the BioPlex®2200, Phadia® and HemosIL AcuStar® assay, 
respectively. Titers of isolated IgA aPL patients were low (Figure 1). Isolated antiCL and aβ2GPI 
IgA titers of patients with clinical manifestation were similar to IgA titers in the control population. 
Of note, upon aPL detection with Phadia®, one patient with a history of thrombosis and one 
patient with known pregnancy morbidity had an antiCL and aβ2GPI IgA titer >100 AU, while all 
patients in the control population had titers <100 AU (Figure 1C-D).  
antiCL and/or aß2GPI IgA titers of triple positive patients 
The majority of triple positive patients (LAC, antiCL and aβ2GPI IgG/M positivity, from the same 
isotype) had a history of thrombosis and/or pregnancy morbidity (Figure 2). antiCL and aβ2GPI 
IgA titers were found to be significantly different between triple positives and non-triple positives, 
independent of the solid phase assay. Triple positives for the IgG isotype (LAC, antiCL IgG and 
aβ2GPI IgG) had higher antiCL and aβ2GPI IgA titers than non-triple positive patients, 
independent of the solid phase assay. antiCL and aβ2GPI IgA titers from triple positives for the 
IgM isotype (LAC, antiCL IgM and aβ2GPI IgM) were also significantly higher than non-triple 
positives, independent of the solid phase assay. antiCL and aβ2GPI IgA titers of triple positives 





Figure 1. Isolated antiCL or antiβ2GPI IgA titers of controls and AID (control), APS thrombosis and non-
APS thrombosis (thrombosis), and APS obstetric and non-APS obstetric (pregnancy morbidity). (A) 
Isolated antiCL IgA titers detected with BioPlex®2200; (B) Isolated antiβ2GPI IgA titers detected with 
BioPlex®2200; (C) Isolated antiCL IgA titers detected with Phadia®; (D) Isolated antiβ2GPI IgA titers 
detected with Phadia®; (E) Isolated antiCL IgA titers detected with HemosIL AcuStar®; (F) Isolated 
antiβ2GPI IgA titers detected with HemosIL AcuStar®; (G) Isolated antiCL IgA titers detected with QUANTA 
Lite® ELISA; (H) Isolated antiβ2GPI IgA titers detected with QUANTA Lite® ELISA. Represented P-values 
were calculated using the Kruskal–Wallis test. antiβ2GPI, anti-β2 glycoprotein I; antiCL, anticardiolipin; 
APS, antiphospholipid syndrome; IgA, immunoglobulin A.  




Figure 2. antiCL or antiβ2GPI IgA titers of triple positive patients and non-triple positive patients. Solid 
dots in black indicate antiCL or antiβ2GPI IgA titers of patients without clinical manifestations of APS. Solid 
dots in red indicated antiCL or antiβ2GPI IgA titers of patients with clinical manifestations of APS.  (A) 
antiCL IgA titers detected with BioPlex®2200; (B) antiβ2GPI IgA titers detected with BioPlex®2200; (C) 
antiCL IgA titers detected with Phadia®; (D) antiβ2GPI IgA titers detected with Phadia®; (E) antiCL IgA titers 
detected with HemosIL AcuStar®; (F) antiβ2GPI IgA titers detected with HemosIL AcuStar®; (G) antiCL IgA 
titers detected with QUANTA Lite® ELISA; (H) antiβ2GPI IgA titers detected with QUANTA Lite® ELISA. 
Mean IgA titers with their 95% confidence intervals are shown. Significance was calculated using the 
Kruskal–Wallis test followed by Mann-Whitney U test.  *P-value <0.0001. antiβ2GPI, anti-β2 glycoprotein 
I; antiCL, anticardiolipin; APS, antiphospholipid syndrome; IgA, immunoglobulin A.  
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Additional value in thrombosis of antiCL and aß2GPI IgA in the current aPL-panel  
Inclusion of antiCL and aβ2GPI IgA antibodies in the current aPL-panel consisting of LAC, IgG 
and/or IgM antiCL and/or aβ2GPI did not increase ORs for thrombosis (Table 5). Replacement of 
IgM by IgA aPL resulted in similar ORs for thrombosis compared to the current classification 
criteria with most solid phase assays tested. However, an aPL panel consisting of LAC, antiCL 
IgG/M/A and aβ2GPI IgG/M/A resulted in similar ORs for thrombosis (2.4 (95% CI, 1.8-3.1)-2.8 
(95% CI, 2.1-3.7)) in comparison to calculated OR with an aPL panel consisting of LAC, antiCL 
IgG/M and aβ2GPI IgG/M (2.4 (95% CI, 1.8-3.2)-2.9 (95% CI, 2.2-3.9)).  
Table 5. Additional value of antiCL and antiβ2GPI IgA antibodies in thrombosis.  
  LAC, 
antiCL IgG, antiβ2GPI 
IgG, 





antiCL IgA and/or 
antiβ2GPI IgA 
LAC, 
antiCL IgG, antiβ2GPI IgG, 
antiCL IgM, antiβ2GPI IgM, 








BioPlex®2200 2.9 (2.2-3.9) 2.8 (2.1-3.7) 2.8 (2.1-3.7) 
Phadia® 2.4 (1.8-3.2) 3.1 (2.3-4.2) 2.4 (1.8-3.1) 
HemosIL AcuStar® 2.9 (2.1-3.8) 3.0 (2.3-4.1) 2.7 (2.0-3.6) 
QUANTA Lite® 
ELISA 2.8 (2.1-3.7) 3.1 (2.3-4.2) 2.6 (2.0-3.5) 
Abbreviations: antiβ2GPI, anti-β2 glycoprotein I; antiCL, anticardiolipin; CI, confidence interval; IgA, 
immunoglobulin A; IgM, immunoglobulin M; LAC, lupus anticoagulant. 
 
Additional value in pregnancy morbidity of antiCL and aß2GPI IgA in the current 
aPL-panel  
Positivity for at least one of the criteria aPL of APS resulted in significant ORs for pregnancy 
morbidity between 4.9 (95% CI, 3.2-7.4) and 6.6 (95% CI, 4.3-10.0), dependent on the solid phase 
assay (Table 6). An aPL panel for the classification of APS, consisting of LAC, IgG antiCL or aβ2GPI, 
antiCL or aβ2GPI IgA reached similar ORs, between 4.6 (95% CI, 3.0-6.9) and 5.1 (95% CI, 3.4-7.7). 
Positivity for LAC, IgG, IgM or IgA did not increase the OR for pregnancy morbidity as ORs 
between 4.6 (95% CI, 3.1-7.0) and 6.2 (95% CI, 4.1-9.4) were obtained.  
 
  
Assessment of antiCL and antiβ2GPI IgA aPL in APS  
117 
6 
Table 6. Additional value of antiCL and antiβ2GPI IgA antibodies in pregnancy morbidity. 
  LAC, 
antiCL IgG, antiβ2GPI 
IgG, 
antiCL IgM and/or 
antiβ2GPI IgM 
LAC, 
antiCL IgG, antiβ2GPI 
IgG, 
antiCL IgA and/or 
antiβ2GPI IgA 
LAC, 
antiCL IgG, antiβ2GPI IgG, 
antiCL IgM, antiβ2GPI IgM, 
antiCL IgA and/or 
antiβ2GPI IgA 
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI) 
BioPlex®2200 5.1 (3.4-7.7) 4.6 (3.0-6.9) 5.0 (3.3-7.6) 
Phadia® 4.9 (3.2-7.4) 4.7 (3.1-7.0) 4.6 (3.1-7.0) 
HemosIL AcuStar® 5.3 (3.5-8.0) 4.8 (3.2-7.2) 5.2 (3.4-7.8) 
QUANTA Lite® 
ELISA 
6.6 (4.3-10.0) 5.1 (3.4-7.7) 6.2 (4.1-9.4) 
Abbreviations: antiβ2GPI, anti-β2 glycoprotein I; antiCL, anticardiolipin; CI, confidence interval; IgA, 
immunoglobulin A; IgM, immunoglobulin M; LAC,lupus anticoagulant. 
 
Discussion  
In this study we evaluated the prevalence of antiCL and aβ2GPI IgA antibodies, tested with four 
solid phase platforms, in 1068 patients. We also investigated the added value of IgA aPL in APS 
classification.  
Of the 1068 included patients 6% up to 19% tested positive for antiCL IgA antiCL and 12%-18% 
for aβ2GPI IgA antibodies, dependent on the solid phase assay used. LAC was by far the most 
prevalent aPL (38%) in our study population consisting of 1068 APS patients and controls. In 
comparison, a retrospective study included 472 patients with aPL testing and found a similar 
distribution of antiCL IgA and aβ2GPI IgA antibodies, 6% and 19% respectively 10. Another study 
included 314 patients suspected for APS or related autoimmune diseases (e.g. SLE) and found 28% 
patients positive for aβ2GPI IgA using the QUANTA Lite® ELISA 15. We only found 12% of the 
patients positive for aβ2GPI IgA in the total population using the QUANTA Lite® ELISA. The lower 
prevalence of aβ2GPI IgA antibodies might be due to a different patient population as we 
included a large number of patients with a history of thrombosis or pregnancy morbidity, but 
negative for any consensus aPL as control population. Another cross-sectional study included 156 
patients that fulfilled the clinical criteria of APS and found a prevalence of 5% and 29% for antiCL 
IgA and aβ2GPI IgA positivity, respectively 8.  
In our study, antiCL as well as aβ2GPI IgA antibodies were correlated with clinical manifestations 
of APS (thrombosis and pregnancy morbidity), independent of the solid phase platform used. In 
agreement with our results, multiple studies have shown an association between clinical 
manifestations of APS and antiCL and/or aβ2GPI IgA antibodies 3-12. However, some studies were 
only able to show a clinical association for either antiCL or aβ2GPI IgA aPL detected with an in-
house ELISA 3,9. One retrospective study including 439 patient samples within a timespan of six 
years found an association between aβ2GPI IgA and thrombosis, but not for antiCL IgA 3. Another 
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retrospective study including 130 SLE patients and 35 patients with primary APS (PAPS) 
demonstrated a correlation of antiCL IgA aPL with a history of thrombosis and recurrent fetal loss, 
but were unable to show any correlation of aβ2GPI IgA aPL with clinical manifestations of APS 9.  
An external quality control program illustrated that antiCL and antiβ2GPI IgG/M assays produce 
variable results 20,25. We have previously shown that even within commercially available solid 
phase assays, detection of antiCL and antiβ2GPI IgG/M differs between platforms 21. Within our 
total population consisting of 1068 patients, 19.4%, 13.8%, 14.3% and 12.7% patients were found 
to be positive for antiCL and/or antiβ2GPI IgA antibodies detected with BioPlex®2200, Phadia®, 
HemosIL AcuStar® and QUANTA Lite® ELISA, respectively. These data indicate that the detection 
of IgA aPL also depends on the solid phase assay that is used. Other studies also showed the lack 
of standardization in IgA aPL detecting assays 26-28. In a subpopulation from the PROMISSE cohort 
antiβ2GPI IgA was detected in 18.9% and 55.6% of the patients, detected with QUANTA Lite® 
ELISA and BioPlex®2200, respectively 26. Taken together, these results indicate that the detection 
and association of IgA aPL is dependent on the solid phase assay and study population.  
In agreement with a previous cross-sectional study, we confirmed the association of antiCL and 
antiβ2GPI IgA with arterial and venous thrombosis 8. However, some studies found an association 
between IgA aPL and venous thrombosis, but were unable to show an association with arterial 
thrombosis and vice versa 17,18,29. In contrast, a recent study could not demonstrate an 
association between antiβ2GPI IgA aPL and thrombosis  15. Positivity for antiβ2GPI IgA aPL was 
found in 31% of the included APS patients  15, as well as a large portion (30%) of SLE patients was 
found to be positive for antiβ2GPI IgA aPL  15. Upon exclusion of SLE patients, a significant 
association was found between antiβ2GPI IgA and venous thrombosis (OR 2.5 (95% CI, 1.1-4.9)) 
15.  
In our cohort, positive antiCL and/or antiβ2GPI IgA results were significantly associated with 
pregnancy morbidity, as defined in the Sydney criteria. However, the non-APS obstetric group 
was relative small (n=33), compared to obstetric APS patients (n=122) which might have affect 
the association of aPL and pregnancy morbidity. Limited data are available on the association 
between IgA aPL and obstetric complications  4,8,9,15. Most studies found a value for antiCL or 
antiβ2GPI IgA testing in pregnancy morbidity 4,8,9. However, a study that included 314 patients 
suspected from APS or related autoimmune diseases (e.g. SLE) did not found a significant 
association for antiCL or antiβ2GPI IgA aPL with pregnancy morbidity 15. Interestingly, no 
association of antiCL IgG/M and antiβ2GPI IgG/M with pregnancy morbidity was found within the 
same study 15.  
Pathogenicity of IgA aPL have been shown in animal models 14,18. In mice, IgA antibodies from 
APS patients increased the mean thrombus area and mean thrombus disappearance time upon 
induced thrombus formation of a non-occlusive thrombus by pinch injury 14. IgA antibodies were 
purified from two APS patients of which one was also positive for antiCL IgG and LAC. The other 
patient was positive for antiCL IgA, but negative for antiCL IgG, antiCL IgM and LAC 14. However, 
the authors did not demonstrate that antiCL is solely responsible for the observed effect 14. 
Another study also showed that IgA isolated from APS patients is pathogenic as thrombus 
formation and tissue factor activity in mice injected with IgA from APS was increased compared 
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to control IgA 18.  These data indicate that IgA aPL can be pathogenic 14,18. However, pathogenic 
IgA aPL seem to correlate with LAC.  
Despite the association of antiCL and/or antiβ2GPI IgA aPL with thrombosis shown in multiple 
studies, only some have suggested an added value for IgA testing in patients suspected of 
thrombotic APS  6,8,10,12,18,30. Although an added value was suggested for so called ‘isolated IgA’ 
by some studies, many studies did not include LAC testing, hampering assessment of true isolated 
IgA aPL 8,12,18,30. In a retrospective study testing 472 patients with suspected or confirmed 
thrombophilia, an autoimmune disease or pregnancy morbidity 10, IgA (antiCL, antiβ2GPI and/or 
anti-phosphatidylserine (antiPS)) aPL positivity was found to be an independent risk factor for 
thrombosis using a multivariate analysis 10 . Detection of antiCL and antiPS IgG, IgM and IgA 
antibodies were performed with another platform than detection of antiβ2GPI IgG, IgM and IgA 
antibodies 10. Considering the high variability between solid phase platforms in antibody 
detection, classification of APS patients and the association of aPL might be affected. It is 
suggested to detect all aPL within the same system for the classification of APS patients  21. In 
addition, the method used to determine the cut-off value for an aPL assay has also shown to 
affect between-assay performance 31. Also, antibody heterogeneity has been suggested to 
attribute to variability in test results 32.  
We defined isolated antiCL and/or antiβ2GPI IgA positivity for antiCL and/or antiβ2GPI IgA aPL, 
as negative for antiCL and/or antiβ2GPI IgG/M and/or LAC. Isolated IgA positivity was rare in the 
total population. Overall, the prevalence of isolated IgA was comparable between patients with 
clinical manifestations of APS and patients without a history of thrombosis or pregnancy 
morbidity. Positivity for isolated IgA aPL was not associated with thrombosis or pregnancy 
morbidity as calculated OR did not reach statistical significance. Titers of IgA positive patients 
were characterized by low antiCL or antiβ2GPI IgA titers, around the cut-off value. Other non-
criteria aPL like anti- phosphatidylethanolamine (PE), negatively charged phospholipids (other 
than cardiolipin), anti-vimentin/cardiolipin, Annexin A5 and anti-
phosphatidylserine/prothrombin (antiPS/PT) antibodies have been suggested to be clinical 
relevant in patients suspected of APS, but negatively tested for consensus aPL 33. A recent 
systematic review showed a strong association between antiPS/PT aPL and clinical 
manifestations of APS, with a high association with LAC 34. However, this needs to be validated 
in a large multicenter study.  
In this study, we aimed to investigate the value of antiCL and antiβ2GPI IgA aPL in addition to the 
current aPL panel (LAC, antiCL IgG/M and antiβ2GPI IgG/M). Positivity for IgA aPL was found to 
be associated with thrombosis and pregnancy morbidity. However, isolated IgA positivity was 
rare and not correlated with clinical manifestations of APS. Our results do not support testing for 
antiCL and/or antiβ2GPI IgA in addition to conventional aPL for the identification of patients with 
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Supplemental Table 1. Cut-off values of antiCL IgG/M/A and antiβ2GPI IgG/M/A detected with 
BioPlex®2200, Phadia®, HemosIL AcuStar® and QUANTA Lite® ELISA.  
  antiCL IgG antiβ2GPI 
IgG 
antiCL IgM antiβ2GPI 
IgM 
antiCL IgA antiβ2GPI 
IgA  
BioPlex®2200 20 20 20 20 20 20 
 








20 20 20 20 20 20 
 
Supplemental Table 2. Prevalence of LAC, antiCL and antiβ2GPI IgG/M/A in the total population 
(n=1068).  
 
LAC IgG IgM IgA 
antiCL antiβ2GPI antiCL antiβ2GPI antiCL antiβ2GPI 
n (%) n (%) n (%) n (%) n (%) n (%) n (%)  
408 (38) 
      
BioPlex®2200 
 
248 (23) 252 (24) 118 (11) 131 (12) 200 (19) 187 (18) 
Phadia® 
 








191 (18) 142 (13) 170 (16) 152 (14) 67 (6) 126 (12) 
Supplemental Table 3. Thrombotic association of antiCL and antiβ2GPI IgG/M antibodies. Odds ratios 
are calculated in a subpopulation including controls, AID, non-APS thrombosis and APS thrombosis 
patients (n=853). 
  BioPlex®2200 Phadia® HemosIL AcuStar® QUANTA Lite® ELISA 
antiCL IgG 3.2 (2.2-4.7) 4.2 (2.7-6.5) 4.1 (2.7-6.3) 4.5 (2.8-7.4) 
N 163 137 144 121 
antiβ2GPI IgG 2.8 (1.9-4.1) 3.5 (2.3-5.4) 2.8 (1.9-3.9) 5.4 (3.0-9.6) 
n 166 134 193 91 
antiCL and antiβ2GPI 
IgG 3.3 (2.2-5.0) 4.1 (2.5-6.7) 4.3 (2.8-6.8) 5.3 (2.9-9.6) 
n 157 113 140 84 
antiCL IgM 2.5 (1.5-4.1) 1.6 (1.1-2.3) 1.7 (1.1-2.5) 2.0 (1.3-3.1) 
n 82 147 119 105 
antiβ2GPI IgM 2.7 (1.6-4.4) 2.2 (1.4-3.4) 2.6 (1.5-4.5) 2.0 (1.3-3.2) 
n 86 94 74 97 
antiCL and antiβ2GPI 
IgM 2.7 (1.6-4.7) 2.7 (1.6-4.6) 2.7 (1.5-4.7) 2.4 (1.4-4.2) 
n 76 79 67 74 
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Supplemental Table 4. Obstetric association of antiCL and antiβ2GPI IgG/M antibodies. Odds ratios are 
calculated in a female subpopulation including controls, AID, non-APS obstetric and APS obstetric patients 
(n=483). 
Pregnancy morbidity BioPlex®2200 Phadia® HemosIL AcuStar® 
QUANTA Lite® 
ELISA 
antiCL IgG 3.5 (2.2-5.7) 5.1 (3.0-8.7) 4.5 (2.7-7.6) 5.2 (2.9-9.2) 
n 89 71 74 59 
antiβ2GPI IgG 3.3 (2.1-5.3) 3.6 (2.1-6.1) 2.8 (1.8-4.4) 4.2 (2.1-8.6) 
n 91 69 102 36 
antiCL and antiβ2GPI 
IgG 3.7 (2.3-6.1) 4.6 (2.6-8.2) 4.6 (2.7-7.7) 3.8 (1.8-7.8) 
n 85 58 72 34 
antiCL IgM 3.0 (1.6-5.7) 2.0 (1.2-3.3) 2.0 (1.2-3.4) 2.9 (1.7-5.0) 
n 41 81 69 61 
antiβ2GPI IgM 3.1 (1.7-5.8) 3.2 (1.8-5.8) 3.6 (1.8-6.9) 2.7 (1.5-4.7) 
n 46 51 40 55 
antiCL and antiβ2GPI 
IgM 3.2 (1.6-6.2) 3.3 (1.6-6.5) 3.7 (1.8-7.5) 2.9 (1.5-5.6) 
n 40 36 36 38 
 
Supplemental Table 5. Association of antiCL and antiβ2GPI IgA with venous or arterial thrombosis. Odds 
ratios are calculated with their respective 95% confidence intervals for each solid phase assay. Significant 
odds ratios are shown in bold.  
 
 
Venous (n=309) Arterial (n=102) 
IgA 
OR (95% CI) 
Isolated IgA 
OR (95% CI) 
IgA 
OR (95% CI) 
Isolated IgA 
OR (95% CI) 














































































Chapter 7  
The clinical relevance of isolated lupus 
anticoagulant positivity in patients with 
thrombotic antiphospholipid syndrome 
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Background: Patients positive for all three types of antiphospholipid antibodies (aPLs) (triple 
positivity) have been identified for having a high risk for thrombotic events. However, the clinical 
significance of isolated lupus anticoagulant (LAC) positivity is debated. 
Objectives: To investigate the clinical relevance of isolated LAC.  
Patients/Methods 456 patients were enrolled in this study; 66 antiphospholipid syndrome 
patients and 390 control patients. The control group existed of autoimmune patients (n=91), 
patients with thrombosis but without aPLs (n=127) and normal controls (n=172). LAC, anti-
cardiolipin (antiCL) and anti-beta2glycoprotein I (antiβ2GPI) IgG and IgM were determined 
according to the ISTH guidelines. antiCL and antiβ2GPI was measured by four different solid 
phase platforms to overcome variability between test systems. The non-criteria IgA antiCL and 
antiβ2GPI, anti-domain I (antiDI) of β2GPI IgG and anti-phosphatidylserine/prothrombin 
antibodies (anti-PS/PT) IgG and IgM were detected according to the ISTH guidelines for solid 
phase assays. 
Results: 70 patients were positive for LAC, of which 44 were negative for both antiβ2GPI and 
antiCL antibodies. We found that isolated LAC proved to be strongly associated with vascular 
thrombosis (Odds ratio (OR) (95% CI) 7.3 (3.3-16.1)), even better than triple positive samples (OR 
4.3 (1.6-12.2)). The titers of the anti-PS/PT IgG and IgM were significantly higher in triple positivity 
samples compared to samples with isolated LAC positivity. The majority of single LAC positives 
were anti-PS/PT negative. We observed that LAC positivity was weaker in isolated LAC positive 
patients compared to LAC activity in triple positive patients. 
Conclusions: Isolated LAC was highly associated with thrombosis. The presence of anti-PS/PT 
antibodies could not explain LAC positivity in isolated LAC. Isolated LAC showed a weaker LAC 
activity compared to triple positive patients.  





Lupus anticoagulant (LAC) is a functional assay that measures phospholipid-dependent 
prolongation of the clotting time. LAC requires a three-step procedure including a screening, a 
mixing and a confirmatory step, as advised by the Scientific and Standardization Committee (SSC) 
of the International Society on Thrombosis and Haemostasis (ISTH) 1-5. Currently, LAC together 
with anti-cardiolipin (antiCL) IgG/IgM antibodies and anti-beta2glycoprotein I (antiβ2GPI) 
IgG/IgM antibodies are included in the international criteria to classify the antiphospholipid 
syndrome (APS) 5-7. Patients positive for the combination of LAC, antiβ2GPI and antiCL antibodies, 
the so-called triple positive patients, exhibit a high risk for developing a first thrombotic event 
and recurrence of thrombosis 8,9.  
Although a positive LAC is considered to be a strong risk factor for thrombosis in APS 10,11, the 
clinical relevance of isolated LAC positivity, in the absence of antiCL and antiβ2GPI antibodies has 
been widely debated. Recent studies showed a poor predictive value for a first thrombotic event 
for isolated LAC 12,13, however, other studies suggested a strong predictive value. A large 
multicenter, population-based case-control study showed that LAC positivity predicts acute 
myocardial infarction and ischaemic stroke, whereas the presence of any other antiphospholipid 
antibodies (aPLs) did not show any clinical association 14. More recently, a prospective 
observational study found that in a LAC positive population the association between occurrence 
of thrombosis and inferior survival was independent of the detection of antiCL and antiβ2GPI 
antibodies 15. Data from 158 stroke cases and 369 controls indicated that LAC is a strong risk 
factor for stroke, especially in young and middle-aged individuals. On the contrary, the presence 
of other aPLs showed very low association with increased risk for stroke 16.  
The aim of this study is to investigate the clinical relevance of isolated LAC positivity, and explore 




In total, 456 patients were included in this study. The study was approved by the Ethics 
Committee of the Ghent University Hospital and conducted according to the Declaration of 
Helsinki (2013). Blood (9 volumes) was drawn aseptically in vacutainer tubes (Greiner Bio-One) 
containing 3.2% sodium citrate (1 volume), from the antecubital vein.  Immediately after blood 
drawing, platelet poor plasma was prepared by centrifuging the blood twice for ten minutes at 




Lupus anticoagulant and antiphospholipid syndrome 
Lupus anticoagulant was determined using the STA-R Evolution®Coagulation Analyzer 
(Diagnostica Stago, Asnieres, France) according to ISTH guidelines 1 applying dilute Russell’s viper 
venom time (dRVVT Screen and dRVVT Confirm, Diagnostica Stago, Asnières-sur-Seine, France) 
and a sensitive activated partial thromboplastin time (aPTT) with silica as an activator (PTT-LA, 
Diagnostica Stago, Asnières-sur-Seine, France). Patient samples were considered positive when 
at least one test system was positive, based on in-house calculated cut-off values for screening, 
mixing and confirmation tests, all expressed as normalized ratio. In the dRVVT system, the 
confirmation step was expressed as a ratio of Screen/Confirm. In the aPTT system, the 
confirmatory step for aPTT is expressed as a difference in clotting time between two aPTTs with 
and without hexagonal phase II phospholipids. Diagnosis of APS was based on the Sydney criteria 
6. 
Solid phase assays 
AntiCL IgG, IgM and IgA and antiβ2GPI IgG, IgM and IgA were detected by four different solid 
phase assays: HemosIL AcuStar® (Instrumentation Laboratories, Bedford, USA), BioPlex®2200 
(Bio-Rad, Bio-Rad Laboratories, Hercules, USA), Phadia® (Thermo Fisher Scientific/Phadia, 
Uppsala, Sweden) and QUANTA Lite® ELISA (Inova Diagnostics, San Diego, USA). Anti- β2GPI IgG 
antibodies recognizing the first domain (antiDI) were detected by the chemiluminescence 
QUANTA Flash® β2GPI domain I assay (Inova Diagnostics, San Diego, USA) on the ACL AcuStar® 
platform. Anti-phosphatidylserine /prothrombin (anti-PS/PT) IgG and IgM antibodies were 
determined by QUANTA Lite antiPS/PT ELISA assay (Inova Diagnostics, San Diego, USA). Results 
were expressed as arbitrary units. All tests were performed following the instructions of the 
manufacturer. The cut-off values from the manufacturers were transferred after confirmation in 
20 healthy individuals according to the guidelines 17. Based on the cut-off values positive samples 
were identified. 
Statistics 
Statistical analysis was performed using IBM SPSS® Statistics (IBM SPSS, New York, USA). 
Association between the presence of the antibodies and the thrombosis risk was investigated by 
calculating Odds ratios (ORs) with the 95% confidence interval (CI). The Chi-squared test was used 
for comparison of prevalence, while the Mann-Whitney U test for comparison of continuous 
variables between two different antibody groups. P-values less than 0.05 (two-tailed) were 
considered to be statistically significant.   
Results 
Antibody profile and patient characteristics 
In total, 456 patients were included in this study. The demographic data and the patient 
characteristics are summarized in Table 1. The mean age of patients was 44 years (±SD, ±13) and 
the male/female prevalence in this group was 27% versus 73%. The population of patients 
consisted of 66 APS patients, 91 autoimmune disease (AID) patients, 127 non-APS thrombosis 




patients and 172 normal controls. The AID control patients had autoimmune diseases other than 
APS, such as systemic lupus erythematosus (n=21) and systemic sclerosis (n=55), without 
thrombotic or pregnancy morbidity complications. Non-APS thrombosis patients were patients 
that had experienced thrombosis in the past, but tested negative for the laboratory criteria for 
APS. The normal controls were patients that were referred for aPL antibody testing for other 
reasons than the clinical criteria of APS, including subfertility (n=115) and prolonged activated 
partial thromboplastin time (n=7). Seventy patients tested positive for LAC and 386 patients were 
LAC negative, of which 11 (3%) were classified as APS patients based on a positive antiCL and/or 
antiβ2GPI IgG/IgM assay. The LAC positive patients were tested positive on 2 separate occasions 
according to the ISTH guidelines 5. Fifty-five out of these 70 patients were diagnosed with APS, 
13 were AID patients and 2 were normal controls.  
When the isolated LAC patients were compared to the triple positive patient group, the age and 
male/female ratio were balanced (p=0.11 and p=0.74, respectively), as well as their clinical 
characteristics (Table 2). Twenty out of 70 LAC positive patients were triple-positive (LAC, antiCL 
IgG or IgM, anti- β2GPI IgG or IgM), in combination with antiCL and/or anti- β2GPI antibody 
positivity in at least one of the four platforms. Out of these 20 triple positive patients 14 were 
APS patients, 4 were AID controls and 1 was a normal control. Of the 15 APS patients, 7 patients 
had a history of venous thrombosis, 1 patient had a history of arterial thrombosis and 7 patients 
had a combination of venous/arterial thrombosis and pregnancy morbidity. Forty-four patients 
were isolated LAC positive and tested negative for antiCL IgG, antiCL IgM, antiβ2GPI IgG and 
antiβ2GPI IgM on all four platforms used to detect the presence of these antibodies. Thirty-six 
(82%) out of 44 were diagnosed as APS patients, 7 were AID patients and 1 was a normal control. 
Of these 36 APS patients, 28 had a history of venous thrombosis, six had a history of arterial 
thrombosis and 2 had a combination of venous thrombosis and arterial thrombosis or pregnancy 
morbidity.  Six out of 70 LAC positive patients were LAC positive with antiCL or anti- β2GPI 
antibodies and 4 (67%) of them were APS patients. 
Non-criteria aPL antibodies, including antiβ2GPI and antiCL IgA antibodies, anti-domain I IgG 
antibodies and anti-PS/PT IgG and IgM antibodies, were studied for their association with both 
isolated LAC and triple positivity (Table 3). For IgA we found a lower prevalence of antiCL and 
antiβ2GPI IgA in the isolated LAC group compared to triple positive patient group (antiCL: 0-5% 
versus 30-55% and antiβ2GPI: 0% versus 30-55%). For anti-domain I antibodies we found no 
patients positive with an isolated LAC compared to 55% in the group of patients with triple 
positivity. Anti-PS/PT IgG (7% versus 40%) and anti-PS/PT IgM (11% versus 80%) were less 
prevalent in the isolated LAC group compared to the triple positive group. Both the anti-PS/PT 
IgG and anti-PS/PT IgM titers were significantly lower in the isolated LAC group compared to the 
triple positive group, with a median anti-PS/PT IgG titer of 6.8 U/ml (interquartile range (IQR) 5.9-
8.6) versus 13.0 U/ml (IQR 6.2-77.9) (Mann–Whitney U test, P = 0.006), and a median anti-PS/PT 
IgM titer of 13.0 U/ml (IQR 8.3-20.5) versus 77.3 U/ml (IQR 34.4-324.5) (Mann–Whitney U test, 
P < 0.0001) (Figure 1A). For the anti-PS/PT IgG and anti-PS/PT IgM positive samples (> 30 U/ml), 
the anti-PS/PT IgG or anti-PS/PT IgM titers did not differ between the isolated LAC positive group 
and the triple positive group (Figure 1B).  
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Table 1: Patient characteristics. The patients are divided into four groups: APS, autoimmune disease, non-
APS and a normal control group. The presence of the antiCL and antiβ2GPI antibodies was tested with 
four solid phase assays (HemosIL AcuStar®, BioPlex®2200, Phadia® and QUANTA Lite® ELISA). Other 
antibodies were detected with the antiPS/PT ELISA or the CLIA anti-domainI (Inova diagnostics). 
  Total n (%) 
Patients 456 
  Female 333 (73) 
  Age [years, mean ± SD] 44 ± 13 
APS group 66 (14) 
  Primary APS 60 (13) 
  Secondary APS 6 (1) 
  APS-thrombosis only 58 (13) 
    Venous thrombosis 42 (9) 
    Arterial thrombosis 14 (3) 
    Both venous thrombosis and arterial thrombosis 2 (0.4) 
  APS-both thrombosis and pregnancy morbidity 8 (2) 
Autoimmune disease group 91 (20) 
  Systemic lupus erythematosus 21 (5) 
  Systemic sclerosis 55 (12) 
  Other autoimmune disease 15 (3) 
Non-APS thrombosis group 127 (28) 
    Venous thrombosis 88 (19) 
    Arterial thrombosis 34 (7) 
    Both venous thrombosis and arterial thrombosis 5 (1) 
Normal control group 172 (38) 
    Subfertility/infertility 115 (25) 
    Prolonged activated partial thromboplastin time 7 (2) 
    non-APS related clinical features 50 (11) 
Antiphospholipid antibodies  
  Lupus anticoagulant 70 (15) 
  Criteria aPL antibodies (antiCL and/or antiβ2GPI IgG/M)  
      HemosIL AcuStar® 56 (12) 
      BioPlex®2200 36 (8) 
      Phadia® 73 (16) 
      QUANTA Lite® ELISA 47 (10) 
  Non-criteria aPL antibodies  
    antiCL and/or antiβ2GPI IgA  
      HemosIL AcuStar® 17 (4) 
      BioPlex®2200 26 (6) 
      Phadia® 45 (10) 
      QUANTA Lite® ELISA 20 (4) 
    anti-Domain I IgG 18 (4) 
    anti-PS/PT IgG 59 (13) 
    anti-PS/PT IgM 66 (14) 
Secondary APS: APS related to autoimmune disease. Abbreviations: APS, antiphospholipid syndrome; aPL, 
antiphospholipid antibodies; antiCL, anti-cardiolipin; antiβ2GPI, anti-beta2glycoprotein I; anti-PS/PT, anti-
phosphatidylserine/prothrombin.  




Table 2: Clinical characteristics of patients with isolated LAC and triple positivity.  
  
Isolated LAC Triple positivity 
P-value 
n (%) n (%) 
Patients  44 20  
  Female  21 (48) 14 (70) 0.113 
  Age [years, median (range)] 47 ± 16 48 ± 15 0.798 
APS group 36 (82) 15 (75) 0.523 
  Primary APS 36 (82) 12 (60) 0.117 
  Secondary APS 0 3 (15)  
  APS-related clinical features 36 (82) 15 (75)  
    Venous thrombosis 28 (64) 7 (35) 0.057 
    Arterial thrombosis 6 (14) 1 (5) 0.419 
    Both venous thrombosis and arterial thrombosis 1 (2) 0  
    Venous thrombosis and pregnancy morbidity 1 (2) 3 (15)  
    Arterial thrombosis and pregnancy morbidity 0 3 (15)  
    Both venous and arterial thrombosis and 
pregnancy morbidity 0 1 (5) 
 
Autoimmune disease group 7 (16) 4 (20) 0.728 
    Systemic lupus erythematosus 2( 5) 2 (10) 0.583 
    Systemic sclerosis 3 (7) 2 (10) 0.644 
    Other autoimmune disease 2 (5) 0  
Normal control group 1 (2) 1 (5) 0.531 
    Superficial phlebitis 1 (2) 0  
    Venous insufficiency 0 1 (5)  
Secondary APS is APS related to autoimmune disease. Abbreviations: APS, antiphospholipid syndrome; 
LAC, lupus anticoagulant.   
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Table 3. Antiphospholipid antibody characteristics of LAC-positive patients. The presence of the antiCL 
and antiβ2GPI antibodies was tested with four solid phase assays (HemosIL AcuStar®, BioPlex®2200, 
Phadia® and QUANTA Lite® ELISA). Other antibodies were detected with the antiPS/PT ELISA or the CLIA 
anti-domain I (Inova diagnostics). 
  Isolated LAC positivity Triple positivity 
Patients (n) 44 20 
Antiphospholipid antibodies n (%)  
 
  Criteria aPL antibodies (antiCL/antiβ2GPI IgG/M)  
 
        HemosIL AcuStar® 0 18 (90) 
        BioPlex®2200 0 17 (85) 
        Phadia®   0 19 (95) 
        QUANTA Lite® ELISA 0 18 (90) 
    Non-criteria aPL antibodies  
 
      antiCL IgA  
 
        HemosIL AcuStar® 0 8 (40) 
        BioPlex®2200 0 11 (55) 
        Phadia®   2 (5) 11 (55) 
        QUANTA Lite® ELISA 0 6 (30) 
      antiβ2GPI IgA  
 
        HemosIL AcuStar® 0 7 (35) 
        BioPlex®2200 0 11 (55) 
        Phadia®   0 6 (30) 
        QUANTA Lite® ELISA 0 6 (30) 
      anti-Domain I IgG 0 11 (55) 
      anti-PS/PT IgG 3 (7) 8 (40) 
      anti-PS/PT IgM 5 (11) 16 (80) 
aPL, antiphospholipid; antiCL, anti-cardiolipin; antiβ2GPI, anti-beta2glycoprotein I; LAC, lupus 
anticoagulant; anti-PS/PT, anti-phosphatidylserine/ prothrombin. 
 







































Figure 1: Comparison of anti-PS/PT IgG and IgM titers between patients with isolated LAC positivity and 
patients with triple positivity. The titers of anti-PS/PT antibodies (A) and the titers of anti-PS/PT positive 
antibodies (B) are expressed as the median with interquartile ranges.  **P < 0.01, ****P < 0.0001. 





Association of isolated LAC and triple positivity with thrombosis 
The association between isolated LAC or triple positivity with thrombosis resulted in an OR (95% 
CI) of 7.3 (3.3-16.1) and 4.3 (1.6-12.2), respectively (Table 4A). To avoid a possible bias, we re-
calculated the association of isolated LAC with thrombosis after removing the triple positive 
samples and we re-calculated the association of triple-positivity with thrombosis after removing 
the samples with isolated LAC. The OR for developing thrombosis of the isolated LAC remained 
higher than the OR of triple-positivity (7.9 (3.6-17.5) versus 5.3 (1.9-14.8)) (Table 4A). The 
association between isolated LAC or triple positivity and APS showed overall higher ORs (Table 
4B), also higher in the isolated LAC group compared to the triple positive group.   
Table 4: Association of isolated LAC and triple positivity with thrombosis. OR of isolated LAC and triple 
positive patients are given for thrombosis versus non-thrombosis patients (A) and for APS versus non-APS 
patients (B). The given OR are either regarding the whole population or by excluding single or triple 
positive patients as indicated. 
A. Thrombosis versus non-thrombosis patients 
Patient group   OR 95%CI 
Isolated LAC 
positivity in total population 7.3 3.3-16.1 
Triple positivity in total population 4.3 1.6-12.2 
Isolated LAC 
positivity in population with taking out triple positivity 7.9 3.6-17.5 
Triple positivity in population with taking out isolated LAC positivity 5.3 1.9-14.8 
 
B. APS versus non-APS patients 
Patient group   OR 95%CI 
Isolated LAC positivity in total population 57.3 24.5-134.3 
Triple positivity in total population 22.6 7.9-64.9 
Isolated LAC positivity in population with taking out triple positivity 113.1 44.9-284.8 
Triple positivity in population with taking out isolated LAC positivity 75.4 24.2-234.8 








Strength of LAC activity; isolated LAC versus LAC in triple positive patients 
Isolated positive LAC patients showed weaker LAC activity compared to triple positive patients, 
although there were differences between the aPTT and the dRVVT (Figure 2). There was no 
difference between the prolongation of the dRVVT Screen in isolated LAC samples compared to 
triple positive samples 1.70 (1.47 - 2.13) versus 1.96 (1.47 - 2.74, P = 0.118). When we analyzed 
the confirmation step, we observed lower Screen/Confirm ratios in the isolated LAC group (1.39 
(1.33 - 1.50)) compared to the triple positive group (1.60 (1.38 - 1.96), p = 0.007) (Figure 2A). The 
aPTT-Screen appeared to be lower in the isolated LAC group compared to the triple positive 
group 1.38 (1.21 - 1.55) versus 1.80 (1.34 - 2.62), P = 0.004), while the confirmation results did 
not show significant differences between the two groups 1.45 (-0.58 - 11.50) seconds versus 4.85 
(1.65 - 12.73) seconds, P = 0.118) (Figure 2B).  
For the mixing step, both dRVVT and aPTT showed lower mix ratios in the isolated LAC group 
compared to the triple positive samples, for the dRVVT the median was 1.17 (1.13 - 1.27) versus 
1.35 (1.21 - 1.66; P = 0.0005) and for the aPTT 1.07 (1.00 - 1.16) versus 1.27 (1.17 - 1.89; P < 
0.0001). 
In the isolated LAC group, the majority of patients were dRVVT positive (98%) and only one 
patient was positive in the aPTT system only. This patient had a high level of C-reactive protein 
(CRP) (100 mg/L). Similar results for the triple positive group were found as 100% was positive in 
the dRVVT and no patient was positive in the aPTT system only. In addition, 25% of the patients 







Figure 2. Comparison of LAC activity between the patients with isolated LAC positivity and patients with 
triple positivity. LAC activity was shown as detected with dRVVT-Screen ratio, mix ratio and confirmation 
(A) and aPTT-Screen ratio, mix ratio and confirmation (B). Results are expressed as the median with 
interquartile ranges; dashed lines indicate the cut-off value of each step test (1.23 for dRVVT-Screen ratio, 
1.10 for dRVVT-mix ratio and 1.26 for dRVVT-confirmation; 1.28 for aPTT-Screen ratio, 1.12 for aPTT-mix 
ratio and 8 seconds for aPTT-confirmation). **P < 0.01, ***P < 0.001, ****P < 0.0001. Abbreviations: 
dRVVT, dilute Russell’s viper venom time; aPTT, activated partial thromboplastin time; LAC, lupus 
anticoagulant, NS: not significant. 
  





In the present study we investigated the clinical significance of an isolated LAC and compared it 
to triple positivity in a cohort of APS and non-APS patients. We defined a plasma sample as 
isolated LAC when tested positive in a dRVVT and/or an aPTT based assay, and tested negative 
for antiCL and antiβ2GPI IgG and IgM antibodies applying four different solid phase platforms. 
This was done to overcome the variability between solid phase assays 18,19. Triple positivity was 
defined as LAC positive and positive in both assays for antiCL antibodies or antiβ2GPI antibodies, 
at least by one solid phase platform. Although patients with isolated LAC positivity and triple 
positivity differed by the presence of antiCL and antiβ2GPI antibodies, they were comparable 
with respect to age, gender and history of thrombosis. 
It is generally accepted that patients with isolated LAC have a lower risk profile in APS 20,21 and 
patients positive for all three aPL antibodies identify individuals at high risk for a first clinical 
event and for recurrence 8,9. Isolated LAC is often observed in absence of clinical symptoms, in 
elderly patients, on a first occasion not confirmed after 12 weeks. Nonetheless the persistence 
of LAC in triple positive patients is very high (up to 100% of patients, also single LAC positives 
remain positive after twelve weeks in 40% of patients 22. Others found no significant lower 
persistence in the single positive patients (93.3%) compared to the double and triple positive 
patients (96.8% and 97.9%, respectively) 23. Moreover, an isolated LAC is an independent risk 
factor for myocardial infarction and ischemic stroke 14. A prospective study showed that in a LAC 
positive population the association between occurrence of thrombosis and mortality was 
independent of antiCL and antiβ2GPI antibodies 15. In our study, triple positivity was strongly 
associated with thrombosis, which is consistent with previous studies 19,24. Interestingly, our 
study showed that an isolated LAC was also strongly correlated with a history of thrombosis with 
an even higher OR.  
LAC can be caused by a heterogeneous subset of inhibitors. Both β2GPI and prothrombin have 
been studied for their role as target for LAC inducing antibodies. Only 8 of the 44 individuals with 
single LAC positivity were positive for anti-PS/PT antibodies, leaving 36 samples with LAC activity 
independent of β2GPI or prothrombin as co-factor. Interestingly, none of the isolated LAC 
samples were positive for anti-domain I antibodies, indicating that this group of samples is 
completely different from the triple positive group. In single LAC positive samples, negative for 
antiβ2GPI and anti-PS/PT antibodies, the antibody is not directed towards the known antigens 
but might be directed against other plasma proteins 25,26. Indeed, other antibodies against 
protein C/S and annexin V have also been shown to interfere with coagulation27,28. aPL binding 
through other co-factors, such as complement C4 or factor H, may also be responsible for the 
LAC positivity 29-31 . Also cofactor independent antibodies have been shown  relevant, although 
clinical data are rare 32,33. 
It is interesting to note that in this study the dRVVT seems to be a more sensitive to pick up LAC 
than the aPTT. In international external quality programs the dRVVT performs better and with 
less variation than an aPTT in identifying APS positive samples 34. This study supports the dRVVT 
as the preferred assay to detect LAC 1. The presence of high levels of CRP can influence the LAC 
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results, especial in the aPTT assay 32. In our study only a single patient was positive for the aPTT 
only, this patient had a higher CRP level and could be a false positive result, as described in the 
literature 32,33.  
International External Quality Assessment Programmes have shown significant inter-laboratory 
variation, especially for weaker LAC samples 2 4 7. Cut-off values in our study were calculated by 
the 99th percentile on 120 healthy donors 5  and LAC was performed according to the ISTH 
guidelines 1,35. Each value above the cut-off should be regarded as positive and the final 
conclusion of LAC positivity can only be made if the three steps of the test procedure (screening, 
mixing, and confirmation) are positive, which was the case in our cohort. We did observe that 
patients with isolated LAC showed significantly less prolongation in the dRVVT and aPTT 
screening tests compared to patients with triple positivity, as previously reported 36. However, 
guidance on categorising LAC according to strength does not seem to be appropriate, since there 
is no established LAC standard available in sufficient quantity. Furthermore, no evidence exists 
on the association of “stronger” LAC with clinical symptoms. But it is likely that the “weaker” 
positives fluctuate and “low positive” results might not be persistently positive. Therefore 
positive results have to be repeated after 12 weeks. In this cohort, all single LAC positive samples 
were confirmed after 12 weeks.  
In conclusion, our study shows that patients with isolated LAC have a comparable or even higher 
risk of thrombosis compared to patients with triple positivity. As samples were negative for 
antibodies against β2GPI and prothrombin, further studies are needed to identify the target 
antigen responsible for isolated LAC.     
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The Solid phase aPLs assays that are included in the laboratory criteria for the diagnosis of APS, 
lack standardization which is limiting their utility in clinical practice. The lack of standardization 
is due to the variability observed between centers, manufactures and research groups. The 
uniformity is also compromised by methodological shortcomings and the heterogeneity of aPLs 
antibodies 1,2.  Currently, only antibodies that bind β2GPI have been included in the official 
criteria used to APS diagnosis. However, this is a heterogenous population of antiβ2GPI 
antibodies. Several different non-continuous epitopes on domain I (DI) of β2GPI  have been 
shown to react with aPL antibodies 3. More and more evidence suggests that detection of a 
subset of aPLs antibodies that are reactive against DI of β2GPI is a promising risk stratification 
tool in APS 4,5.  Nowadays, various assays that specifically measure antiDI antibodies have been 
developed and been reported in the literature. 
History of antiDI assay  
As summarized  in chapter 2, Iverson et al. showed in 1998 that aPL antibodies are able to 
recognize epitopes on DI of β2GPI 6. In 2000 Reddel et al. demonstrated that inducing a charge 
altering mutation of Gly-to-Glu at position 40 and of Arg-to-Gly at position 43 of DI, resulted in a 
decreased β2GPI antigen binding 7. In 2002 there were two studies that confirmed that the 
charged surface patch defined by residues 40-43 on β2GPI was a dominant target epitope for 
autoantibodies8,9.  Based on this information, de Laat et al. developed the first antiDI assay in 
2005 10. In this assay, DI is coated on a hydrophobic and a hydrophilic plate. The arbitrary binding 
of DI on the hydrophobic plate will ensure enough exposure of the G40-R43 epitope. On the 
contrary, the binding of DI on a hydrophilic plate will make the positive epitope G40-R43 bind 
strongly to the plate, masking the epitope for binding by antibodies. In 2006 a simple direct antiDI 
ELISA was developed and used to confirm that the G40-R43 epitope and the adjacent arginine 39 
(R39) residue play a major role in the binding to antibodies by using site-directed mutants of DI 
11. In 2010, a chemically synthesized DI was used to inhibit the binding of antibodies to whole 
β2GPI immobilized on a 96 wells plate in a competitive inhibition ELISA assay 12. In 2014, by using 
the same recombinant DI of β2GP1 obtained from the baculovirus expression system, INOVA 
Diagnostics developed an ELISA 13 and a chemiluminescence (CLIA) assay for the measurement 
of antiDI antibodies by coupling DI to paramagnetic beads14 (Table 1). 
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Table1. Overview of assays used for the detection of antibodies against domain I of β2GPI (antiDI). 
CLIA: chemiluminescence immunoassay; ELISA: enzyme-linked immunosorbent assay; NS: not specified 
Clinical role of various antiDI assays  
As antiDI antibodies represent a specific pathogenic population of aPLs antibodies, the 
representative assays were expected to improve the classification and risk stratification of APS 
compared to conventional aPLs criteria tests. However, when reviewing the laboratory and 
clinical performance characteristics of the different antiDI assays (chapter 2), we found that there 
was no consensus regarding the added value of measuring antiDI antibodies in the classification 
criteria of APS. Some studies applying antiDI assays have demonstrated a higher correlation with 
thrombosis compared to the traditional antiβ2GPI assays, whereas other studies have failed to 
show an added value of the antiDI assays. Regarding the different antiDI assays, it is the two-step 
antiDI IgG ELISA in particular that showed high odds ratios (ORs) rather than IgG antibodies 
targeting other domains of β2GPI 10,15. The commercially available CLIA is currently the most 
widely used method to detect antiDI IgG antibodies. However, the results regarding the added 
clinical value of antiDI IgG measured by the CLIA assay are not consistent. Some studies showed 
an added value of the addition of the detection of antiDI antibodies to the aPL antibody panel16-
19, whereas other studies failed 20-22. None of the remaining three assays (i.e. the direct antiDI 
ELISA, the competitive inhibition ELISA and the commercial developed INOVA antiDI ELISA) 
showed an added value of detecting antiDI IgG compared to other antiβ2GPI IgG antibodies. 
Taken together, the observed inconsistency probably explains why antiDI antibodies have not yet 
been included in the laboratory criteria 2. The inconsistent results might be due to differences in 
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non-assay related factors, such as different patient population and sample handling protocols, as 
well as the assays used to detect antibodies against DI.  
To further investigate the added value of measuring antiDI antibodies on top of the current APS 
classification criteria we initiated a multicenter study. In this multicenter study, antiCL and 
antiβ2GPI antibodies were detected by four different commercially available platforms in a large 
cohort of APS and non-APS patients (chapter 3). We were able to demonstrate that the detection 
of antiDI IgG by antiDI CLIA was less sensitive, but more specific compared to the current 
laboratory criteria assay. This resulted in higher ORs for developing thrombosis and pregnancy 
morbidity. Moreover, antiDI IgG antibodies are mainly present in high-risk triple positive patients. 
The combination of antiDI antibodies and triple positivity, confers a higher risk for clinical 
symptoms compared to triple positivity. In contrast to our expectation, the addition of antiDI or 
the replacement of antiβ2GPI IgG by antiDI hardly improved the ORs for developing thrombosis 
or pregnancy morbidity. We were unable to demonstrate the added value of measuring antiDI 
IgG on top of the laboratory criteria, independent of the platform used to measure antiCL and 
antiβ2GPI antibodies. We hypothesized that the reduced exposure of the pathogenic DI epitope 
in the automated CLIA assay was a possible explanation for the lack of added value. This 
hypothesis came from our previously published results, where we demonstrated the large 
variability in commercially available antiCL and antiβ2GPI assays. Part of the variability can be 
explained by the variable exposure of the pathogenic G40-R43 epitope on DI of β2GPI, which 
could lead to incorrect patient classification 23.  
In chapter 1, we demonstrated the importance of coating β2GPI on a hydrophilic surface, as this 
results in the conformational change of β2GPI which leads to the exposure of cryptic epitopes. It 
has been shown that antibodies directed against this cryptic epitope G40-R43 on DI are 
pathogenic. Hence, the results obtained by the antiβ2GPI assays depend on the conformation of 
the coated β2GPI (i.e. whether epitope G40-R43 is exposed), which depends of the type of solid 
phase surface used to immobilize β2GPI as well as the source of the protein. By coating only DI 
of β2GPI, this issue does not exist. However, as epitope G40-R43 is positively charged, the charge 
of the coating surface could also influence the availability of the G40-R43 epitope. De Laat et al.10 
showed that the use of a neutral coating surface results in an arbitrary orientation of DI including 
orientations in which epitope G40-R43 is exposed. When a negative surface is used, the positive 
epitope will bind to the surface thereby preventing its availability for antibodies present in the 
sample. It cannot be excluded that the beads used in the CLIA assays are charged, which makes 
the exposure of epitope G40-R43 uncertain. To verify our hypothesis we used two human-
derived monoclonal antibodies (P1-117 and P2-6) to determine whether the pathogenic epitope 
is exposed in the antiDI CLIA assay. Antibody P1-117 recognizes epitope G40-R43 and can only 
bind to β2GPI when it is coated in its open conformation, while antibody is able to recognize DI 
regardless of its conformation 24. Our data showed that only the P2-6 antibody could bind to the 
DI of the CLIA assay. Contrary to our expectation, this would mean that the CLIA antiDI assay does 
not expose epitope G40-R43 on the surface of the beads, thereby missing the patient samples 
with antibodies towards this epitope. In addition, a high agreement was observed between 
antiβ2GPI and antiDI in the same CLIA device, suggesting that both assays measure almost the  
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same antibody population directed against DI excluding the antibodies that bind to epitope G40-
R43.  
Detection of antiDI IgG by a hydrophobic ELISA 
Other methods than the CLIA assay are available to detect antiDI antibodies. In 2005, an in-house 
two-step ELISA was developed that ensures the exposure of the cryptic epitope. By the use of 
this assay we demonstrated that the presence of antiDI IgG antibodies could identify APS patients 
at high risk for developing thrombosis and/or pregnancy morbidity 10,15. This two-step ELISA is 
performed by coating DI of β2GPI on a hydrophilic and a hydrophobic ELISA plate. The difference 
in type of plate used to immobilize DI resulted in a different exposure of the pathogenic DI 
epitope (Figure 1). We used our in-house assay (chapter 4) and compared it to the commercial 
antiDI CLIA assay in a large cohort of APS and non-APS patients. When DI was coated on the 
hydrophilic plate, no antibodies could be detected. However, when DI was coated on the 
hydrophobic plate, the antibodies against DI could be detected, resulting in significantly higher 
optical density (OD) values in the APS samples compared to the control group. In addition, we 
observed that 18 out of 101 samples with a history of thrombosis were negative in the antiDI 
CLIA assay, but positive in the in-house antiDI hydrophobic ELISA. This would indicate that the in-
house assay is more sensitive for the detection of pathogenic samples than the commercial antiDI 
CLIA assay. Moreover, the in-house antiDI hydrophobic ELISA was able to detect more samples 
with clinical manifestations of APS. 
 
Figure 1. The two types of solid phase assays for detection of antiDI IgG antibodies. (A) When DI is coated 
on a hydrophobic surface, the arbitrary orientation of immobilized DI allows exposure of the cryptic 
epitope G40-R43. Antibodies against this pathological epitope will be able to bind to the epitope. (B) when 
DI is coated on a hydrophilic surface, the positively charged G40-R43 epitope will bind strongly to the 
hydrophilic surface, thereby preventing the binding of antibodies to this epitope. 
Many antiDI assays are available, but they have the same problems as the full-length antiβ2GPI 
assays. As with antiβ2GPI assays, standardization of the antiDI assay is of utmost importance. An 




epitope, to ascertain that at least one specific pathogenic antibody population can be measured. 
The charge of the solid phase surfaces used to immobilize DI will influence the exposure of the 
epitope G40-R43 of DI. Although CLIA can provide a large surface for antibody binding to DI, our 
data revealed an impaired exposure of the pathogenic epitope in CLIA. In addition, we found that 
when DI was coated on a hydrophilic suface, no antibodies could be detected. On the contrary, 
our in-house antiDI hydrophobic ELISA was able to detect more samples with clinical 
manifestations of APS compared to the antiDI IgG CLIA assay. Therefore, it may be interesting to 
verify correct exposure of the cryptic epitope in all available antiDI assays, which will also help to 
improve the standardization process of the antiDI assays.  
Clinical value in detecting non-criteria antiCL and 
antiβ2GPI IgA antibodies in APS 
The interpretation of immunoassays must take into consideration the isotype of the detected 
antibodies. Current criteria recommend increased levels of antiCL and antiβ2GPI IgG and IgM for 
the diagnosis of APS, whereas the detection of antiCL and antiβ2GPI IgA antibodies is not included 
in these criteria 2,25 . The pathogenicity of IgA aPL antibodies has been shown in animal models, 
however, the authors did not demonstrate that the IgA antibodies were solely responsible for 
the observed effect 26. The role of IgA remains controversial in clinical events related to APS. 
Multiple studies have shown that antiCL and antiβ2GPI IgA antibodies are associated with 
thrombosis and pregnancy morbidity 27-37. Nevertheless, a recent systematic review indicated 
that several studies failed to demonstrate utility of adding antiCL and antiβ2GPI IgA testing. This 
was probably due to either the low prevalence of these antibodies and their association with 
other aPL antibodies, or because of the lack of improved diagnostic accuracy of IgA antibodies 38. 
Data proving the clinical significance of antiCL or antiβ2GPI IgA testing in addition to the current 
aPL-panel is still lacking 25,39 . 
Therefore, we set up a multicenter study (chapter 6) and used four commercially available solid 
phase assays to detect antiCL and antiβ2GPI IgG/IgM/IgA, to assess for a possible association of 
antiCL and antiβ2GPI IgA with thrombosis or obstetric complications. In our study cohort, we 
included APS patients and non-APS patients that served as controls. Our study showed that antiCL 
and antiβ2GPI IgA antibodies did correlate with the clinical manifestations of APS (thrombosis 
and pregnancy morbidity), independently of the solid phase platform used. An external quality 
control program illustrated that the different antiCL and antiβ2GPI IgG/IgM assays produced 
variable results 40 41. Our study also demonstrated that by the use of different solid phase assays 
a different proportion of APS patients was positive for antiCL and/or antiβ2GPI IgA antibodies. 
These data indicate that the detection of IgA aPL antibodies also depends on the solid phase 
assay used, as well as the study population. Although an added value was suggested for so called 
‘isolated IgA’ positivity by some studies30,32,34,36,37,42, many of these studies did not include LAC 
testing, thereby hampering the assessment of true isolated IgA. We defined isolated antiCL 
and/or antiβ2GPI IgA positivity as positivity for antiCL and/or antiβ2GPI IgA and negativity for 
antiCL and antiβ2GPI IgG/IgM and LAC. Isolated IgA positivity was rare in the total population. 
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Overall, the prevalence of isolated IgA was comparable between patients with clinical 
manifestations of APS and patients without a history of thrombosis or pregnancy morbidity. 
Positivity for isolated IgA aPL was not associated with thrombosis or pregnancy morbidity as the 
calculated OR did not reach statistical significance. Our results do not support antiCL and/or 
antiβ2GPI IgA testing in addition to the conventional aPL testing in identifying patients with 
clinical manifestations of APS. 
The clinical relevance of isolated lupus anticoagulant 
positivity in patients with thrombotic APS  
Currently, the presence of LAC together with antiCL and/or antiβ2GPI IgG/IgM antibodies are 
included in the international criteria for the classification of APS 2,25,43,44. Triple positive patients 
(i.e. positive for the combination of LAC, antiβ2GPI and antiCL IgG/IgM antibodies), exhibit a high 
risk for thrombotic and/or obstetric manifestations 44-47. However, the clinical relevance of an 
isolated LAC has been debated in the past. Although both retrospective and prospective studies 
suggested that LAC has a strong predictive value for thrombosis and adverse pregnancy outcome 
48-55, recent studies showed a poor predictive value of isolated LAC positivity for the first 
thrombotic event 56,57. Therefore, we repeated a study to investigate the correlation of isolated 
LAC with thrombosis and compared it to triple positivity in a cohort of APS and non-APS patients 
(chapter 7).  In order to overcome the variability between solid phase assays 58,59, we defined a 
plasma sample as isolated LAC when tested positive in a dRVVT and/or an aPTT based assay, and 
tested negative for antiCL and antiβ2GPI IgG and IgM antibodies applying four different solid 
phase platforms. Triple positivity was defined as being positive for LAC, antiCL antibodies and 
antiβ2GPI antibodies, by at least one solid phase platform. In our study, triple positivity was 
strongly associated with thrombosis (OR 5.3(1.9-14.8)), which is consistent with previous studies 
59,60. Interestingly, we found that an isolated LAC also correlated strongly with thrombosis with 
an even higher OR (7.6 (3.6-17.5)). 
Many possible mechanisms for the pathogenicity of APS are described in chapter 5. Different 
proteins have been identified to be involved in the pathogenesis of APS. The LAC assay can be 
affected by a heterogeneous group of autoantibodies that are binding to the negatively charged 
phospholipids present in the assay. Both β2GPI and prothrombin have been studied for their role 
as a target for LAC-inducing antibodies 10,24,61-63. In Chapter 2,3 and 4, we showed that antiDI IgG 
antibodies are mainly present in patients with triple positivity, independent of the assays used 
to measure these antibodies. Moreover, this is also independent of the platform used to measure 
antiCL and antiβ2GPI IgG/IgM antibodies. We also demonstrated that 55% of the triple positive 
patients tested also positive for antiDI IgG, whereas none of the isolated LAC patients were 
positive for antiDI IgG. In addition, in chapter 6 we showed that only very few patients with 
clinical manifestations of APS were positive for isolated antiCL/antiβ2GPI IgA. Most of the IgA 
positive patients were also positive for antiCL and/or antiβ2GPI IgG/IgM. This was also shown in 
chapter 7, hardly any of the isolated LAC patients were also positive for antiCL and/or antiβ2GPI 




group of isolated LAC positive patients differed from the triple positive patient group. Studies 
have shown that antibodies against phosphatidylserine/prothrombin (anti-PS/PT) are frequently 
present in APS patients and are strongly associated with LAC 64,65. We found that 18 out of 20 
triple positive patients were also positive for anti-PS/PT antibodies (mainly of the IgM isotype). 
On the contrary, only 8 of the 44 individuals with single LAC positivity were also positive for anti-
PS/PT antibodies (Table 2). 
Table 2.  Antiphospholipid antibody characteristics and the Odds ratios (95% confidence interval for 
thrombosis of two antibody patterns: isolated LAC and triple positivity. 












Positive Negative Negative Negative Negative <20% 7.6 (3.6-17.5) 
Triple 
positivity Positive Positive Positive Half is positive 
Half is 
positive >80% 5.3 (1.9-14.8) 
 
As mentioned previously, isolated LAC correlated significantly with thrombosis. This would 
indicate that other phospholipids-binding proteins (other than β2GPI and prothrombin) could be 
responsible of the development of thrombotic events 66,67. In fact, antibodies against protein C/S 
and annexin V have also been shown to interfere with coagulation 68,69. aPLs antibody binding 
through other co-factors, such as complement C4 or factor H, may also be responsible for LAC 
positivity 70-72 . Also cofactor-independent antibodies have been shown to be relevant, although 
clinical data demonstrating this are rare 73,74. The presence of high C-reactive protein (CRP) 
plasma levels can influence LAC results as well, especially in the aPTT assay 73. In our study only 
one single patient tested positive for only the aPTT, however, this patient had also a high CRP 
plasma level and could therefore be false positive 73,74. Further studies are needed to identify the 
target antigen responsible for isolated LAC activity in the absence of antiPS/PT and antiβ2GPI 
antibodies. 
Isolated LAC positive patients showed weaker LAC activity compared to triple positive patients. 
The International External Quality Assessment Programmes have shown significant inter-
laboratory variation, especially for weaker LAC samples 43,75,76. Cut-off values in our study were 
calculated by the 99th percentile of the results of 120 healthy donors 2 and LAC was performed 
according to the ISTH guidelines 77. Each value above the cut-off should be regarded as positive 
and the final conclusion of LAC positivity can only be made if the three steps of the test procedure 
(screening, mixing, and confirmation) are positive. We did observe that  patients with isolated 
LAC showed a significantly less prolonged dRVVT and aPTT screening tests compared to triple 
positive patients 64. However, guidance on categorising LAC according to strength does not seem 
to be appropriate, since there is not an established LAC standard available in sufficient quantity. 
Furthermore, no evidence exists on the association of “stronger” LAC with the risk of the clinical 
symptoms. But it is likely that the “weaker” positive patients fluctuate in their results and that 
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“low positive” results might not be persistently positive. Therefore, consensus was reached that 
the positive results should be repeated after 12 weeks to confirm their positivity. In our cohort, 
all single LAC positive samples were retested and reconfirmed after 12 weeks. 78,79. 
In conclusion, patients with isolated LAC have a comparable or even higher risk of developing 
thrombosis compared to triple positive patients. Further studies are needed to identify the target 
antigen responsible for the pathogenicity in isolated LAC. 
Conclusions 
The clinical symptoms of the APS occur frequently irrespectively of the syndrome, making the 
diagnosis of APS difficult and predominantly depends on the laboratory criteria. Currently, the 
laboratory diagnosis of APS is still challenging due to the lack of standardization and the 
heterogeneity of aPLs antibodies. We showed that it is important to verify the correct exposure 
of the cryptic epitope in all available antiDI assays to improve standardization of the antiDI assays. 
Furthermore, isolated IgA was rare and did not correlate with the clinical manifestations of APS. 
However, patients with isolated LAC have a comparable or even higher risk of thrombosis 
compared to patients with triple positivity. Further studies are needed to address the 
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Het antifosfolipidensyndroom (APS) wordt gediagnosticeerd wanneer een patiënt lijdt aan een 
trombose of zwangerschapsmorbiditeit met de persistente aanwezigheid 
antifosfolipidenantilichamen (aFLs) 1. Aangezien vasculaire trombose en 
zwangerschapsgerelateerde morbiditeit vaak voorkomen in de algemene bevolking en niet altijd 
gerelateerd zijn aan APS, hangt de diagnose van APS voornamelijk af van de 
laboratoriummethode die gebruikt wordt voor de bepaling van aFLs. Doordat patiënten met APS 
vaak een intensievere antistollingstherapie nodig hebben, rust er een zware last op de testen die 
worden gebruikt om de aanwezigheid van circulerende aFLs te detecteren. 
Laboratoriumdiagnose van APS: de huidige problemen 
De huidige herziene laboratoriumcriteria voor APS-classificatie bestaan uit een combinatie van 
verschillende laboratoriumtesten om aFLs te detecteren. Deze laboratoriumcriteria omvatten 
één functionele stollingstest die bekend staat als lupus anticoagulans (LAC), en twee 
immunologische testen die immunoglobuline (Ig) G en/of IgM meten met bèta2-glycoproteïne I 
(antiβ2GPI) als antigeen, de anticardiolipin antistofstest en de anti- β2GPI antistof test. Om vals-
positieve testen door infecties te voorkomen, moeten positieve testen worden herhaald met een 
interval van ten minste 12 weken 1. 
Momenteel vertoont de detectie van aFLs grote verschillen tussen de verschillende assays en 
tussen de laboratoria2,3. Er zijn namelijk problemen bij de standaardisatie van deze testen, wat 
de laboratoriumdiagnose van APS moeilijker maakt. De huidige criteria voor de detectie van aFLs 
betreft een heterogene populatie antilichamen. Het is nog niet bekend welke eiwitten en 
factoren bijdragen aan de productie van aFLs en hoe deze antilichamen trombose en 
zwangerschapsmorbiditeit kunnen veroorzaken. Daarom moet er op verschillende manieren 
worden onderzocht of een nieuwe aFLs-assay mogelijk nuttig kan zijn bij de diagnose van APS: 
ten eerste moet men aantonen dat de antilichamen pathogeen zijn in APS-diermodellen, ten 
tweede moeten de antilichamen een sterke associatie vertonen met de klinische manifestaties 
van APS (trombose of zwangerschapscomplicaties). Als dit voldaan is, dan kan het gebruik van 
deze testen niet alleen de diagnose van APS verbeteren, maar zou het ook kunnen helpen bij de 
risicostratificatie van de patiënten. 
Is er een toegevoegde waarde van het detecteren van anti-
domein I van β2GPI IgG bovenop de huidige APS 
laboratoriumcriteria? 
De antilichamen gericht tegen het eerste domein (DI) van β2GPI blijken pathogeen te zijn in een 
diermodel4,5. DI bevat een belangrijk pathogeen epitoop (G40-R43) dat cryptisch is en alleen 
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wordt blootgesteld wanneer β2GPI zich in zijn open conformatie bevindt 6-8. Er is een hoge 
variatie aan blootstelling van dit epitoop in de anti-β2GPI IgG-assays, waardoor er DI-reactieve 
stalen gemist worden in deze assays 3. 
Klinische rol van antiDI-assays 
Recent zijn er testen ontwikkeld die specifiek antiDI-antilichamen detecteren. Echter, er is nog 
geen consensus bereikt over de toegevoegde waarde van antiDI-antilichamen in de 
classificatiecriteria van APS (hoofdstuk 2). Sommige onderzoeken toonden een hogere correlatie 
aan met trombose, terwijl andere geen toegevoegde waarde van antiDI-assays konden bewijzen. 
Van alle testen die antiDI IgG detecteren, was het vooral de tweestaps antiDI-ELISA die aanzienlijk 
hogere Odd Ratio's (OR's) voor antiDI IgG vertoonde dan de antilichamen die gericht zijn op 
andere domeinen van het eiwit. De chemiluminescentie-immunoassay (CLIA) is momenteel de 
meest gebruikte methode om antiDI IgG antilichamen te detecteren. AntiDI IgG gemeten door 
CLIA blijken te correleren met de klinische manifestaties van APS, maar de toegevoegde klinische 
waarde is echter niet consistent. Sommige studies konden wel de toegevoegde waarde van antiDI 
aantonen, terwijl andere studies niet. Geen van de overige drie assays, namelijk de directe antiDI 
ELISA, de competitieve inhibitie ELISA en de commercieel ontwikkelde INOVA antiDI ELISA, kon 
een toegevoegde waarde van antiDI IgG aantonen in vergelijking met de andere antiβ2GPI IgG 
antilichamen. De inconsistente resultaten kunnen te wijten zijn aan verschillen in niet-assay 
gerelateerde factoren (zoals verschillende onderzoekspopulaties en, behandelingsprotocollen), 
maar ook aan factoren die verband houden met de methodologie om antiDI, antiCL en anti-β2GPI 
antilichamen te detecteren. 
Detectie van antiDI IgG door CLIA 
Op basis van de literatuurresultaten hebben we  data van een multicenter studie gebruikt om te 
onderzoeken of er een meerwaarde is van het meten van antiDI-antilichamen met de  CLIA 
aanvullend  op de huidige APS-classificatiecriteria. Dit werd getest bij een grote cohort van APS- 
en niet-APS-patiënten, waarbij er dan ook gekeken werd naar antiCL en antiβ2GPI die gemeten 
werden met vier verschillende commercieel beschikbare assays (hoofdstuk 3). In deze 
multicenterstudie vonden we dat de detectie van antiDI IgG door CLIA minder gevoelig, maar wel 
specifieker was in vergelijking met de huidige laboratoriumcriteria aFL-tests. Dit resulteerde in 
een hogere OR voor trombose en zwangerschapsmorbiditeit. Bovendien zijn anti-DI IgG 
voornamelijk aanwezig bij triple-positieve patiënten met een hoog risico en die ook hogere 
concentraties aFL’s vertonen. Bovendien geeft de combinatie van antiDI antilichamen met een 
drievoudige positiviteit een hoger risico op klinische symptomen dan alleen drievoudige 
positiviteit. Echter, in tegenstelling tot onze verwachting, verbeterde de toevoeging van antiDI of 
de vervanging van antiβ2GPI IgG door antiDI, de OR's voor trombose of 
zwangerschapsmorbiditeit nauwelijks. Daarom kon onze studie geen toegevoegde waarde 
aantonen van het meten van antiDI IgG bovenop de huidige laboratoriumcriteria. Dit bleek ook 
onafhankelijk te zijn van type assay dat gebruikt werd om antiCL en antiβ2GPI antilichamen te 
meten. Een mogelijke verklaring hiervoor kan zijn dat de CLIA assay een verminderde 
blootstelling heeft van het pathogene DI-epitoop, wat mogelijk  implicaties geeft voor de juiste 




In hoofdstuk 1 hebben we het belang aangetoond van het gebruik van een hydrofiel oppervlak 
om β2GPI op te coaten, waardoor de conformationele verandering wordt geïnduceerd die 
resulteert in de blootstelling van het cryptisch pathogeen epitoop op DI van β2GPI. Zoals 
hierboven beschreven, blijken de antilichamen die gericht zijn tegen het cryptische epitoop G40-
R43 op DI pathogeen te zijn in vivo en vitro studies. De resultaten die met antiβ2GPI-assays 
worden verkregen, zijn dus afhankelijk van de conformatie van het gecoate β2GPI (d.w.z. de 
blootstelling van het epitoop G40-R43). Dit wordt dus beïnvloed door het type oppervlak dat 
gebruikt wordt om β2GPI te immobiliseren. Aangezien in antiDI-assays DI wordt gecoat in plaats 
van het volledige β2GPI eiwit, werden vergelijkbare problemen met deze assay niet verwacht. 
Echter, dient er ook rekening te worden gehouden met de positieve lading van het epitoop G40-
R43. Hierdoor kan de lading van het coatingoppervlak mogelijk ook de beschikbaarheid van het 
G40-R43 epitoop beïnvloeden. Er wordt namelijk verondersteld dat het gebruik van een neutraal 
coatingsoppervlak resulteert in een willekeurige oriëntatie van DI, en dus ook in de blootstelling 
van epitoop G40-R43. Maar wanneer men een negatief oppervlak gebruikt, dan gaat het 
positieve epitoop daarop binden, waardoor het niet beschikbaar is voor de antilichamen. Bij de 
CLIA-assay kan een mogelijke lading van de gebruikte beads niet worden uitgesloten, waardoor 
de blootstelling van het epitoop G40-R43 onzeker is. Om dit na te gaan hebben we twee 
monoklonale antilichamen (P1-117 en P2-6) gebruikt in de CLIA. Antilichaam P1-117, dat epitoop 
G40-R43 herkent, kan alleen binden op DI wanneer β2GPI zich in zijn open conformatie bevindt, 
terwijl P2-6 DI herkent ongeacht de conformatie van β2GPI 9. Onze data toonden aan dat P2-6 
kon worden gedetecteerd, terwijl er geen signaal werd verkregen voor P1-117 in deze antiDI CLIA. 
In tegenstelling tot de verwachting, is het epitoop G40-R43 in deze antiDI-assay niet beschikbaar, 
waardoor patiëntenstalen met antilichamen die het epitoop G40-R43 herkennen dus worden 
gemist. De commercieel verkrijgbare antiDI CLIA detecteert dus antilichamen tegen DI, met 
uitzondering van de meer specifieke antiDI-antilichaampopulatie gericht tegen het epitoop G40-
R43. Bovendien kwamen de resultaten van anti-β2GPI en antiDI gemeten op hetzelfde platform 
met elkaar overeen, wat suggereert dat beide testen bijna dezelfde antilichaampopulatie meten 
die dus gericht zijn tegen DI, maar niet tegen het G40-R43-epitoop. 
Detectie van antiDI IgG door een hydrofobe ELISA 
Afgezien van de antiDI CLIA-assay, zijn er andere methoden beschikbaar om antiDI-antilichamen 
te detecteren. Al in 2005 gaf een in-huis ELISA aan dat het testen van antiDI IgG de identificatie 
mogelijk maakt van APS patiënten met het hoogste risico op het ontwikkelen van trombose of 
zwangerschapsmorbiditeit 10,11. Hierbij werd nogmaals bevestigd dat de juiste blootstelling van 
het G40-R43-epitoop van uitermate belang is 11. In deze ELISA word DI zowel op een hydrofiele 
ELISA-plaat, als een hydrofobe ELISA-plaat gecoat, wat resulteert in een verschil in blootstelling 
van het pathogene DI-epitoop.  
In hoofdstuk 4 hebben we deze in-huis test vergeleken met de commerciële antiDI CLIA in een 
groot cohort van APS- en niet-APS-patiënten. Wanneer DI werd gecoat op een hydrofiele plaat, 
werden er geen antilichamen gedetecteerd in alle stalen. Echter, wanneer DI op een hydrofobe 
plaat werd gecoat, konden de antilichamen wel worden gedetecteerd en waren de waarden van 
de optische dichtheid (OD) van de APS-stalen significant hoger dan die van de controlegroepen. 
Daarnaast hebben we vastgesteld dat 18 van de 66 stalen met trombose negatief waren met de 
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antiDI CLIA, maar positief met de in-huis antiDI hydrofobe ELISA. Dit resulteerde in een hogere 
gevoeligheid van de in-huis antiDI hydrofobe ELISA in vergelijking met de commerciële antiDI 
CLIA. Bovendien detecteerde de in-huis antiDI-hydrofobe ELISA meer stalen met klinische 
manifestaties van APS in vergelijking met de antiDI IgG-CLIA.  
Samengevat suggereren deze resultaten dat de antiDI hydrofobe ELISA een meer specifieke 
antiDI-antilichaampopulatie kan meten die gericht is tegen G40-R43, vergeleken met de 
commercieel verkrijgbare antiDI CLIA die alle antilichamen tegen DI detecteert, met uitzondering 
van antilichamen gericht tegen het epitoop G40-R43. Onze gegevens benadrukken het belang 
van het meten van antistoffen gericht tegen het cryptische epitoop G40-R43, niet alleen in de 
antiβ2GPI-assays, maar ook in de antiDI-assays om er zeker van te zijn dat in ieder geval deze 
pathogene antilichaampopulatie niet wordt gemist. 
Kortom, net als bij de antiβ2GPI-assay, is standaardisatie van antiDI-assays van het grootste 
belang. Deze standaardisatie omvat de bevestiging van een bevredigende blootstelling van het 
G40-R43 epitoop om er zeker van te zijn dat ten minste één specifieke pathogene 
antilichaampopulatie wordt gemeten. Hierbij is de lading van het oppervlak dat gebruikt wordt 
om DI te immobiliseren van belang, aangezien het de blootstelling van het G40-R43 epitoop kan 
beïnvloeden. Het is dus interessant om de blootstelling van dit epitoop in alle beschikbare antiDI-
assays te verifiëren, wat ook de standaardisatie van antiDI-assays kan verbeteren. 
Is er een meerwaarde om de IgA-isotype antiCL-antilichamen en 
antiβ2GPI-antilichamen in APS te detecteren? 
De huidige criteria zeggen dat men IgG en IgM antiCL en antiβ2GPI moet detecteren om de 
diagnose van APS te bevestigen, en zijn de IgA antilichamen niet opgenomen in de huidige 
classificatiecriteria. In hoofdstuk 6 onderzochten we of er een toegevoegde waarde is van het 
meten van antiCL en antiβ2GPI IgA antilichamen naast het huidige aFLs paneel bestaande uit LAC, 
antiCL en antiβ2GPI IgG/M. We vonden dat positiviteit voor antiCL en/of antiβ2GPI IgA 
antilichamen inderdaad geassocieerd was met trombose en zwangerschapsmorbiditeit. Echter, 
een geïsoleerde IgA positiviteit was zeldzaam en correleerde niet met klinische manifestaties van 
APS. Onze resultaten ondersteunen dus niet de meting van antiCL- en/of antiβ2GPI-IgA naast de 
conventionele aFLs bij het identificeren van patiënten met klinische manifestaties van APS. 
Is een geïsoleerde LAC in afwezigheid van antiCL- en anti-β2GPI-
antilichamen klinisch relevant? 
LAC detecteert een functioneel effect van een heterogene groep aFLs antilichamen. De klinische 
relevantie van een geïsoleerde LAC, in afwezigheid van antiCL en antiβ2GPI IgG en IgM, is 
discutabel. Daarom hebben we in hoofdstuk 7 gekeken naar de correlatie van een geïsoleerde 




APS- en niet-APS-patiënten. We ontdekten dat een geïsoleerde LAC een zwakkere LAC-activiteit 
vertoonde in vergelijking met triple positieve patiënten. Patiënten met een geïsoleerde LAC 
hebben echter een vergelijkbaar of zelfs hoger risico op trombose in vergelijking met patiënten 
met triple positiviteit. De aanwezigheid van anti-PS/PT-antilichamen kon de LAC-positiviteit niet 
verklaren in alle stalen met geïsoleerde LAC.  Aangezien de stalen negatief waren voor 
antilichamen tegen β2GPI en antiPS/PT  zijn verdere studies nodig om het antigeen te 
identificeren dat verantwoordelijk is voor een geïsoleerde LAC. 
Conclusie 
De klinische symptomen van APS komen vaak voor, ongeacht het syndroom, waardoor de 
diagnose van APS moeilijk is en voornamelijk afhankelijk is van de laboratoriumcriteria. 
Momenteel is de laboratoriumdiagnose van APS nog steeds een uitdaging vanwege het gebrek 
aan standaardisatie en de heterogeniteit van aFLs-antilichamen. We toonden aan dat het 
belangrijk is om de juiste blootstelling van het cryptische epitoop in alle beschikbare antiDI-
assays te verifiëren om de standaardisatie van de antiDI-assays te verbeteren. Bovendien was 
een geïsoleerde IgA zeldzaam en correleerde het niet met de klinische manifestaties van APS. 
Patiënten met een geïsoleerde LAC hebben echter een vergelijkbaar of zelfs hoger risico op 
trombose in vergelijking met patiënten met triple positiviteit. Verdere studies zijn nodig om de 
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是跟 APS 相关，诊断 APS 主要取决于实验室检测 aPLs。由于 APS 患者通常需要加强的抗凝
治疗，因此检测循环 aPLs 负担沉重。 
APS 的实验室诊断：当前的问题 
当前修订的 APS 分类实验室标准要求结合不同的实验室方法来检测 aPLs。这些实验室标准
包括一种名称为狼疮抗凝剂（LAC）的功能性凝血检测以及两种免疫学检测。免疫学检测
分别以心磷脂（CL）和 β2-糖蛋白 I (β2GPI) 作为抗原来检测免疫球蛋白 (Ig) G 和/或 IgM，
命名为抗心磷脂 (antiCL) 抗体检测和抗 β2GPI 抗体检测。为避免与感染相关的假阳性测试，
应至少间隔 12 周重复进行阳性测试 1。 
目前，aPLs的检测结果在不同的检测方法和实验室之间显示较大的差异 2,3。这些检测方法
的标准化存在问题，使 APS 的实验室诊断变得更加困难。当前检测 aPLs 的标准涉及抗磷
脂抗体的异质群体。目前尚不清楚哪些蛋白质和蛋白因子有助于 aPLs 的产生，以及这些
抗体是如何诱导血栓形成和妊娠发病的。 因此，以多种方式研究新的 aPLs 检测方法是否
可能对 APS 的诊断有用是有必要的：首先，必须证明抗体在 APS 动物模型中具有致病性，
其次，抗体必须与 APS 的临床表现（血栓形成或妊娠并发症）有很强相关性。如果满足这
几点，使用这些测试不仅可以改善 APS 的诊断，还可以帮助对患者进行风险分层。 
在当前 APS 实验室标准之上，检测抗 β2GPI 结构域 I (DI) IgG 抗
体是否有附加价值？  
针对 β2GPI 第一个结构域 (DI) 的抗体在动物模型中呈现致病性 4,5。 DI 包含一个主要的致病
表位 (G40-R43)，该表位是隐蔽的，仅当 β2GPI 处于其开放构象时才会暴露 6-8。 在抗 β2GPI 
IgG 检测方法中，该表位是否暴露存在很大差异，导致有些抗 β2GPI IgG 检测方法会漏掉对 
DI 有反应的样本 3。 
抗 DI 抗体检测方法的临床应用 
近，已经开发出用于检测抗 DI 抗体的检测方法。然而，APS 分类标准中抗 DI 抗体是否
有附加价值尚未达成共识（第 2 章）。一些研究表明检测到的抗 DI 抗体与血栓形成有更
高的相关性，而其他的研究则未能证明检测到的抗 DI 抗体相对于已有的标准检测方法有
附加价值。在检测抗 DI IgG 的所有方法中，特别是用两步抗 DI ELISA 检测抗 DI IgG 与血栓
形成的比值比(OR)显着高于靶向 β2GPI 其他结构域的抗体 9,10。化学发光免疫分析（CLIA）
是目前使用 广泛的检测抗 DI IgG 抗体的方法。通过 CLIA 测量的抗 DI IgG 与 APS 的临床表
现相关，但是否有附加的临床价值研究结果并不一致：一些研究能够证明 antiDI 的附加价
值，而另一些研究则显示没有附加价值。其他三种检测方法，即直接抗 DI ELISA、竞争性




研究人群和样本处理程序），也有可能是由于与抗 DI、抗 CL 和抗 β2GPI 抗体的检测方法
相关的因素引起。 
通过 CLIA 检测抗 DI IgG 抗体 
基于文献结果，我们使用来自多中心的数据来研究在当前的 APS 分类标准以外，采用商业
CLIA 检测抗 DI 抗体是否具有附加的临床价值。检测在 APS 患者和非 APS 对照组患者中进
行，通过四种不同的商业平台检测 antiCL 和 antiβ2GPI 抗体（第 3 章）。在这项多中心研
究中，我们发现与当前的实验室标准 aPLs 检测相比， CLIA 检测抗 DI IgG 的灵敏度较低，
但具有更高的特异性，从而导致与血栓形成和妊娠发病率的相关性（OR 值）更高。此外，
抗 DI IgG 主要存在于高风险的三重阳性患者中，这些患者也表现出更高的抗 DI IgG 水平。
而且，与单独三重阳性相比，抗 DI 抗体阳性联合三重阳性具有更高的发生临床症状的风
险。然而，与我们的预期相反，添加抗 DI IgG 或用抗 DI 替代抗 β2GPI IgG 几乎没有改善血
栓形成或妊娠发病率的 OR 值。因此，我们的研究无法证明在当前的实验室标准之上，用
CLIA 检测 antiDI IgG 抗体的附加的临床价值，并且此结果与用于检测 antiCL 和 antiβ2GPI 的
实验平台无关。对此的可能解释是，用 CLIA 检测方法，致病性 DI 表位的暴露减少了，这
可能对正确的患者分类产生影响 3。 
在第 1 章中，我们阐述了使用亲水性表面包覆 β2GPI 的重要性，亲水性表面能诱导 β2GPI
构象变化，使 β2GPI 的 DI 中的隐性病原性表位暴露。如前所述，针对 DI 上隐蔽表位 G40-
R43 的抗体在体内和体外研究中显示是致病性的。因此，用抗 β2GPI 检测方法检测 aPLs 获
得的结果取决于包被于检测平面的 β2GPI 的构象（即表位 G40-R43 是否充分暴露），这些
会受到用于固定 β2GPI 的固相表面类型的影响。由于在抗 DI 检测中是 DI 被包被，而不是
整个 β2GPI 蛋白被包被，因此我们期待抗 DI 检测不会出现类似的问题。然而，考虑到表
位 G40-R43 是带正电荷的，检测平台涂层表面的电荷也可能影响 G40-R43 表位的暴露。事
实上，如果涂层表面是中性的（不带任何电荷），包被 DI 的方向将会是随机的，因此表
位 G40-R43 可能会有一个充足的暴露。但是，当使用带有负电荷的表面时，带有阳性电荷
的表位 G40-R43 会与其结合（向下），从而使抗体无法与之结合。在 CLIA 检测中，不能
排除所用磁珠的电荷，因此表位 G40-R43 的暴露是不确定的。为了验证这一点，我们在 
CLIA 中使用了两种单克隆抗体（P1-117 和 P2-6）。P1-117 抗体能识别表位 G40-R43，仅在 
β2GPI 处于其开放构象时才能与 DI 结合；而 P2-6 识别 DI，无论 β2GPI 的构象如何 11。我们
的数据显示在该抗 DI CLIA 中可以检测到 P2-6，而未能检测到抗体 P1-117 抗体 。表位 G40-
R43 在该抗 DI CLIA 中不暴露，因此可能漏检具有表位 G40-R43 抗体的患者样本。因此，商
业抗 DI CLIA 可以检测针对 DI 的抗体，但是可能漏检针对表位 G40-R43 的更特异的抗 DI 抗
体群。此外，在同一平台上测量的抗 β2GPI 和抗 DI 的结果高度一致，这表明这两种分析
检测的抗体群几乎相同，是靶向 DI，而不是靶向 G40-R43 表位。 
通过疏水 ELISA 检测抗 DI IgG  
除了抗 DI CLIA 检测以外，还有其他方法可用于检测抗 DI 抗体。早在 2005 年，一项实验室
开发的 ELISA 检测抗 DI IgG 能够识别出具有血栓形成或妊娠发病高风险的患者 9,10。这重申
了 G40-R43 表位的正确暴露至关重要。在该 ELISA 中，DI 被包被在亲水性 ELISA 板和疏水
性 ELISA 板上，导致致病性 DI 表位暴露的差异。 在第 4 章中，我们纳入 APS 和非 APS 患





抗体，并且 APS 样品的光密度 (OD) 值显着高于对照组。此外，我们发现 66 份具有血栓形
成症状的患者样本中有 18 份用抗 DI CLIA 检测抗体呈阴性，但用此抗 DI 疏水 ELISA 检测抗
体呈阳性，与商业抗 DI CLIA 相比，抗 DI 疏水 ELISA 的灵敏度更高，能检测到更多具有 APS
临床表现的样本。 综上所述，这些结果表明，与检测除针对表位 G40-R43 的抗体以外的
所有 抗 DI 抗体的商业化抗 DI CLIA 相比，抗 DI 疏水 ELISA 可以测量到更多的针对 G40-R43 
的抗 DI 抗体群。我们的数据强调了测量针对隐蔽表位 G40-R43 的抗体的重要性，不仅在
抗 β2GPI 测定中，而且在抗 DI 测定中，以确保至少不会遗漏这种致病性抗体群。 
总之，与抗 β2GPI 抗体检测一样，抗 DI 抗体检测的标准化至关重要。 这种标准化包括确
认 G40-R43 表位的暴露是否令人满意，以确保至少测量到该种特定的致病性抗体群。在抗
体检测中，用于包被固定 DI 的固相表面的电荷很重要，因为它会影响 G40-R43 表位的暴
露。 因此，在所有可用的抗磷脂抗体检测中验证该表位的暴露是很有趣的，这也可能提
高抗磷脂抗体检测的标准化。 
检测 APS 中 IgA 同种型抗 CL 抗体和抗β2GPI 抗体是否有附加的临
床价值？  
目前的标准必须检测 IgG 和 IgM 抗 CL 和抗 β2GPI 抗体才能确诊 APS，而 IgA 抗体不包括在
目前的分类标准中。 在第 6 章中，我们研究了除了由 LAC、抗 CL 和抗 β2GPI IgG/M 组成的
当前 aPLs 谱之外，检测抗 CL 和抗 β2GPI IgA 抗体是否有附加的临床价值。 我们发现抗 CL 
和/或抗 β2GPI IgA 抗体的阳性确实与血栓形成和妊娠发病率有关。 然而，单独的 IgA 阳性
很少见，并且与 APS 的临床表现无关。 因此，我们的结果不支持在识别具有 APS 临床表
现的患者时，除常规 aPL 外还测量抗 CL 和/或抗 β2GPI IgA。  
在没有抗 CL 和抗 β2GPI 抗体的情况下单独的 LAC 是否具有临床相
关性？  
LAC 检测一组异质性的 aPLs 抗体的功能效应。 在缺乏抗 CL 和抗 β2GPI IgG 和 IgM 的情况
下，单独 LAC 阳性的临床相关性是有争议的。 因此，在第 7 章中，我们研究了单独存在的 
LAC 阳性与血栓形成的相关性，并在包含 APS 和非 APS 患者的队列研究中将其与三重阳性
进行了比较。 我们发现，与三重阳性患者相比，孤立的 LAC 表现出较弱的 LAC 活性。 然
而，与三重阳性患者相比，单独 LAC 阳性患者的血栓形成风险相当甚至更高。 抗磷脂酰




APS 的临床症状血栓形成于妊娠并发症经常与 APS 不相关，这使得 APS 的诊断很困难，主




正确暴露以提高抗体检测的标准化非常重要。 此外，单独的 IgA 阳性很少见，并且与 APS 
的临床表现无关。 然而，与三重阳性患者相比，单独的 LAC 阳性患者的血栓形成风险更
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The main purpose of this thesis was to explore the optimization of the laboratory diagnosis of 
the antiphospholipid syndrome (APS). The detection of antiphospholipid antibodies (aPLs) is 
problematic due to the lack of standardization. Moreover, we showed the results of a multicenter 
study in which we investigated a newly developed aPLs-assay that might be a useful tool in the 
diagnosis and management of APS.  
APS: a societal and economic burden 
APS patients suffer from a systemic autoimmune disease characterized by recurrent venous or 
arterial thrombosis and/or pregnancy morbidity most likely caused by persistent aPLs 1. APS 
affects approximately 1 on 2000 people2, and is therefor one of the most common causes of 
acquired hypercoagulability and miscarriages in people under 50 years of age. The median age 
of disease onset is 31 years 3. APLs-related vascular events exert a strong clinical impact in terms 
of morbidity and mortality. aPLs positivity was observed in patients with deep vein thrombosis, 
myocardial infarction, stroke and pregnancy morbidity 4. Other non-criteria clinical 
manifestations are also frequently reported, as e.g. thrombocytopenia, autoimmune haemolytic 
anaemia, livedo reticularis, superficial thrombophlebitis, nephropathy, cognitive dysfunction, 
skin ulcers, epilepsy and cardiac valve dysfunction. Moreover, the catastrophic variant of APS 
(CAPS) is a serious, life-threatening aPLs-related manifestation characterized by the acute 
development of extensive thrombosis, leading to failure of three or more organs in less than 
a week. Despite treatment, mortality rate is still high and ranges between 30% to 50% 5. Such 
epidemiological evidence implies that APS diagnosis and management carries an enormous social 
and economic costs.  
Improving the diagnostic laboratory for APS  
Laboratory diagnosis of APS: current problems 
As the clinical symptoms of APS occur frequently irrespectively of the syndrome, classification of 
APS predominantly depends on a combination of different laboratory assays measuring the 
presence or function of aPLs. These laboratory criteria include one functional coagulation assay, 
known as lupus anticoagulant (LAC), and two immunological assays measuring anti-cardiolipin 
(antiCL) or anti-beta2-glycoprotein I (antiβ2GPI) immunoglobulin (Ig) G and/or IgM. Positive tests 
should be repeated and reconfirmed at least 12 weeks apart 1. Currently, the detection of aPLs 
show large inter-platform and -laboratory variation. The heterogeneity of aPLs and the lack of 





Heterogeneity of aPLs  
The antiCL assay detects different types of antibodies: antibodies directed against cardiolipin 
itself, directed against a complex of cardiolipin and β2GPI and directed against other cardiolipin-
binding proteins 6. AntiCL antibodies directed against cardiolipin itself are thought to be 
infection-related and transient 7. Therefore, antiβ2GPI assays using immobilized β2GPI have a 
better specificity for the laboratory diagnosis of APS. Studies have shown that aPLs that recognize 
the cryptic epitope G40-R43 on domain I (DI) of β2GPI have been proven to be pathogenic, while 
antibodies against other domains of β2GPI appear to be unrelated to the clinical symptoms of 
APS. 
Detection of antibodies against thrombosis-related DI epitope  
Various assays for detecting antiDI antibodies have been developed and are expected to improve 
the laboratory diagnosis of APS. However, no consensus is reached on whether detecting antiDI 
antibodies is of added value for the classification of APS (chapter 2). Chemiluminescence (CLIA) 
is currently the most widely used method to detect antiDI IgG antibodies, whose presence is a 
strong indicator for clinical manifestations of APS. We found that the antiDI CLIA was less 
sensitive but more specific compared to the laboratory criteria aPLs tests. However, it hardly 
improved the Odds Ratio for the occurrence of thrombosis or pregnancy morbidity. Therefore, 
our study demonstrated that measuring antiDI IgG by CLIA was not of added value on top of the 
current criteria (Chapter 3). A possible explanation could be the high variability in exposure of 
the G40-R43 epitope on DI. This epitope has proven to be cryptic and only exposed when β2GPI 
is in its open conformation.  
Interestingly, our in-house antiDI ELISA that ensures enough exposure of the cryptic epitope, was 
able to detect more samples with clinical manifestations of APS, which resulted in a higher 
sensitivity compared to the antiDI CLIA assay (Chapter 4). Taken together, our results suggest 
that this antiDI ELISA is able of detecting a specific population of pathogenic antiDI antibodies, 
thereby preventing that the patients are misdiagnosed as false negative.  
Standardization of assays for detecting aPLs 
Standardization of the assays used to detect aPLs antibodies in APS is of utmost importance. This 
standardization includes the confirmation of enough exposure of the pathogenic epitope G40-
R43 on DI of β2GPI to ascertain that at least the specific pathogenic antibody population is 
detected. The charge of the solid phase surface used to immobilize antigen (β2GPI or DI) can 
affect the amount of exposure of this epitope. Therefore, verifying the correct exposure of the 
cryptic epitope in all available aPLs assays will help to improve standardization of aPLs assays and 
thereby patient classification.  
Relevance for patients  
The current APS diagnostic procedure may result in misdiagnosis of the syndrome, with major 
implications regarding the treatment of patients. Current treatments for APS are aimed at 
attenuating the procoagulant state of the patient and take into account the risk of recurrence of 




based on oral anticoagulant therapy. Given the fact that also non-pathogenic antiβ2GPI 
antibodies exist, quantitative assays measuring reactivity against the full protein, will result in 
false positive results. Patients with thrombosis and aPLs antibodies may be given indefinite oral 
anticoagulant treatment. Falsely diagnosed patients may thus be exposed to a high risk of 
bleeding, without having any benefit of such treatment. AntiDI assays measuring the reactivity 
of anitbodies against DI can improve the specificity of APS laboratory diagnosis, thereby reducing 
the false positive rate. 
Current laboratory tests included in the criteria fail to exploit potential pathophysiological 
processes associated with aPLs antibodies, thereby resulting in false negative results. False-
negative results also have serious consequences for patients suspected having APS because they 
need long-term anticoagulation to prevent recurrence. Our study firstly determined the impact 
of the variable exposure of the pathogenic DI epitope of β2GPI in the commercial antiDI assays 
on the patient classification. Subsequently, we provided preliminary results of our in-house anti-
DI hydrophobic ELISA. We demonstrated that our in-house anti-DI ELISA is able to detect the 
specific anti-DI antibody population against the pathogenic G40-R43 epitope, thereby improving 
patient diagnosis sensitivity and reducing the false negative rate. In addition, our study proved 
that at least this specific thrombosis-associated antibody population will not be missed when 
there is enough exposure of the G40-R43 epitope, thereby improving the standardization of 
existing aPLs assays based on the binding of aPLs to β2GPI. 
Improving risk stratification of APS patients  
The current laboratory criteria include LAC, antiCL IgG and IgM and antiβ2GPI IgG and IgM. It is 
sufficient for the diagnosis of APS to have one positive test when the patient is also positive for 
one of the clinical criteria 1. However, not every test has the same predictive value and positivity. 
Therefore, risk stratification can be done by categorizing patients according to the number of 
positive tests and by the analysis of the aPLs profile. Each aPLs profile confers a characteristic 
thrombotic risk. When LAC is positive together with antiCL and antiβ2GPI antibodies (triple 
positivity), it carries a significant risk for a first thrombotic event 8 and for recurrence of 
thrombosis 9. Triple positivity is also an independent risk factor for pregnancy failure 10. Our study 
observed that anti-DI IgG antibodies are highly correlated with triple positivity, indicating that 
anti-DI IgG positivity confirms the patients at higher risk for clinical events related to APS.  
Moreover, combined DI and triple positivity confirms an even higher risk for both thrombosis and 
pregnancy morbidity compared to only triple positivity (Chapter 3).  
The LAC assay measures the functional effect of a heterogeneous group of aPLs antibodies. LAC 
positivity could be based on antiβ2GPI antibodies or anti-phosphatidylserine (PS) or prothrombin 
(PT) antibodies, or possibly even other inhibitors. A positive LAC is considered to be a strong risk 
factor for thrombosis in APS. We demonstrated that an isolated LAC (in the absence of antiCL 
and antiβ2GPI IgG and IgM) was also strongly correlated with a history of thrombosis with an 
even higher predictive value for thrombosis than triple positivity. The presence of anti-PS/PT 
antibodies could not explain LAC positivity in isolated LAC. As samples were negative for 
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antibodies against β2GPI and PT, further studies are needed to identify other target antigen 
responsible for isolated LAC activity (Chapter 7). 
Relevance for patients  
Identifying the presence of factors associated with a high risk for thrombotic and/or obstetric 
events is critical for patient management. Our study demonstrated that a major risk factor is: the 
presence of LAC, the presence of triple (all three subtypes) aPLs positivity or antiDI IgG positivity. 
Improving the risk stratification of patients can better define high-risk and low-risk aPLs profiles 
and better describe the risks associated with different aPLs profiles to improve patient 
management.  
A high-risk aPLs profile not only indicates the first clinical event8, but also suggests recurrence 9. 
Clinical decision may be modified if APS patients have a high-risk aPLs profile.  For patients with 
APS and a first unprovoked venous thrombosis, it is recommended to receive long-term 
treatment with vitamin K antagonists (VKA) 11. While for patients with a provoked first venous 
thrombosis, when patients have a high-risk aPLs profile, longer anticoagulation could be 
considered to avoid recurrence. Based on the current evidence, treatment with direct oral 
anticoagulants (DOACs, such as Rivaroxaban) is not recommend in triple aPLs-positive patients 
with obstetric APS and APS with arterial events, due to the high risk of recurrent events12,13 . 
Furthermore, for women with prior obstetric APS, if an individual has a high-risk profile, it is 
recommended to combine treatment with low dose aspirin heparin during pregnancy.   
Conclusion  
The results of our study provide evidence for an update of the diagnostic criteria including risk 
stratification for the diagnosis and management of APS.  Hereby is assay standardization of 
utmost importance. Subsequently, the improved diagnosis and risk stratification should improve 
the current treatment procedures and reduce APS-related morbidity and mortality. In addition, 
our findings open the way for investigating new potentially important antigen targets in the 
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